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Abstract 
Postmenopausal osteoporosis is a skeletal disorder characterised by bone loss. 
Declining oestrogen levels postmenopause disrupt bone remodelling by over-
stimulating resorption. Although the disorder is currently studied in animals, we 
should aim to minimise their use. Therefore, this thesis explored the feasibility of 
developing an in vitro model of postmenopausal osteoporosis using tissue engineering 
principles. 
The response of three osteoblast cell lines, MC3T3-E1, MLOA5, and IDG-SW3, to 
oestrogen was explored, finding only MC3T3-E1 was stimulated by the hormone. The 
ability of RAW264.7 to undergo osteoclastogenesis was strongly influenced by 
seeding density and proliferation. Additionally, tartrate-resistant acid phosphatase 
(TRAP) activity could be suppressed by oestrogen exposure. Due to its ability to 
support osteoclastogenesis in co-culture, IDG-SW3 was the most suitable osteoblast 
cell line for the model. 
Bone-matrix deposition over 28 days on three scaffolds (PolyHIPE, polyurethane, 
Biotek) was compared to select the most appropriate for the model. PolyHIPE and 
polyurethane scaffolds supported significantly more matrix deposition than the Biotek. 
Mineralisation on the scaffold could be detected by micro-computed tomography; 
however, the presence of PBS interfered with this. Due to its cellular performance and 
ease of manufacture, the polyurethane scaffold was identified as the most suitable for 
the model. 
Changes in mineral content, TRAP and alkaline phosphatase activity were confirmed 
as markers for osteoclast and osteoblast activity in co-culture. RAW264.7 pre-
treatment with oestrogen to mimic pre-menopause had lasting effects on their ability 
to undergo osteoclastogenesis.  2D co-cultures using oestrogen withdrawal to mimic 
menopause resulted in increased resorption, analogous to the effect seen in vivo. From 
the conditions assessed in 3D co-cultures, no equivalent response was observed. This 
thesis demonstrates it is possible to imitate the onset of postmenopausal osteoporosis 
in vitro. However, a 3D system that uses human cells and longer time periods is 
necessary to provide a valid alternative to animal models. 
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1. Introduction 
Osteoporosis is a skeletal disease common in the elderly population which is often 
underdiagnosed and undertreated. Demographics are changing, resulting in more 
people above the age of 60 in the population, thereby increasing the incidence of this 
disorder. An estimated three million people in the United Kingdom have osteoporosis, 
with health and social care costs for associated hip fractures alone being approximately 
£2.3 billion each year [1]. Osteoporosis occurs when the balance of bone resorption 
and formation is disrupted. Endocrine changes associated with ageing result in an 
over-stimulation of bone resorption and inhibition of bone formation. This results in a 
reduced bone mineral density and strength, as well as a deterioration of the 
microarchitecture. When the bone mineral density falls below a certain threshold, the 
patient is classed as having osteoporosis [2].  
Current treatments for osteoporosis are physical, dietary or pharmacological. 
However, despite these approaches reducing fracture risk and increasing bone mineral 
density, they are associated with side effects ranging from gastrointestinal problems 
for bisphosphonates, to cardiovascular complications with hormone replacement 
therapy, and osteosarcoma from parathyroid hormone treatments [3]–[5]. From this it 
is clear that a better understanding of the disease mechanisms, improvements to 
current treatments, and an understanding of how to prevent osteoporosis is essential in 
reducing its prevalence and improving patients’ quality of life. 
The most common method of studying osteoporosis and testing new therapeutics is 
through the use of animal models due to their ability to provide a uniform approach to 
research with a level of experimental control that is not possible in humans. In fact, 
the US Food and Drug administration (FDA) requires a new osteoporosis drug to be 
preclinically tested on a rodent and a validated large animal model [6]. Although 
viewed as the gold standard for testing the safety and efficacy of new therapies and 
are an essential step in preclinical development, differences between animal and 
human physiology means that they cannot accurately model the human response. The 
use of in vivo models should align with the principles of the ‘3Rs’ – replacing, 
reducing and refining animal testing [7]. In addition to these principles, in September 
2010 the EU Directive ‘Directive 2010/63/EU – Legislation for the protection of 
animals used for scientific purposes’ was adopted. This supports the principles of the 
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3Rs, widening their scope and laying down standards for housing and care of animals. 
In addition to this, it establishes a Union reference laboratory for the validation of 
alternatives to animal models in order to promote their development, validation and 
implementation [8]. This directive is in fact part of the impetus behind this project; if 
aspects of in vivo models can be replicated in vitro then certain facets of animal testing 
can be replaced.   
Previous work within the Reilly group has shown that culturing osteoblastic cells on 
porous polymer scaffolds can induce the formation of an immature mineralised bone-
like matrix [9]. This thesis focuses on combining this with osteoclast culture and a 
regimen of oestrogen treatments to investigate whether an applicable model of 
postmenopausal osteoporosis can be developed in vitro.  
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2. Background 
2.1 Bone – Physiology, hierarchy and healing 
2.1.1 Anatomy and function 
Bone performs several roles. It provides support, protects vital organs, facilitates 
movement by acting as levers, stores minerals such as calcium and phosphorus, 
contains cells that produce blood such as haematopoietic red marrow, and stores 
energy in the form of lipid filled yellow marrow. There are two types of osseous tissue, 
cortical bone (also known as compact bone) and cancellous bone (also known as 
trabecular or spongy bone). Cortical bone makes up approximately 80% of the bone 
mass of an adult skeleton and usually has a porosity below 5% [10], [11]. Cancellous 
bone makes up the remaining 20% and has much higher porosity, approximately 50-
90%. It contains thin (50-400 μm), interconnecting rods and plates of bone termed 
trabeculae. Rods give an open cell structure and plates a closed cell structure, and the 
spaces between the trabeculae are filled with bone marrow and blood vessels. This 
high porosity results in a much lower compressive strength but a greatly increased 
surface area in comparison to cortical bone [12]–[15]. 
2.1.2 Macrostructure 
The adult human skeleton contains 206 bones which are classified by shape to give 
five types: long, short, irregular, flat, and sesamoid. Long bones are longer than they 
are wide, act as levers, and are typically found in the legs and arms but also in the 
fingers and toes. They consist of three regions, the diaphysis, epiphysis, and 
metaphysis. The diaphysis is the hollow shaft that connects to the proximal and distal 
epiphyses via the proximal and distal metaphyses. It is formed from a hollow tube with 
the outside constructed from cortical bone and the medullary cavity filled with bone 
marrow. The epiphysis is the end of the bone, and has a specialised shape depending 
on the location and function. It is predominantly cancellous bone with an outer surface 
composed from cortical bone.  The metaphysis, also known as the epiphyseal plate, is 
part of the growth plate, the portion of bone that grows during childhood.  
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Short bones are normally cubic, with approximately equal dimensions in all three axes. 
They give stability and allow limited movement and are only found in the wrists and 
ankles. They have a trabecular centre covered with cortical bone. Flat bones are 
composed of a layer of cancellous bone between two layers of cortical bone. Found 
predominantly in the skull, shoulder blades, sternum, and ribs, they provide protection. 
Irregular bones do not meet the requirements of the previous categories, for instance 
the vertebrae or facial bones containing the sinuses. Their complex shapes afford 
protection and support. Finally, the sesamoid bones are small, round bones that occur 
in tendons. Their formation is pressure dependant, developing when large compressive 
forces are exerted onto a tendon. This means that the number and location of sesamoid 
bones varies from person to person, with the exception of the patellae. 
With the exception of articular cartilage covering joint surfaces, the outer surface of 
bone is covered by connective tissue termed the periosteal membrane. Formed from 
two layers, the outside contains dense, irregular collagenous tissue containing blood 
vessels and nerves and the inside is a single layer of bone cells. The outer layer is 
continuous with attached tendons and ligaments, and some collagen fibres (Sharpey’s 
fibres) even penetrate the periosteum and bone tissue, strengthening the attachment. 
Blood vessels within the periosteum also penetrate the bone through nutrient foramina, 
minute holes within the tissue. Endosteum is a connective tissue membrane which 
lines the inner surface of bone and is also formed from a layer of bone cells [14], [16]. 
(Fig. 2.1) 
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Figure 2.1: Macroscopic and microscopic anatomy of an adult long bone. (Right) 
Macroscopic view of an adult femur. (Top left) Cross section view of the intersect 
between cortical and trabecular bone. (Bottom left) Cut away of a single osteon. 
(Bottom centre) cross section of a single trabeculae. Image used with the kind 
permission of Rebecca O’Neill. 
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2.1.3 Micro and nanostructure 
Osseous tissue is a composite material with an organic phase, inorganic phase, and 
cellular phase. The organic phase provides bone with its tensile strength and reduces 
the brittleness allowing for bending, and the inorganic phase gives compressive 
strength. The combination of these two phases is known as the bone matrix or osteoid 
and the cellular phase deposits, maintains, and resorbs this. By dry weight, osseous 
tissue is one third organic and two thirds inorganic. The inorganic phase is mainly 
constituted from hydroxyapatite (~85%), but there is also calcium carbonate (~10%), 
and small amounts of other minerals [16]. 
The organic phase is predominantly type I collagen (~90%) with trace amounts of type 
III and V, but is also formed from ~10% non-collagenous proteins such as 
glycosaminoglycans, proteoglycans, and glycoproteins. The majority of these have a 
high affinity for calcium ions due to their aspartic and glutamic acid residues [17]. 
Examples of these proteins include osteocalcin, osteopontin, osteonectin and alkaline 
phosphatase. Osteocalcin, a skeletal gla protein, can be used as a late-marker of 
osteogenic differentiation and is implicated in bone remodelling. Additionally, its 
inhibition may be used in the control of mineralisation [18], [19]. Osteopontin is a 
sialoprotein involved in cell attachment to bone matrix and bone remodelling [20], and 
osteonectin is a glycoprotein which is likely involved with mineralisation due to its 
binding affinity to calcium, hydroxyapatite and collagen.  
Alkaline phosphatase (ALP), specifically tissue non-specific alkaline phosphatase, is 
an enzyme secreted from osteoblasts which promotes hydroxyapatite crystal formation 
within the bone matrix, and it is considered to be a highly specific marker of bone-
forming osteoblasts [18], [21]. Therefore, ALP activity is often used during in vitro 
analyses as an early indicator of osteogenic differentiation [22]. However, the exact 
mechanism of its involvement is unknown. The key substrate for ALP in bone is 
thought to be inorganic pyrophosphate (PPi). PPi inhibits hydroxyapatite formation, 
but its hydrolysation by ALP provides inorganic phosphate (Pi) which is required for 
the formation of hydroxyapatite [23], [24].  
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Osseous tissue has a hierarchical structure. The cortical and cancellous bone form the 
macrostructure, the microstructure (500 µm – 10 µm) is composed of osteons and 
trabeculae. The sub-microstructure (10 µm – 1 µm) is the lamellae, the nanostructure 
(1 µm - ~500 nm) is the collagen fibres, and the sub-nanostructure (below ~500 nm) 
is the fibrils and molecules that form collagen fibres (Fig. 2.2). 
 
Figure 2.2: Hierarchical structure of cortical bone. Reprinted from Rho, et al., with 
the kind permission of Elsevier [25]. 
Depending on the organisation of collagen fibrils within the osteoid, osseous tissue 
can be classified as either woven or lamellar bone. The former contains randomly 
orientated collagen and is formed during foetal development or fracture repair. It is 
the only type of bone that can be formed de novo, and does not contain any osteons. It 
is laid down randomly and rapidly in response to the need for a stiff tissue to be formed 
in a short period of time. This disorganisation gives isotropic mechanical properties 
and increases flexibility. Conversely, lamellar bone has highly organised collagen 
fibrils which are formed in alternating orientations. Each layer (lamellae) is between 
3 and 7 μm thick and within each layer collagen fibres lie parallel. In adjacent layers, 
collagen fibres also lie parallel, but at an angle to neighbouring lamellae. This high 
level of orientation yields anisotropic mechanical properties, meaning its mechanical 
performance depends on the direction of the applied force. This results in lamellar 
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bone being much stronger than woven bone in the long axis of the collagen fibres, but 
also less flexible [13], [14]. 
The microstructure of cortical and trabecular bone is notably different (Fig. 2.3). The 
microstructure of cortical bone consists of lamellae wrapped concentrically around a 
blood vessel canal. The combination of lamellae and the canal within which the blood 
vessel and nerves reside forms an osteon, the building block of cortical bone. Osteons 
can be divided into two groups, primary and secondary. Primary osteons occur during 
the mineralisation of cartilage as bone tissue is formed for the first time, and secondary 
osteons occur when existing bone is replaced during bone remodelling and are also 
known as Haversian systems. These tend to have more lamellae and larger canals than 
primary osteons. Cancellous bone also contains lamellae; however, these are not 
concentric, meaning that there are no osteons.  
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Figure 2.3: Synchrotron image of a transverse cross section of a bone. Sample taken 
from the lower trochanter of a 101-year-old human female revealing the 
microstructure of cortical and trabecular bone. Haversian systems their canals are 
only visible in the cortical region. Osteocyte lacunae are present throughout. 3 mm 
diameter sample. Image acquired by author at Diamond Light Source I13-2, 
experiment MT15886. 
Osteons run parallel to the long axis of the bone and are joined via Volkmann’s canals 
(Fig. 2.4). Haversian and Volkmann’s canals contain blood vessels, nerves and lymph 
vessels. Lacunae are found between the lamellae and are connected by canaliculi. The 
lamellae underlying the periosteum and endosteum of cortical bone are termed 
circumferential lamellae, and any residual lamellae remaining after remodelling that 
lie between osteons are referred to as interstitial lamellae (Fig. 2.5).  
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Figure 2.4: Network of Haversian (white arrows) and Volkmann’s (red arrows) 
canals. Reconstructed volume from a synchrotron scan of a cortical bone sample taken 
from the femoral midshaft of an 86-year-old male. By thresholding for opacity only 
the empty volumes are left visible. The small volumes surrounding the network are 
osteocyte lacunae. Image acquired by author at Diamond Light Source I13-2, 
experiment MT15886. 
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Figure 2.5: Synchrotron image of the microstructure of cortical bone. Transverse 
cross section of a sample taken from the femoral midshaft of an 86-year-old male. 
Volkmann’s canals appear as elliptical Haversian canals where they span between 
two osteons. Lamellae are not immediately visible, but their path can be traced by 
viewing lacunae. Concentric lamellae can be seen around osteons and interstitial 
lamellae between them. Field of view is 1 mm. Image acquired by author at Diamond 
Light Source I13-2, experiment MT15886. 
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2.1.4 Cell biology of bone 
There are four main cell types present within bone, mesenchymal progenitors, 
osteoblasts, osteoclasts, and osteocytes, with each performing a different role and 
function. Mesenchymal progenitors, osteoblasts and osteocytes are all of the same 
osteoblastic lineage, where mesenchymal progenitors undergo osteogenesis and 
differentiate into pre-osteoblasts and osteoblasts, a subset of which ultimately 
terminally differentiate into osteocytes with the remainder undergoing apoptosis or 
becoming bone lining cells (Fig. 2.6a) [26]. In contrast, osteoclasts are derived from 
haematopoietic stem cells (HSCs).  
The differentiation of mesenchymal progenitors into osteoblasts can occur by two 
different processes depending on where it occurs in the skeleton. Direct differentiation 
from mesenchymal progenitor to osteoblast occurs during intermembranous 
ossification. In mammals, this mechanism is limited to certain skull bones and the 
clavicle. All other parts of the skeleton are formed by endochondral ossification. Here, 
mesenchymal progenitors initially differentiate into chondrocytes and perichondral 
cells. At first these chondrocytes are proliferative; however, they then exit the cell 
cycle and become hypertrophic. This triggers the differentiation of osteoblasts from 
the perichondral cells (Fig. 2.6b) [13], [26]. Due to the ability of mesenchymal 
progenitors to differentiate into osteogenic cells and the ease with which they can be 
isolated and expanded in culture, they hold a great deal of promise in the field of bone 
tissue engineering. However, their proliferative and differentiation capability 
decreases during ex vivo expansion which limits their clinical use but inspires research 
into overcoming these limitations [27]. 
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Figure 2.6: Osteoblastic and osteoclastic cell lineages. (a) Osteoclasts are derived 
from haematopoietic stem cells (HSCs) and pre-osteoblasts, osteoblasts, osteocytes 
and bone lining cells from mesenchymal progenitors (MPs). (b) Different pathways of 
osteoblastic differentiation from mesenchymal progenitors (MP). Reprinted from 
Long, with the kind permission of Nature Publishing Group [26]. 
Osteoblasts are mononucleate, deposit the extracellular matrix of bone at a rate of 0.5 
– 1.5 µm per day and regulate its mineralisation [28]. Identifiable by their cuboidal 
morphology and located on the surface of the osteoid, they produce the collagen and 
non-collagenous proteins that form the organic phase of bone. They are anchorage 
dependent and require cell-matrix and cell-cell contacts to maintain function. This is 
achieved through either specific receptors for signalling molecules, such as cytokines, 
hormones and growth factors, or transmembranous proteins, for instance connexins, 
cadherins and integrins. If osteoblasts become fully embedded and trapped within their 
own calcified osteoid, they change phenotype and develop into osteocytes [13], [28].  
It is widely reported that once the differentiation through the osteoblastic lineage has 
progressed to the osteoblast phenotype, these mature osteoblasts are post-mitotic [29]–
[32]. Therefore, mature osteoblasts can only be created via mesenchymal progenitor 
differentiation. Although this lineage of cells is classically divided into four 
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phenotypes (progenitor, pre-osteoblast, osteoblast, and osteocyte) due to these discrete 
divisions being useful when discussing bone biology, progression through the lineage 
is a continuous process meaning that there are not well defined identities for each 
phenotype [26]. As osteoblastic lineage cells differentiate from mesenchymal 
precursors, there is a period of active proliferation and mitotic activity as demonstrated 
by expression of cell cycle and cell growth genes. At this time, genes associated with 
extracellular matrix production (e.g. type I collagen) that are fundamental to the 
osteoblast phenotype are also expressed. In the subsequent stages of differentiation, 
these proliferation genes are downregulated and DNA synthesis declines whilst ALP 
expression rapidly increases as the extracellular matrix is prepared for mineralisation. 
Therefore, it appears that this cessation of proliferation is required for the genes 
specific to bone mineralisation to be activated [33]. 
Osteocytes reside within the lacunae and account for 90% of all cells in the human 
skeleton. They can survive for decades and although derived from osteoblasts, have a 
markedly different function and morphology. They are smaller than osteoblasts, have 
a reduced number of organelles but an increased nucleus-to-cytoplasm ratio, and are 
star shaped (stellate) with multiple cytoplasmic extensions (Fig. 2.7) [34]. These 
processes penetrate the canaliculi that connect the lacunae and make contact with other 
osteocytes, osteoblasts, cells lining the bone surface, and vasculature via gap junctions 
[35]. Surrounding the osteocytes in the lacunocanalicular network is interstitial fluid. 
As the osteocyte network has no vascular supply, it relies on diffusion through this 
fluid to provide oxygen and nutrients to the osteocytes [36]. This network of 
osteocytes forms a complex communication system that enables them to sense and 
respond to stresses placed upon the bone. Currently, it is thought that this is achieved 
by bone deformation causing the interstitial fluid surrounding the osteocytes to flow 
from regions of high pressure to those of low pressure. This flow is sensed by 
osteocytes, stimulating them to produce signalling molecules that regulate resorption 
and formation activity in osteoclasts and osteoblasts, respectively [37]. The 
lacunae/canaliculi system has a huge surface area that signalling molecules produced 
by osteocytes can affect. Even though it contains only 1% of the bone fluid volume, it 
has a surface area 400 times greater than the Haversian and Volkmann’s systems 
combined, and 133 times greater than cancellous bone [38].  
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Figure 2.7: Schematic representation of an embedded osteocyte within its lacuna. 
Processes can be seen penetrating the canaliculi within the bone matrix. These 
interconnect via gap junctions with other osteocytes, osteoblasts, the marrow space 
and vasculature to allow nutrients to diffuse through the interstitial fluid. Reprinted 
from Dallas, et al., with the kind permission of Oxford Academic [36]. 
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Unlike osteoblasts and osteocytes, osteoclasts are ultimately derived from 
haematopoietic stem cells [39]. They are multinucleated bone resorbing cells formed 
from fused monocyte progenitors. Their average lifespan is 15-20 days before 
undergoing apoptosis, and they degrade osteoid using hydrogen ions and enzymes. 
Initially hydrochloric acid dissolves the mineral content of the matrix before 
proteolytic enzymes, such as tartrate-resistant acid phosphatase (TRAP), matrix 
metalloproteinase 9 (MMP-9), gelatinase, and cathepsin K, degrade the organic 
component. The result is visible resorption cavities in the bone called Howslip’s 
lacunae [40]. An active osteoclast can resorb bone at a rate of up to 200,000 µm3/day; 
to replace this volume of bone takes up to ten generations of osteoblasts [28]. When 
resorbing, osteoclasts tightly attach to bone through a sealing zone created through 
cytoskeleton rearrangement to form a ring of actin. Within this ring the plasma 
membrane enlarges and becomes convoluted forming a ruffled membrane with finger-
like projections to increase surface area and therefore contact with the bone matrix. 
The acids and enzymes are secreted through the ruffled border to degrade the bone 
below, forming the resorption cavities (Fig. 2.8) [28], [41]–[43].  
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Figure 2.8: Colourised scanning electron micrograph of an active osteoclast and a 
resorption pit. Image used with the kind permission of Prof. Timothy Arnett, University 
College London. Original image available on boneresearchsociety.org. 
 
 
 
 
 
 
54 
 
2.1.5 Bone remodelling 
Bone remodelling occurs throughout life and is an essential physiological process. It 
maintains or improves bone strength by replacing primary, immature bone and old, 
micro-damaged or fractured bone, as well as maintaining calcium homeostasis. The 
resorption and formation processes are balanced, and remodel approximately 5% of 
cortical and 20% of trabecular bone each year. Whilst the latter accounts for only 25% 
of the total bone volume, the increased surface area to volume ratio results in a ten 
times higher metabolic rate. Bone remodelling is a continuous event throughout life, 
but the balance between resorption and formation changes. In healthy individuals, 
formation dominates for the first three decades until peak bone mass is achieved. This 
bone mass is then maintained for approximately 20 years until resorption begins to 
outweigh formation and mass declines [44].  
Remodelling occurs via basic multicellular units (BMUs). These are composed from 
discrete packets of osteoclasts and osteoblasts accompanied by a blood supply and 
supporting connective tissue. BMUs form and refill tunnels through cortical bone and 
in trabecular bone they create trenches on the surface. The osteoclasts are at the front, 
forming the cutting cone or hemicone in the case of trabecular BMUs, with osteoblasts 
behind forming the closing cone or hemicone. The BMU can move in all three axes in 
cortical BMUs and two axes in trabecular BMUs as they are on the surface [13], [45] 
(Fig. 2.9). 
The action of osteoblasts and osteoclasts within the BMU is tightly coupled via 
biochemical pathways. Once osteoclast precursors have arrived at the remodelling site 
from the bloodstream or surrounding marrow, two factors are predominantly 
responsible for their maturation into osteoclasts: macrophage-colony stimulating 
factor (M-CSF) and receptor activator of nuclear factor kappa-B ligand (RANKL). 
These factors bind to their respective receptors on the precursors, colony-stimulating 
factor-1 receptor (c-fms) and receptor activator of nuclear factor kappa-B (RANK) 
and initiate osteoclastogenesis. 
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Figure 2.9: Bone multicellular units in (top) trabecular and (bottom) cortical bone. 
In trabecular bone they initiate underneath bone remodelling canopies and in cortical 
bone at points within Haversian canals. Reprinted from Sims and Martin, with the 
kind permission of Nature Publishing Group [46]. 
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The earliest haematopoietic precursor that can give rise to an osteoclast is the 
granulocyte-macrophage colony forming cell (GM-CFU). M-CSF is produced by 
osteoblasts and stromal cells and its activation of c-fms promotes the survival and 
proliferation of the GM-CFU [47], [48]. RANKL is expressed by osteoblasts, T cells 
and endothelial cells and its conjugation with RANK commits the GM-CFU to the 
osteoclast lineage, upregulating key markers such as TRAP. Continued exposure to 
both factors stimulates the preosteoclasts to fuse, and once activated, they bind to the 
bone surface and express markers specific to osteoclasts such as cathepsin K [49]. The 
binding of RANKL to RANK can be antagonised by osteoprotegerin (OPG), a decoy 
receptor for RANKL that inhibits osteoclastogenesis. Therefore, whether and how 
much resorption occurs is determined by the RANKL:OPG ratio [50]. Like RANKL, 
OPG is also produced by osteoblasts meaning that they have a key role in controlling 
the balance between bone formation and resorption (Fig. 2.10).  
 
Figure 2.10: Diagram of how the RANKL/RANK/OPG axis and M-CSF direct 
osteoclastogenesis and activation. 
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Through the use of tetracycline dyes, the rate of longitudinal BMU advance is 
calculated to be approximately 25 μm per day and they can continue for between 6 
and 9 months. As the lifespans of the constituent cells of the BMU are much shorter, 
they must be continuously replaced for the unit to operate correctly [51]. There are 
approximately 35 million BMUs operating within the skeleton at any one time, with 
5-10% of the existing bone being replaced each year. This means that every 10 years 
the skeleton is entirely renewed [44]. 
It has recently been discovered that trabecular BMUs are separated from the 
surrounding bone marrow by a canopy to create a bone remodelling 
compartment (BRC). These canopies are likely formed by an extension of the bone-
lining cells due to their expression of typical osteoblastic markers. The BRC generates 
a unique microenvironment conducive to paracrine signalling and facilitates BMU 
formation and function. It allows control over osteoblast-osteoclast coupling and 
ensures tightly regulated bone remodelling. BRCs cover practically all resorptive 
surfaces and over 50% of formative surfaces, indicating that they form as resorption 
initiates and are closed as formation completes. Capillaries penetrate the BRC and are 
thought to serve as conduits for the precursor cells needed to form and maintain BMUs 
as their lifespan is 6 to 9 months, much longer than the constituent cells (osteoclasts 
2 weeks, osteoblasts 3 months). Disruption of the BRC negatively affects bone 
turnover and can result in uncoupled remodelling, where bone is resorbed without 
being replaced [52]–[58].   
There are five stages in bone remodelling: the quiescent, activation, resorption, 
formation, and mineralisation phases (Fig. 2.11). During the quiescent phase the bone 
is inactive. It is not known exactly what factors initiate remodelling, but the most likely 
causes are micro-fracture, to maintain normocalcaemia during pregnancy or a 
deficient diet, or a change in the mechanical loading of the tissue sensed by osteocytes. 
This results in the production of factors such as insulin growth factor-1, tumour 
necrosis factor-α, parathyroid hormone and interleukin-6 which activate the bone 
lining cells [59], [60]. The activation phase prepares the surface of the bone for 
resorption. Bone lining cells, elongated mature osteoblasts on the endosteal surface, 
retract and the endosteal membrane is broken down by collagenase, exposing the 
mineralised bone matrix. Mononuclear monocyte-macrophage osteoclast precursors 
are recruited from the circulation and activated, which fuse to form multinucleate 
osteoclasts. These bind to the exposed bone matrix through interactions between 
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integrin receptors in the cell membrane and peptides containing RGD (arginine, 
glycine, asparagine) in the matrix [13].  
The resorption phase then begins, with osteoclasts using a combination of hydrogen 
ions and lysosomal enzymes to degrade and dissolve the matrix, forming resorption 
cavities. Osteoclasts then undergo apoptosis and macrophages complete this process, 
facilitating the release of growth factors from within the matrix [44]. At the end of 
resorption there is a transition to the formation phase which can take up to five weeks. 
This is sometimes classed as the reversal phase. When resorption is completed the 
resorption cavities contain monocytes, osteocytes that have been freed from within the 
matrix, and preosteoblasts. It is not yet known what signals couple resorption and 
formation phases, but it is likely bone matrix-derived factors [61].  
Formation and mineralisation can be viewed as a two-step process. Preosteoblasts are 
recruited to the resorption cavity by the chemotactic growth factors released from the 
matrix. They synthesise a cementing substance on the surface which acts as a 
foundation for new tissue and express bone morphogenetic proteins responsible for 
differentiation. After a few days, osteoblasts first deposit the collagenous organic 
matrix then regulate its mineralisation, filling the resorption cavity with osteoid. Once 
the collagen has been secreted, mineralisation is triggered by the osteoblasts releasing 
membrane-bound vesicles termed matrix vesicles which establish conditions 
conducive to mineralisation. This involves increasing the concentration of calcium and 
phosphorus ions and degrading inhibitors of mineralisation, such as some 
proteoglycans present in the organic matrix. Mineralisation begins 30 days after 
osteoid deposition and finishes after 90 or 130 days later for cancellous and cortical 
bone, respectively. As this occurs, some osteoblasts become embedded and undergo 
osteocytogenesis. After completion, the remaining osteoblasts either undergo 
apoptosis or become bone lining cells [12], [44], [61], [62]. 
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Figure 2.11: The five stages of bone remodelling. Reprinted and adapted from Feng 
and Macdonald under the Creative Commons Attribution Licence [63]. 
At the completion of remodelling there should be no net loss or gain of bone. Any 
difference in resorption and formation is referred to as the ‘bone balance’. BMUs on 
the periosteal surface of cortical bone have a marginally positive bone balance; 
therefore, with ageing, the circumference of the periosteal surface increases as the net 
gain from each remodelling cycle accumulates. Conversely, endosteal BMUs have a 
marginally negative bone balance; therefore, the marrow cavity circumference 
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increases with age. However, the net loss on the endosteal surface is greater than the 
net gain on the periosteal surface, resulting in cortical thinning with age. This, 
combined with a slightly negative bone balance on the surface of the trabeculae 
resulting in thinning of the cancellous bone, increases the fracture susceptibility of 
bones with large surface area, such as the vertebrae or distal radius. Therefore, bone 
remodelling in the elderly results in a loss of bone, which can eventually manifest as 
osteopenia or osteoporosis depending on the severity [12], [44], [61], [62]. 
2.1.6 Bone tissue engineering 
In the United Kingdom the incidence of bone fractures is 3.6 per 100 people per year, 
with 38.2% of people experiencing a bone fracture in their lifetime [64]. Fractures can 
be divided into two categories, pathologic/fragility fractures and traumatic fractures. 
The former are fractures of diseased bone at a stress lower than that required to fracture 
a healthy bone, and are associated with conditions such as osteoporosis. Traumatic 
fractures are the result of excessive force on the bone due to events such as falls and 
vehicle accidents [16]. The treatment method for bone fractures is dependent on the 
severity of the break, and the options range from pain management to surgery. A bone 
graft may be necessary for the most complex fractures, facial and cranial 
reconstruction, and defects caused by bone cancer. There are estimated to be 2.2 
million bone grafts performed each year, making it the second most transplanted tissue 
after blood [65].  
Tissue engineering aims to improve on current medical treatments and therapies by 
imitating nature; creating, repairing and regenerating tissues and organs to restore the 
original function. In order to achieve this successfully, engineering principles are 
applied to the life sciences, drawing knowledge from a wide range of fields including 
physics, chemistry, engineering, biology, materials science and medicine [19], [66].  
Autologous bone grafts are considered the gold standard. Commonly sourced from the 
iliac crest, these grafts contain osteoblasts, osteoid, and factors such as bone 
morphogenetic proteins. This results in an osteogenic (causes bone formation because 
of the implantation of viable cells), osteoinductive (stimulates bone to form when 
implanted, typically inducing osteoblastic differentiation) and osteoconductive 
(composition, shape or surface topology promotes bone formation along its surface) 
graft which when implanted at the injury site, promotes a bone healing response [67]. 
Autografts are also relatively cheap when compared to commercial alternatives, there 
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are no concerns regarding disease transmission, and fusion rates are relatively high. 
However, there is limited tissue availability, donor site morbidity and pain, as well as 
multiple surgeries required for the procedure [68].  
Allografts are an alternative to autografts which use bone tissue from cadavers. Bone 
is readily available; however, there are concerns with disease transmission, immune 
rejection, and tissue compatibility. The success rate of these grafts is lower than 
autografts and although transmission of pathogens from donor to host is infrequent, it 
is possible [19], [68]. Between 1999 and June 2007 in the United States, improper 
donor evaluation was the most common reason for allograft recall (67.2%), followed 
by contamination (21.5%) and recipient infection (14.6%) [69].  
Xenogeneic grafts are bone harvested from one species and implanted into another. 
Tissue is readily available as with allografts and due to similar structures of 
hydroxyapatite between bovine and human mineral, they have a potentially better 
suitability for bone grafting than synthetic materials. As with allografts, processing 
procedures such as donor cell and antigen removal and the elimination of pathogens 
are essential. However, it is important not to damage the natural biological properties, 
such as mechanical strength and osteoinductivity [70]. In addition, strong immune 
responses preclude the use of most xenografts resulting in allografts being generally 
considered more effective [71]. For both allografts and xenogeneic grafts, sterilisation 
and freeze-drying techniques diminish osteoinductive and mechanical properties of 
the graft.  
Synthetic bone grafts or bone graft substitutes aim to achieve the osteoinductive, 
osteoconductive, biocompatible, bioresorbable nature of natural bone grafts whilst 
removing the possibility of immune rejection and pain associated with donor site 
morbidity. Ceramics, bioactive glasses, glass ionomers and hydroxyapatite derivatives 
are just a small selection of materials attempted for use as a bone graft substitute. 
Bioactive glasses are osteoinductive, and it is this biological activity that encourages 
their use as bone graft substitutes [72]. Bioactive glasses can also be combined with 
polymers, such as poly(lactic-co-glycolic acid) (PLGA), to improve its 
osteoinductivity and mechanical properties. The resulting composite can be used for 
bone tissue engineering as the superior mechanical properties make it more suitable 
for load-bearing applications [73]. Depending on the type of bioactive glass used, the 
resulting composite material can either promote or inhibit osteoblast and osteoclast 
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activity in vitro [74], [75], and are capable of inducing ectopic bone formation in vivo 
as a demonstration of their osteoinductivity [76].  
However, synthetic bone graft substitutes are yet to be as successful as natural bone 
grafts due to poor wear properties and brittleness limiting their use in locations with 
considerable shear stress, torsion or bending [77], [78]. As a result they are usually 
provided as granules [79], [80]. Synthetic substitutes also have minimal biological 
activity, acting as defect fillers with osteoconductive properties that promote 
osseointegration. To improve biological activity synthetic grafts may be incorporated 
with auto- or allografts, creating a composite. Ideally, synthetic grafts would have the 
ability to act as a delivery system for factors that regulate bone remodelling at the 
defect site, resulting in a graft with a controlled resorption and delivery rate that has 
sufficient mechanical properties to act as a framework for bone formation [71], [81]. 
Bone tissue engineering is an emerging field that is a promising alternative to bone 
grafting as it could overcome the associated limitations. The general principle is to 
obtain cells from the patient, expand them in culture, seed them onto a scaffold, and 
implant the scaffold back into the patient where it will resorb over time [82]. These 
scaffolds are biodegradable, and provide physical and chemical cues that direct cell 
differentiation, adhesion, and growth, forming three-dimensional (3D) tissues [83]. 
Despite tissue engineering and regenerative medicine being hailed as the future of 
medicine, with the exception of the medical device and implant industry, it is yet to 
fulfil expectations [66]. Whilst there are products in the market, they are mainly skin 
substitutes and tissue engineering remains a fledgling industry. This is due to the 
technical challenges of creating effective “off the shelf” products that contain cells, 
but which also have an appropriate shelf life and can still treat millions of different 
individuals. The properties and mechanisms of the scaffolds also need to be improved, 
such as preserving mechanical strength whilst retaining adequate porosity for 
sufficient and timely vascularisation of scaffolds after implantation [84], and in vitro 
experiments need to retain their efficacy when scaled up to clinical applications [85].   
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2.2 Osteoporosis  
2.2.1 Prevalence and clinical consequence 
Osteoporosis is a systemic disease which affects bone, reducing its strength through a 
reduction in mass and deterioration of the microarchitecture. This results in an increase 
in fragility and an increased susceptibility to fracture [86]. The World Health 
Organisation state that the deterioration of bone mass and quality is classed as 
osteoporosis when the bone mineral density (BMD) is 2.5 standard deviations below 
the mean for young normal healthy adults (T score of -2.5). However, how to utilise 
this criterion properly is unclear when diagnosing individuals of different gender, 
ethnicity and age [2]. Osteoporosis refers to a group of conditions, rather than a 
specific, single entity. It is traditionally classified as primary or secondary, with 
primary type being subdivided into two further categories. Primary type I is the most 
common form of the disorder and is often referred to as postmenopausal osteoporosis. 
This disorder is common within the postmenopausal demographic as decline in 
oestrogen levels as a result of menopause is an important factor in the pathogenesis. 
Primary type II osteoporosis, also known as senile or age-related osteoporosis, is 
associated with both men and women and the onset is associated with ageing. Finally, 
secondary osteoporosis refers to when the disorder is present as a consequence of an 
adverse response to a medication, change in physical activity, or another medical 
condition. Common examples of this iatrogenic condition include glucocorticoid- and 
immobilisation-induced osteoporosis [63].  
There are an estimated three million people in the United Kingdom with osteoporosis, 
and approximately three hundred thousand fragility fractures per year [1]. Currently, 
fifty percent of women and twenty percent of men over the age of fifty will have a 
fragility fracture, with the health and social care costs for treating hip fractures alone 
currently exceeding £2.3 billion per year in the United Kingdom. However, the 
demographics of western countries are changing with an increasing proportion of the 
population exceeding fifty years of age, thus further increasing the incidence and cost 
each year [87].  
Hip fractures are often considered the most devastating, accounting for around one in 
five osteoporotic fractures and 20% of these cases resulting in fatality within the first 
year [1]. However, the adverse effects of vertebral fractures due to osteoporosis can 
often be underestimated and underdiagnosed. They are an often-neglected 
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consequence of the disorder that can result in substantial pain and disability and 
increased mortality risk. They are also are an indicator of future fracture risk [88]. 
Multiple thoracic fractures and lumbar fractures can result in restrictive lung disease 
and changes in the abdominal anatomy, respectively. The latter can lead to pain, a 
reduction in appetite and the patient feeling sated prematurely [89]. Wrist fractures are 
also common in osteoporotic patients; however, relevant data is sparser than for the 
previous types, perhaps due to the mortality rate being similar to that of the general 
population [90]. As a consequence of osteoporotic fracture, there may also be 
psychological effects on the patient due to the pain, disability and changes in 
appearance, resulting in depression, reduced self-esteem and anxiety [91]. 
2.2.2 Aetiology, pathogenesis and risk factors 
Bone strength is dependent on two key factors: density and quality. Skeletal fragility 
can be a result of improper development during growth resulting in sub-optimal mass 
and strength, excessive resorption which decreases mass and deteriorates the 
microarchitecture, and/or insufficient formation in response to resorption [86]. 
Osteoporosis is diagnosed when the BMD falls below a certain threshold. However, 
this may not be the optimum diagnostic criterion as it does not take bone quality into 
account. The geometry, microarchitecture and material properties all affect the 
strength of bone and its susceptibility to fracture. In postmenopausal osteoporosis, 
abnormalities in bone remodelling affect all these properties. If a diagnostic approach 
integrated all of these and was combined with bone turnover markers, it may be 
superior and able to evaluate more accurately bone strength and fracture risk than 
BMD alone [89]. In healthy tissue, bone turnover is balanced with complimentary 
amounts of osteoclastic resorption and osteoblastic formation. Postmenopause, the 
rate of bone turnover increases and remains elevated, resulting in progressive bone 
loss in both cortical and cancellous bone that deteriorates the bone strength (Fig. 2.12). 
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Figure 2.12: Vertebral cancellous bone of a (A) 21-year old male and (B) 65-year old 
female. Adapted from Ritchie, et al., and reprinted with the kind permission of 
Dr. James Weaver, Wyss Institute, Harvard University [92]. 
The pathogenesis of primary type I osteoporosis is predominantly due to the decline 
in oestrogen caused by cessation of ovarian function. This hypothesis was first 
proposed in the 1940s when it was demonstrated that postmenopausal women have a 
negative calcium balance [63]. Although initially believed that the deficiency resulted 
in insufficient formation, later work showed that it is increased resorption that impairs 
bone quality [93]. Although both aspects of bone turnover are increased 
postmenopause, resorption exceeds formation causing a negative bone balance [94]. 
Once identified as playing a central role in the pathogenesis of the disorder, 
investigations into the mechanisms by which this occurs have been investigated in 
order to better understand the disease and develop new therapies (Fig. 2.13).  
Studies in the 1980s found that osteoclastogenesis is regulated by several cytokines 
such as interleukin (IL)-1 and IL-6, tumour necrosis factor (TNF), and M-CSF. IL-1 
and TNF are powerful stimulants of bone resorption and inhibitors of formation. They 
enhance osteoclast formation by stimulating the proliferation of precursors and can 
also induce other cytokines, such as IL-6, which regulate precursor differentiation into 
mature osteoclasts [95]. Oestrogen inhibits these cytokines, indicating it may perform 
a protective role by modulating their production.  
The discovery of the interaction of RANK/RANKL/OPG in the 1990s was a 
significant milestone in understanding the pathogenesis of postmenopausal 
osteoporosis, as well as other bone metabolic disorders [63]. RANKL binds to its 
receptor, RANK, but OPG can compete with RANK for binding to RANKL, 
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antagonising its function. The interactions between these three regulate osteoclast 
formation and function [96]. During normal bone remodelling, cells from the 
osteoblast lineage, such as osteoblasts and osteoprogenitors, express M-CSF and 
RANKL which conjugate with their respective receptors on osteoclast precursors, c-
fms and RANK, stimulating osteoclast formation. Oestrogen stimulates the expression 
of OPG which reduces formation; therefore, deficiency results in increased 
osteoclastogenesis [97]. Additionally, the expression of RANKL is elevated 
postmenopause, demonstrating the role of this system in osteoporosis pathogenesis 
[98]. Oestrogen has also been shown to modulate osteoclast life span by promoting 
apoptosis, further indicating its preventative role against osteoporosis [99].  
 
Figure 2.13: The central role of oestrogen in postmenopausal osteoporosis. Dates 
indicate when effects were discovered. Reprinted from Feng and Macdonald under the 
Creative Commons Attribution Licence [63]. 
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The likelihood of developing postmenopausal osteoporosis is dependent on a large 
number of risk factors, including clinical, medical, behavioural, nutritional and genetic 
variables. The major determinant is the peak bone mass which typically occurs during 
the third decade of life, with the majority of bone mass attained during adolescence. 
After the cessation of ovarian function, the rate of bone turnover increases and remains 
elevated causing BMD to continually decline. Therefore, ageing itself is a risk factor 
for bone loss and osteoporosis [89].  
Postmenopausal women with low body weight, percentage body fat, or body mass 
index (BMI) are also at an increased risk of osteoporosis due to the positive correlation 
between body mass and bone size [100]. Medical risk factors are therapies or disorders 
that would cause secondary osteoporosis, the most commonly implicated of which is 
glucocorticoids. Postmenopausal women who have low BMD that are not yet at the 
threshold for being classed as osteoporotic will achieve this sooner when taking 
glucocorticoids than those who are not. Several behaviours, including smoking [101] 
and a low level of physical activity [102], have been correlated with increased bone 
loss. With regards to nutrition, dietary calcium is correlated with BMD in women with 
low BMI, and in the elderly vitamin D deficiency increases bone turnover resulting in 
bone loss, as well as adversely affecting mineralisation, reducing bone strength and 
elevating fracture risk [102], [103]. 
Genetic risk factors for osteoporosis have also been identified. Race is a determinant 
of BMD, with white and Asian women at the highest risk of fracture above the age of 
50 [89]. From studies involving twins and families, the heritability of BMD is 
estimated to be between 50 and 85% [104].  In exceptionally rare circumstances, 
osteoporosis can be inherited in a Mendelian manner. For example, osteoporosis can 
be caused by the inactivation of the oestrogen receptor α gene [105]. More commonly, 
multiple genes each constituting a modest effect on BMD cumulatively account for 
the individual’s genetic risk factor.  These include genes coding for vitamin D 
receptors and type I collagen [104] 
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2.2.3 Diagnosis and current treatments 
A diagnosis of osteoporosis is typically given by assessing the BMD using a 
radiological approach. The gold standard for this is dual-energy X-ray absorptiometry 
(DXA) as quantitative measurements of BMD can be derived quickly and relatively 
cheaply from all locations within the body with radiation levels 90% lower than a 
standard chest X-ray [89]. However, surrounding soft tissues can introduce 
measurement errors, it cannot distinguish between cortical and cancellous bone so an 
‘integral’ BMD is given, and variations in bone size affect measurements as density is 
expressed as areal BMD (g/cm2) [106]. DXA studies are usually reported as T scores. 
Quantitative computed tomography (QCT) is an alternative to DXA which can also be 
used to measure BMD. It can only be used on the lumbar spine or peripheral locations 
and involves relatively high doses of X-ray (2,000 µSV versus 5 µSV for DXA for 
scans of two vertebrae). However, it can differentiate between cortical and cancellous 
bone, is less prone to errors from soft tissue, and can measure volumetric BMD 
(mg/cm3). 3D volumetric images can also be used to evaluate changes in bone 
geometry [107]. Whilst these two radiological techniques are excellent at determining 
BMD for diagnosing osteoporosis, their use when determining fracture risk is limited 
as it does not take bone quality into account, a key determinant of bone strength. In 
fact, approximately 50% of osteoporotic fractures occur in patients with a BMD above 
defined thresholds [108].  
Biochemical markers of bone formation, such as alkaline phosphatase and osteocalcin, 
and bone resorption, such as hydroxyproline from collagen degradation and tartrate-
resistant acid phosphatase, are measured in research and clinical trials of new therapies 
as a method of determining efficacy. Whilst they will never be a replacement for 
radiological evaluation of BMD, they could potentially be used as a predictor of future 
fracture risk and monitor drug efficacy in patients [89], [109].  
The National Osteoporosis Foundation guidelines for clinicians recommend that all 
women greater than 65 years of age have their BMD measured and postmenopausal 
women between 50 and 69 if their risk factor profile raises concern. Once patients are 
being treated for osteoporosis, their BMD should be reassessed every 2 years [110]. 
Non-pharmacological approaches to treatment are typically behavioural, for instance 
smoking cessation and limiting alcohol and caffeine intake, as well as physical 
exercise and nutritional advice to ensure adequate vitamin D and calcium intake [111].  
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Bisphosphonates are typically the first-line therapy when a patient is diagnosed with 
osteoporosis as they have been shown to reduce bone turnover; increasing BMD and 
lowering fracture risk in postmenopausal women. However, orally administered 
bisphosphonates have gastrointestinal side effects including dyspepsia and abdominal 
pain, and intravenous bisphosphonates can result in influenza-like side effects. These 
can result in a lack of patient compliance and persistence with the therapy [3]. With 
oral bisphosphonates, such as sodium alendronate or sodium risedronate, doses are 
limited by the gastrointestinal side effects due to the low bioavailability of the drug, 
whereas intravenous alternatives, such as zoledronate, have increased potency which 
reduces bone turnover for longer and do not have to be administered as often. 
However, these are generally more expensive than oral alternatives (Table 2.1). 
Hormone replacement therapy (HRT) has been shown to reduce the risk of hip and 
vertebral  in patients with osteoporosis as well as reducing menopausal symptoms such 
as reduced libido, vaginal dryness and hot flushes [112]. However, oestrogen based 
HRT has been associated with an increased risk of stroke, and oestrogen-progesterone 
based HRT with breast cancer and heart disease [4]. From this, many organisations 
recommend HRT is only used at the minimum effective dose after in-depth discussion 
with the patients so they can consider carefully the risk to benefit ratio [113].  
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Table 2.1: Various treatments for osteoporosis available on the NHS and their 
approximate annual cost per patient [114]. 
Drug Type Approximate annual 
cost to the NHS 
Generic sodium 
alendronate 
Oral bisphosphonate £14 
Fosamax® - branded 
sodium alendronate 
Oral bisphosphonate £296 
Generic sodium 
risedronate 
Oral bisphosphonate £220 
Zometa® or Aclasta® - 
branded Zoledronate 
Intravenous 
bisphosphonates 
£174 / £253 
Protelos®  Strontium ranelate £330 
Prolia® - Denosumab Denosumab £366 
Evista® Raloxifene £220 
Forteo® Teriparatide £3,540 
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Strontium ranelate has been shown to reduce bone resorption and increase formation 
as well as reducing vertebral, non-vertebral, and hip fracture risk over a period of five 
years when compared to a placebo [115]. A periodic safety update report on the drug 
produced by the European Medicines Agency in November 2012 showed that patients 
treated with strontium ranelate are at increased cardiovascular risk, and therefore it 
should not be prescribed to patients with a history of cardiovascular disease [116] 
[117]. In February 2014, they recommended further restricting the use of the medicine 
to patients who cannot be treated by any other approved drug, and those who do 
continue should be regularly monitored for heart and circulatory problems [118]. 
Denosumab is a human monoclonal antibody that inhibits RANKL. It is administered 
via a subcutaneous injection of either 60 mg twice or 30 mg four times per year. Over 
a 36 month trial it has been shown to reduce the risk of vertebral, non-vertebral and 
hip fracture [119]. Romosozumab is another monoclonal antibody-based treatment 
that is currently undergoing clinical trials for treating osteoporosis. Rather than 
targeting RANKL, it binds to sclerostin, a protein released by osteocytes that inhibits 
bone formation. The phase 2 clinical trial found that a one year treatment with 
Romosozumab administered by monthly subcutaneous injection significantly 
increased BMD and lowered markers of bone turnover and the risk of vertebral 
fracture [120].     
Raloxifene, a selective oestrogen receptor modulator (SERM), inhibits bone 
resorption but does not stimulate the uterine endometrium. It has been approved for 
use in the prevention and treatment of postmenopausal osteoporosis and has been 
shown to increase BMD in the spine and femoral neck, reducing vertebral fracture risk 
by 30 – 50% in comparison to a placebo, but has not been demonstrated to significantly 
lower fracture risk at other anatomical locations. Bazedoxifene, another SERM, was 
also shown to reduce vertebral fracture risk, as well as fracture incidence at other 
anatomical sites in women characterised as having higher fracture risk [113], [121]. 
The most common adverse reactions of SERMs are vasomotor effects such as hot 
flushes and leg cramps. However, as with HRT, patients are also at a heightened risk 
of venous thromboembolism [122]. These side effects combined with limited clinical 
data on its effect on fracture risk render SERMs a second line approach to osteoporosis 
treatment.  
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Teriparatide (human recombinant parathyroid hormone 1-34) is an anabolic analogue 
of PTH administered via a once daily subcutaneous injection. Unlike antiresorptives, 
this biologic increases formation and resorption; however, in doing so changes the 
bone balance of the BMUs to positive, resulting in increased BMD [123]. Bone quality 
also improves, with cortical thickening and increased cancellous bone connectivity 
[124]. It has been shown to increase BMD and reduce the risk of vertebral and non-
vertebral fractures by 65 - 69% and 35 – 40%, respectively [113]. Use of teriparatide 
is typically reserved for patients with severe osteoporosis, primarily due to the high 
cost and inconvenience of daily injections [125]. Treatment may increase the 
incidence of nausea, dizziness and leg cramps, but in comparison to other treatments, 
it has an acceptable side effect profile. Maximum treatment duration of two years is 
recommended due to limited evidence of treatment efficacy beyond this duration and 
long term toxicology concerns due to the development of osteosarcoma in rats [5]. 
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2.2.4 Animal models of osteoporosis 
Animal models provide a uniform approach to research with a level of experimental 
control that is not possible in humans. Compared to human trials, the cost is much 
lower and the time frame much shorter. Osteoporosis is a disorder with slow 
progression which means that human studies have a duration of several years, slowing 
data acquisition. Therefore, even if only a small representation of human function is 
made within an animal model, it can still be of use.  
Postmenopausal osteoporosis only occurs naturally in humans and some non-human 
primates. Therefore, to study this disorder in other animals, it has to be induced. This 
is typically done by ovariectomy (OVX), surgical removal of the ovaries to suppress 
oestrogen production in order to simulate the postmenopausal condition. Other 
methods or combinations of approaches can be used to induce osteoporosis, such as 
restricted diet, glucocorticoids, immobilisation and breeding, but this review will 
focus on the main OVX animal models that simulate postmenopausal 
osteopenic/osteoporotic bone [87].  
Animal models are essential to ongoing osteoporosis research, but this presents a 
paradox - how can we design a good animal model of a disorder we do not fully 
understand? [126].  Furthermore, osteoporosis is not a disease caused by a single 
factor; it is a description of the remaining bone after a multitude of factors has altered 
its metabolism. As a result, there is no single animal model that represents the entire 
condition. Instead, each is able to mimic a specific aspect. Therefore, selection of a 
suitable animal model presents a challenge. The key factors to be considered were 
rationally defined by Rogers, et al., who state that the model should be convenient, 
relevant to the human condition, and appropriate to the particular phenomenon you 
are investigating, with the limitations candidly stated [127].  
In vivo models of osteoporosis can be divided into two categories; small and large 
animal models. Typically, mice and rats are selected for small animal models whilst 
sheep or non-human primates are used for large animal studies. When introducing a 
new osteoporotic drug the FDA require preclinical evaluation that involves testing at 
clinical dose and five times clinical dose on a rat as well as a  validated, large animal 
model [6].  
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The rat animal model of postmenopausal osteoporosis is by far the most common. In 
contrast to large animal studies there is relatively minimal public opposition to its use, 
housing, handling and feeding costs are reduced and ethical implications are in 
general, lower [128]. OVX rats are frequently used when efficacy and toxicity of new 
potential therapies are beginning to be evaluated [129]. After surgery, bone balance 
initially becomes negative resulting in bone loss. However, bone turnover eventually 
becomes balanced again, meaning that the BMD stops decreasing and settles, albeit at 
a much lower level than pre-OVX. Significant loss of bone is seen after 14 days in the 
proximal tibial metaphysis, 30 days in the femoral neck, and 60 days in the lumbar 
vertebrae [130]–[133].  
Two types of rat are used, aged and mature. Aged rats have reached skeletal maturity 
(~12 months); therefore, skeletal changes post-OVX can be regarded as a response to 
oestrogen deficiency. Mature rats are simply those that have reached sexual maturity 
(~3 months) and therefore are capable of responding to oestrogen and its deficiency. 
However, skeletal changes due to aging are still taking place so changes seen post-
OVX  may not be attributed exclusively to reduced oestrogen [126]. With age, the 
mechanism by which bone turnover occurs in the rat skeleton changes. Bone turnover 
can occur by two mechanisms; remodelling and modelling. Bone remodelling is the 
coupled, both spatially and temporally, action of formation and resorption by BMUs. 
Bone modelling is independent, uncoupled formation and resorption of bone at a 
specific site that occurs separately over extended time periods [134]. As rats age they 
transition from modelling to remodelling, with the latter becoming the dominating 
mechanism at 12 months. Although aged rats have more of the ideal characteristics for 
an in vivo model, they are more expensive, availability is limited, and substantial bone 
loss post-OVX may not be seen for several months [129]. This is not the case for 
mature rats, which are cheaper, more readily available, and skeletal changes can be 
seen within weeks.  
A potential limitation of rat models is that they lack Haversian remodelling, a feature 
that is present in large animal models. In humans, osteons form the majority of the 
cortical porosity, but these units are not present with rat cortical bone. Despite this, 
performing OVX on adult rats still results in a condition similar to postmenopausal 
osteoporosis in humans, with an altered bone balance that leads to increased bone 
remodelling and bone loss at the endosteal surface and the trabeculae [135]. It is bone 
loss at these sites that is the hallmark of postmenopausal osteoporosis, rather than 
intracortical bone loss within the osteons [136].  
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Murine models of osteoporosis have the same size based limitations as rat models. 
Skeleton size does not scale linearly with body size and as a proportion of total body 
mass, a human skeleton is much larger than a mouse or rats. Furthermore, the 
proportion of trabecular bone mass in rodents is much smaller than in humans. Clearly, 
this makes these models incapable of being used for surgical or implant based studies 
for osteoporotic fracture. Despite this, mouse models are ideally suited to studying the 
genetic contribution to bone remodelling, allowing specific factors, proteins and 
pathways to be elucidated, an important tool in understanding metabolic bone 
disorders. However, just because a gene or factor can affect bone mass does not mean 
it is necessarily linked to osteoporosis.  
Whilst the value of genetically modified mouse models is clear, justification for the 
use of murine OVX models is not well established. Post-OVX, trabecular bone is lost 
and this effect can be mitigated with oestrogen replacement in the form of 17β-
estradiol [137]. However, whilst bone turnover is affected by OVX, the effects are 
highly strain dependent, and are much less consistent than in rats [136]. This, in 
combination with the small amount of trabecular bone available making accurate 
analysis of changes in bone volume extremely challenging, results in the use of murine 
OVX models being less reliable than rat models. 
Many large animals have been used for OVX models of osteoporosis, including dogs, 
cats, sheep, monkeys and apes. Public opposition to the use of dogs and cats is high as 
they are seen as companion animals. Despite dogs having extensive BMU based 
remodelling, they are of limited use when studying postmenopausal osteoporosis due 
to an apparent skeletal resistance to oestrogen deficiency. They only ovulate twice 
annually and therefore have very low oestrogen levels for most of the year; however, 
increased skeletal fragility is not seen. Similarly, many owners have their cat’s ovaries 
removed to prevent unwanted breeding, yet as with dogs, fragility fractures are rare. 
Therefore, cats and dogs are of more use when studying secondary osteoporosis [6]. 
Ovine animal models are well established in orthopaedic research. They are docile, 
compliant, relatively cheap in terms of acquisition and maintenance, and society has 
low opposition to their use as they are seen as food animals, reducing the emotional 
attachment in comparison to cats and dogs. In addition to this, sheep have similar bone 
architecture to humans. Both have cortical and trabecular bone, Haversian systems, 
and remodelling is performed by BMUs. However, sheep have higher BMD and 
mineral content than humans which increases the mechanical stability of their bones, 
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meaning that fragility fractures post-OVX are rare. They also have a variable oestrus 
cycle and a much lower oestrogen peak, meaning that OVX has a reduced effect on 
bone mass and structure in comparison to humans [138]. It is also worth noting that 
the biomechanical loads experienced by quadrupeds are clearly different to those 
experienced by bipeds, especially in the spine where humans have an inward curvature 
(lordotic) whereas sheep have an outward curvature (kyphotic) [139].  
Post-OVX, BMD is reduced three months after surgery in sheep [140], [141]. 
However, this bone loss is not always sustainable, with several groups reporting bone 
turnover and BMD stabilising then returning to pre-OVX levels due to bone formation 
also increasing [140], [142]–[144]. Other groups still detected significant changes in 
BMD and structure up to 24 months after OVX [145], [146]. Therefore, ovine bone 
metabolism seems similar to human and OVX results in rapid bone loss for three 
months, although this reduction may eventually be restored by increased formation. 
Conflicts in these results may be due to variations in BMD with the seasons. Humans 
have lower bone mass in winter than in summer, and bone turnover in sheep also 
changes throughout the year [147]. 
Unsurprisingly, non-human primates have been used extensively to create in vivo 
models of osteoporosis. Their gastrointestinal and endocrine systems closely resemble 
humans, with macaques and baboons having a 28-day and 33-day menstrual cycle, 
respectively, and both having similar oestrogen and progesterone patterns. There is 
also Haversian-based osteon remodelling, age-related bone loss, and natural 
menopause in some species [148]. Furthermore, they have similar physiological 
loading due to their upright posture and comparable immune systems, all of which 
combine to make them the most relevant model of human physiology [128]. 
Although primates undergo natural menopause, acquisition of aged animals is 
prohibitively expensive. Therefore, OVX is often performed on skeletally immature 
animals [6]. Non-human primate OVX models have been performed since 1986 and 
have become established as the best characterised large animal model in osteoporosis 
research [149]. Multiple primate species have been used in osteoporosis research, 
including cynomolgus, rhesus, baboon, and African green monkeys, with cynomalgus 
being the most common due to its availability, smaller size, lower relative cost, and 
extensive characterisation [150]. In ovariectomised cynomalgus, bone turnover is 
increased and rapid bone loss ensues, stabilising 8-9 months later [151].  
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Primate models have been used extensively to test therapies such as bisphosphonates 
and parathyroid hormone (PTH) in order to assess efficacy and safety, as well as their 
treatment mechanism [152], [153]. However, there are very few laboratories 
worldwide that can legally perform these studies and the associated costs are 
tremendous. Primates for research are often wild-caught and can be aggressive, which 
increases the risk of zoonotic disease transmission to humans [154]. Public opposition 
to their use is extreme; therefore, they are not standard animal models and are of most 
use during final preclinical testing before human trials, after investigations on other 
large animals have been performed.  
Animal models are viewed as the gold standard for testing the safety and efficacy of 
new therapies and are an essential part of the preclinical development of new 
medicines. However, their use should align with the principles of the ‘3Rs’ – 
replacing, reducing and refining, in order to conduct humane animal research [7]. No 
animal model is the perfect representation of postmenopausal osteoporosis and all 
have clear advantages and limitations. Therefore, it is realistic that some of the work 
currently performed in vivo could be replicated in vitro, reducing the number of 
animals required as well as the cost of drug development. Indeed, this directive is part 
of the impetus behind this research project; if aspects of animal models can be 
replicated or even improved in vitro, then this should be pursued.  
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2.3 Bone remodelling in vitro 
2.3.1 The need for in vitro models 
In 2015, 2.08 million experimental procedures were performed on animals in the 
United Kingdom. 1.1 million were for basic research purposes, with 25,381 of these 
within the field of musculoskeletal research. 89% of these studies were conducted on 
mice and rats [155]. The popularity of rodent models for bone disorders arises from a 
relatively minimal public opposition to their use, as well as low cost and ease of 
housing in comparison to other, larger animal alternatives [128]. Furthermore, their 
size makes them amenable to non-invasive, high resolution in vivo imaging techniques 
such as x-ray micro-computed tomography (MicroCT) [156], [157] and the 
application of mechanical loading in vivo [158]. However, despite becoming a 
fundamental component of pre-clinical research, animal physiology does not 
accurately represent the human condition, with many aspects of human anatomy not 
well represented in a rodent model. This is demonstrated by the poor translation of 
pre-clinical efficacy in animal models to human clinical trials and the vast majority of 
promising discoveries failing to enter routine clinical use [159]–[162]. 
Although in vivo models are viewed as the gold standard for studying diseases and 
testing new therapies, their use should align with the philosophy of the 3Rs [7].  The 
limitations of in vivo models gives rise to the development of in vitro alternatives. 
However, the clinical relevance of these systems should be interpreted with caution as 
they lack the complexity of in vivo physiology. Despite this, if aspects of preclinical 
testing can be replicated or improved upon in vitro before proceeding to in vivo then 
the use of some animals can be reduced.  
Reviews of in vitro models of bone diseases such as osteoarthritis have been performed 
previously [163]; however, to the author’s knowledge, no such summary of in vitro 
models of  bone remodelling has been completed. To perform this review, a search in 
PubMed for “in vitro AND osteoblast AND osteoclast AND (co-culture OR co 
culture) AND remodelling”, limiting results to relevant original research articles 
written in English (last updated: 17/07/2017). The resulting papers were divided into 
three categories: remodelling fundamentals; which explore bone cell signalling, 
differentiation and matrix formation/degradation to elucidate key pathways in bone 
remodelling, remodelling models; which attempt to mimic the process in vitro as a 
tool for understanding physiology or drug/material testing, and disease-orientated 
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models; which introduce additional cells or factors (e.g. cancer cells or inflammatory 
molecules) to the osteoblast-osteoclast co-culture to investigate their effects on bone 
remodelling.  
In cell culture, co-cultures of different cell types can be performed either indirectly or 
directly. Indirect methods include conditioned media and the use of transwell inserts. 
The former takes media from one cell type and adds it to another, whereas the latter 
uses a permeable insert to provide two culture surfaces in the same well, allowing 
exchange of soluble factors but no cell-cell contact between the two types. Direct 
methods co-culture both cell types on the same surface, be it a planar, two-dimensional 
(2D) tissue culture well or a three-dimensional scaffold (Fig. 2.14). Common 
osteoclastic and osteoblastic cell types featured in the following review are 
summarised in tables 2.2 and 2.3, respectively, and proteins, genes and molecules 
referred to throughout this review are summarised in table 2.4. 
 
 
Figure 2.14: Different methods of co-culturing cells. Conditioned media transfers 
media used in one culture to another. Well inserts culture cells in the same well but 
only soluble factors can exchange between cell types. Direct co-cultures can be 
performed in 2D or 3D and permit membrane bound and soluble factors to exert 
influence. 
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Table 2.2: Common osteoclastic lineage cell types used in vitro. 
Name Abbreviation Description 
Human 
Peripheral 
Blood 
Monocyte 
hPBMC Mononuclear cells isolated from peripheral blood. 
Typically via density gradient centrifugation and 
negative selection using magnetic-activated cell 
sorting. Purity can be confirmed by flow cytometry 
using antibodies against CD14 and CD45 [164], 
[165] 
RAW264.7 
(ATCC® 
TIB-71™) 
RAW264.7 Murine leukemic monocyte macrophage cell line 
that can undergo osteoclastic differentiation by 
RANKL exposure. A key advantage over other 
precursors is that they do not require co-stimulation 
with M-CSF [166], [167] 
THP-1 THP-1 Human monocytic cell line derived from the blood 
of a boy with acute monocytic leukaemia [168] 
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Table 2.3: Common osteoblastic lineage cell types used in vitro. 
Name Abbreviation Description 
Primary Human 
Osteoblast 
hOB Osteoblast-like cells typically extracted 
from human trabecular bone fragments 
[169], [170] 
Primary Murine 
Osteoblast 
mOB Osteoblast-like cells typically extracted 
from murine calvaria [171], [172] 
SaOS-2 SaOS-2 Human osteosarcoma cell line reported 
to be derived from the primary 
osteosarcoma of an 11-year-old 
Caucasian female [173] 
MG-63 MG-63 Human osteosarcoma cell line derived 
from the osteosarcoma of a 14-year 
Caucasian old boy [174] 
Immortalised 
osteoblast precursors 
from human bone 
marrow stroma  
hMS(2-15) Osteoblast precursor cell line developed 
from human bone marrow stromal 
fraction [175] 
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ST-2 ST-2 Clone of murine stromal cells isolated 
from BC8 mice that develop an 
osteoblastic phenotype when cultured 
with ascorbic acid [176] 
MC3T3-E1 MC3T3-E1 Spontaneously immortalised clonal 
osteoblast precursor cell line generated 
using the 3T3 passaging protocol from 
the calvaria of newborn C57BL/6 mice 
by Kodama, et al. [177] 
Human periodontal 
ligament cells 
(between alveolar 
bone and the tooth 
root) 
PDL Osteoprogenitor cells of periodontal 
ligament connective tissue [178], [179]. 
MLO-Y4 MLO-Y4 Osteocyte cell line cloned from cells 
isolated from murine long bones [180] 
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Table 2.4: Common factors analysed during in vitro bone cultures. 
Name Abbreviation Description 
Receptor activator of 
nuclear factor κβ 
RANK Receptor for RANKL expressed on 
osteoclast-lineage cells [181] 
Receptor activator of 
nuclear factor κβ 
ligand 
RANKL Member of TNF cytokine family. 
Ligand for RANK receptor 
predominantly produced by osteoblast-
lineage cells, but also by stromal and T 
cells [181] 
Osteoprotegerin OPG Decoy receptor that prevents RANK 
activation by binding with RANKL 
[181] 
Macrophage colony 
stimulating factor 
M-CSF Cytokine that influences differentiation 
and survival of haematopoietic 
precursors, produced by osteoblasts and 
stromal cells [47] 
Alkaline phosphatase ALP Enzyme secreted from osteoblasts which 
promotes hydroxyapatite crystal 
formation within the bone matrix. 
Considered a highly specific marker of 
bone-forming osteoblasts [23] 
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Collagen type 1 alpha 
1 
COL-1α1 Protein that constitutes ~90% of the 
organic phase of bone [17] 
Runt-related 
transcription factor 2 
RUNX2 Key transcription factor associated with 
osteoblast differentiation [182] 
Osterix OSX Transcription factor also known as Sp7 
required for bone formation, works 
downstream of RUNX2 [183] 
Osteopontin OPN OPN is an extracellular matrix 
glycoprotein. During remodelling, it 
anchors osteoclasts to the bone matrix 
[184]    
Integrin binding 
sialoprotein/Bone 
sialoprotein-2 
IBSP/BSP-II Human variant of BSP, significant 
component of bone extracellular matrix 
[185] 
Tartrate-resistant acid 
phosphatase 
TRAP Enzyme secreted by osteoclasts. 
Activity strongly correlates with bone 
resorption and TRAP knockout mice 
develop osteopetrosis [186] 
Cathepsin K Cathepsin K Osteoclastic protease that catabolises 
bone by breaking down elastin, collagen 
and gelatine [187] 
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Matrix 
metalloproteinase-9 
MMP-9 Osteoclastic enzyme that degrades 
extracellular matrix components such as 
collagen, fibronectin and laminin [188] 
Osteoclast associated 
receptor 
Oscar An IgG-like receptor that is an 
important osteoimmunological mediator 
and acts as a co-stimulatory  receptor for 
osteoclast differentiation [189] 
Tumour necrosis factor 
alpha   
TNF-α A pro-inflammatory cytokine that can 
upregulate RANKL production and 
directly stimulate osteoclast precursor 
differentiation [190], [191] 
Parathyroid hormone PTH A hormone that can indirectly stimulate 
osteoclastogenesis by action on 
osteoblasts. Depending on concentration 
and frequency of application, it can have 
a catabolic or anabolic effect [192] 
1α,25(OH)2D3 Vitamin D3 1α,25-dihydroxyvitamin D3 is the active 
form of vitamin D3. It has been shown 
to stimulate RANKL expression in 
osteoblasts and osteocytes  [193]–[195]. 
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2.3.2 Remodelling fundamentals 
It was discovered in the 1980s that osteoblasts were producing factors that stimulate 
osteoclastic resorption, and in vitro conditioned media experiments were essential in 
their elucidation. For example, in the discovery of interleukin-6 and M-CSF, as well 
as the RANKL/RANK/OPG axis that mediates osteoclast formation and function [63], 
[95], [196]–[199], and that M-CSF and RANKL can be produced as either membrane 
bound (mM-CSF/mRANKL) and/or secreted, soluble forms (sM-CSF/sRANKL).  
One of the first events in bone remodelling is an increase in osteoclastic resorption. 
One way osteoclasts can form is by the adhesion of osteoclast precursors to osteoblasts 
or bone marrow stromal cells. To investigate this mechanism in vitro, Tanaka, et al., 
investigated how the expression of intercellular adhesion molecule (ICAM)-1 
mediates this process. They found that hOBs could easily be identified as ICAM-1 
positive or negative, and that hPBMCs in co-culture tightly adhered to the ICAM-1+ 
cells even in the presence of anti-RANKL monoclonal antibodies, indicating that 
mRANKL alone is not sufficient for a high affinity adhesion. Furthermore, ICAM-1+ 
osteoblasts highly expressed RANKL and stimulated the formation of TRAP positive, 
multinucleated osteoclasts, indicating that it is this subgroup that is predominantly 
involved in osteoclastogenesis [169]. 
The production of sM-CSF  can be upregulated in osteoblasts by the presence of TNF-
α and PTH [200], [201]. Yao, et al., found that upregulation of mM-CSF is also seen 
in the presence of PTH and TNF-α in SaOS-2 and MG-63, respectively; however, in 
hOB cultures, only TNF-α resulted in an increased expression with PTH having no 
significant effect. Furthermore, they found that mM-CSF alone is sufficient to induce 
osteoclast formation, as NIH3T3 murine fibroblasts transfected to produce only mM-
CSF co-cultured with murine bone marrow cells consistently formed osteoclasts [202]. 
However, this is inconsistent with majority of the literature concerning the role of M-
CSF, where the consensus is that its role is in the proliferation and survival of 
osteoclast precursors. In an attempt to define the biological role played by mM-CSF, 
Yao, et al., generated mM-CSF knockout (KO) mice, which have increased bone 
mineral density (BMD) in vivo. The formation of osteoclasts when KO osteoblasts 
were co-cultured with wild type (WT) osteoclasts was reduced in comparison to WT 
osteoblasts, indicating that the increased BMD was due to reduced resorption [203].  
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The urokinase/urokinase receptor (uPAR) axis is most commonly activated in 
response to inflammatory, tissue remodelling, or cancerous diseases in order to 
regulate extracellular proteolytic cascades and activate intracellular signalling 
pathways [204]. Anaraki, et al., investigated whether this system was also involved in 
the regulation of osteoblast-osteoclast communication and osteoclastogenesis. 
Lentivirus-based silencing of uPAR in human mesenchymal stem cells (hMSCs) 
significantly reduced the expression of M-CSF mRNA and both mM-CSF and sM-
CSF protein production. However, it did not affect RANKL expression. Conditioned 
media from uPAR silenced hMSCs and co-cultures of hMSC with hPBMCs using well 
inserts generated significantly fewer TRAP positive osteoclasts resulting in less 
resorption, indicating reduced osteoclastogenic potential with uPAR loss in 
osteoblasts. Using the same silencing technology on monocultures of hPBMCs and 
THP-1, uPAR deficient osteoclast precursors generated fewer TRAP positive 
osteoclasts and reduced resorptive capability. Double-deficient co-cultures reduced 
osteoclastogenesis even further, confirming the dual action the uPAR receptor has on 
bone remodelling [165]. 
In addition to its effect on osteoblasts, TNF-α can also affect osteoclast precursors. 
When applied to rat bone marrow depleted of stromal cells it can induce the formation 
of TRAP positive mononuclear pre-osteoclasts and upregulate cathepsin K mRNA 
expression. Co-culture of these pre-osteoclasts with primary rat osteoblasts on dentine 
resulted in the formation of significantly more multinucleated osteoclasts and greater 
resorption with the application of TNF-α [205].  
Bone is a vascular tissue, and this blood supply is essential for bone development, 
remodelling and cell recruitment. In fact, human microvascular endothelial cells 
(HMVECs) express mRNA transcripts for RANKL and OPG. Collin-Osdoby, et al., 
found that unlike RANKL and OPG of osteoblast-origin, the production of these 
factors is not modulated by PTH and vitamin D3, but rather by inflammatory molecules 
such as TNF-α in a dose-dependent manner, and that RANKL expression steadily 
increases over time whereas OPG peaks and then declines. RANKL protein expression 
on HMVECs was found to be in the form of mRANKL. It was capable of forming 
bone resorbing osteoclasts from hPBMCs and its action could be halted by addition of 
OPG. Interestingly, sections of human osteoporotic bone had higher RANKL staining 
on HMVECs near areas when resorbing osteoclasts were active [206]. Osteoblastic 
and vascular endothelial cells are not the only types capable of influencing 
osteoclastogenesis. Adipocytes found within bone marrow cultured with 
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dexamethasone have increased RANKL expression compared to untreated controls, 
and when co-cultured in direct contact with osteoclast precursors, treated adipocytes 
significantly enhanced osteoclast formation. However, when the cell types were 
separated using a well insert, no osteoclastogenesis was observed indicating soluble 
isoforms of RANKL were not being synthesised [207]. 
Interleukin-1 (IL-1) is a pro-inflammatory cytokine that can act on a wide variety of 
tissues, and can regulate bone remodelling through action on both osteoblasts and 
osteoclasts by stimulating RANKL expression and inducing fusion of osteoclast 
precursors as well as enhancing osteoclast resorptive activity. IL-1 KO mice have 
increased bone mass and BMD in comparison to WT due to decreased resorption, and 
co-cultures of their IL-1 KO bone marrow cells with either WT or KO osteoblasts 
resulted in significantly decreased osteoclast formation in vitro. Interestingly, this 
decrease is seen despite high levels of RANKL in the WT osteoblast / KO osteoclast 
co-culture, and more efficient formation is seen in KO osteoblast / WT osteoclast co-
cultures which have low RANKL and high IL-1, indicating both IL-1 and RANKL are 
required for effective osteoclastogenesis [208].  
Immune system T cells are capable of producing a range of osteoclastogenic factors, 
such as TNF-α, IL-6, IL-7 and RANKL, as well as molecules that inhibit osteoclast 
formation, such as transforming growth factor-β (TGF-β), granulocyte macrophage-
colony stimulating factor (GM-CSF) and interferon-γ (IFN-γ). Co-cultures of SaOS 
and hPBMC generate TRAP positive multinuclear osteoclasts, but the addition of 
T cells completely inhibits their formation via GM-CSF and IFN-γ production. 
Addition of fixed T cells has no inhibitory effect, indicating that cytokines expressed 
by the T cells, not molecules on their surface, are necessary for this inhibition [209]. 
Although RANKL and OPG are produced by cells of the osteoblastic lineage, their 
expression varies depending on the progression of their differentiation from precursor 
to osteocyte. Culture of hMS(2-15) in osteogenic medium over 21 days sees an 
increase in ALP activity and mineralised matrix production over time. During this 
period, RANKL mRNA levels decrease and OPG mRNA levels increase in 
comparison to cultures in basal media, decreasing the RANKL:OPG ratio. 
Undifferentiated hMS(2-15) with a greater RANKL:OPG ratio are able to differentiate 
murine osteoclast precursors in to TRAP positive multinucleated osteoclasts in co-
culture, whilst differentiated cells could not without the further addition of exogenous 
sRANKL [210].  
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However, the ability to generate osteoclasts does not necessarily diminish as 
osteoblastic cells continue to differentiate. Osteoblasts that terminally differentiate 
into osteocytes and become embedded within the mineralised matrix of bone have the 
ability to modulate bone remodelling. MLO-Y4 can induce the formation and 
activation of osteoclasts capable of resorbing dentine in co-culture with murine spleen 
or marrow cells without the addition of any exogenous factors, although 
supplementation with vitamin D3 enhances their production. However, conditioned 
media from MLO-Y4 cannot generate osteoclasts, despite producing sM-CSF. This 
indicates that M-CSF alone cannot induce osteoclastogenesis, and that MLO-Y4 must 
stimulate osteoclast formation through the mRANKL detected on their surface and 
dendritic processes, meaning that direct cell contact is required [211]. It is thought that 
osteocytes inhibit bone resorption in areas of high mechanical loading by producing 
signalling molecules in response to changes in fluid flow that occur within the tissue 
[212]. Kulkarni, et al., applied pulsatile fluid flow (PFF) to MLO-Y4, finding that this 
decreased their ability to induce osteoclastogenesis in murine bone marrow cells by 
decreasing the RANKL:OPG ratio [213]. Kim, et al., also investigated the effect of 
fluid flow on RANKL and OPG expression by applying oscillating fluid flow (OFF) 
to co-cultures of ST-2 and RAW264.7. OFF decreased the RANKL:OPG ratio by 
decreasing RANKL and increasing OPG mRNA expression, resulting in decreased 
osteoclast formation in comparison to a static control [214]. Cells can also be 
stimulated via direct mechanical loading. Using a transwell co-culture system where 
RAW264.7 were cultured on a membrane above mechanically strained MC3T3-E1, 
Zhang, et al., found that loading of the osteoblasts resulted in higher ALP activity and 
lowered osteoclast activity, as demonstrated by a decline in TRAP activity, resorption, 
cathepsin K and MMP-9 expression, in comparison to static controls. This was due to 
a decreased RANKL:OPG ratio by increased OPG expression [215]. 
To investigate how osteocytes may regulate osteoclast activity, Gu, et al., cultured 
primary rat osteoclasts on rat calvarial slices that had been stripped of the periosteum 
and endosteum to leave predominantly osteocytes in the samples. These were either 
cultured to maintain living cells or devitalised using water and sonication or freeze-
thawing. Cultures on devitalised bone produced significantly more and deeper 
resorption pits in comparison to living bone, and conditioned media from living bone 
samples inhibited osteoclast resorption, indicating the live osteocytes were preventing 
resorption. Inducing osteocyte apoptosis via glucocorticoid application prior to 
osteoclast culture increased resorption in comparison to untreated calvaria [216]. The 
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alteration of this ratio over time may help co-ordinate the osteoblasts and osteoclasts 
during the remodelling cycle.  
There are a wide range of factors which can modulate the RANKL:OPG ratio and 
therefore osteoclastogenesis and bone remodelling. Retinoids are important for normal 
bone growth and development. Geranylgeranoic acid (GGA), a synthetic acyclic 
retinoid, can promote a positive bone balance through a dual action of stimulating 
osteoblast differentiation and inhibition of osteoclast formation, as demonstrated by 
Wang, et al., who found it suppressed MC3T3-E1 proliferation whilst increasing ALP 
activity, reduced osteoclast formation in co-cultures of murine bone marrow cells and 
osteoblasts, and upregulated OPG mRNA expression in ST-2 cells after it has been 
chemically suppressed. Furthermore, it inhibited osteoclast formation in sRANKL and 
sM-CSF treated bone marrow cultures, indicating it can act on both osteoblasts and 
osteoclasts [217].  
Hydrolysed collagens have also been shown to promote a positive bone balance in 
vitro, with 2 kDa hydrolysed collagen molecules increasing ALP activity and 
decreasing resorption in co-cultures of  mOBs and bone marrow cells [218]. Omentin-
1, an adipokine also known as intelectin-1, decreases the formation of TRAP positive, 
multinucleated osteoclasts in co-cultures of hOBs and hPBMCs as well as MC3T3-E1 
and RAW264.7 through stimulation of OPG and inhibition of RANKL protein 
expression [170]. Lactoferrin is a glycoprotein that has an anabolic effect on bone by 
promoting osteoblast proliferation and differentiation as well as decreasing osteoclast 
formation [219], [220]. By coupling it to hydroxyapatite nanocrystals, Montesi, et al., 
showed that these two compounds can work synergistically act as a bone anabolic by 
increasing OSX and IBSP mRNA expression in osteoblasts, reducing osteoclast 
formation, and downregulating Oscar and cathepsin K mRNA expression in co-
cultures of MC3T3-E1 and RAW264.7 [221]. 
Galectins are glycan-binding proteins that can link ECM components and cell-surface 
receptors. Vinik, et al., investigated how galectin-8 (GAL-8) can regulate RANKL 
production by co-culturing mOBs from calvaria with murine bone marrow cells and 
treating with GAL-8, finding that the protein stimulates a six-fold increase in RANKL 
mRNA expression and a 2.5-fold increase in sRANKL production whilst reducing 
OPG expression by 30%, resulting in a 15-fold increase in TRAP positive, 
multinucleated osteoclast generation. Furthermore, osteocytes extracted from the same 
calvaria treated with GAL-8 also had increased RANKL expression [172]. 
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Glycosaminoglycans (GAGs) are found in the extracellular matrix (ECM) of bone and 
have been used in biomaterial applications to stimulate osteogenesis. Salbach-Hirsch, 
et al., used GAGs and sulphated-GAGs (sGAGs) to create artificial ECMs for 
culturing RAW264.7 in the conditioned media of mOBs generated from MSCs. They 
found that sGAG matrices significantly increased ALP, osteocalcin and OPG 
expression as well as mineralized matrix deposition. However, supernatants could not 
induce osteoclast formation due to the absence of sRANKL and the high level of OPG. 
Addition of exogenous sRANKL permitted osteoclast formation, but the lowest levels 
of differentiation and resorption were seen in the sGAG groups due to the increased 
OPG production, indicating that GAGs can have an anabolic effect on bone through 
action on the osteoblasts [222]. 
Downstream of tyrosine kinase (DOK) 3 is an adapter protein that limits tyrosine 
kinase-mediated signalling downstream of cell surface receptors on osteoclasts [223]. 
Cai, et al., found that DOK3 KO mice are osteoporotic due to an increase in TRAP 
positive osteoclasts. In vitro, osteoclasts differentiated from KO bone marrow had 
increased sensitivity to RANKL resulting in increased osteoclastogenesis, larger 
osteoclasts with more nuclei, and increased resorptive capability. Osteoblasts derived 
from DOK3 KO mice produce less mineralised matrix and reduced expression of 
Runx2, OSX, COL-1α1 and ALP mRNA, as well as reduced RANKL and increased 
OPG expression in comparison to WT. In direct co-culture, WT osteoblasts induced 
the formation of more osteoclasts from KO precursors than WT precursors, and KO 
osteoblasts induced fewer osteoclasts from KO and WT precursors than WT 
osteoblasts. This indicates that DOK3 promotes osteoblastogenesis and impedes 
osteoclastogenesis [224]. 
Parathyroid hormone (PTH) plays a major role in calcium and phosphate homeostasis. 
Continuous production of PTH, for example in hyperthyroidism, has a catabolic effect 
on bone, whereas intermittent application can have an anabolic result by increasing 
formation in both cancellous and cortical regions. Intermittent PTH increases bone 
formation by promoting osteoblast differentiation through activation of Wnt signalling 
in osteoblasts, inhibiting sclerostin in osteocytes, and stimulating the mitogen-
activated protein kinase (MAPK) and phospholipase A and D pathways. This results 
in activation and differentiation of bone lining cells, as well as increasing osteoblast 
lifespan by inhibiting apoptosis. In contrast, continuous exposure to PTH inhibits the 
expression and synthesis of extracellular matrix proteins, such as collagen I, 
osteocalcin, and ALP [192], [225]. Despite this decrease in matrix formation, PTH 
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mediated catabolism of bone is not primarily due to decreased osteoblast function, but 
increased osteoclast activity. However, this is not through direct action on osteoclasts 
as they are not thought to have a PTH receptor. Instead, it is an indirect response to 
altered osteoblast function as continuous PTH increases RANKL and decreases OPG 
expression, increasing the RANKL:OPG ratio [226].  
β-arrestin2 is an adaptor/scaffold protein that can regulate intracellular signalling 
initiated by the PTH-receptor. In comparisons of β-arrestin2 KO versus WT bone 
marrow cultures, increased osteoclastogenesis is seen in the KO phenotype due to an 
increased RANKL:OPG ratio [227]. Lössdorfer, et al, co cultured PDL cells with 
RAW 264.7 in the presence of intermittent PTH, finding that the response is dependent 
on the maturity of the PDL cells. When applied to co-cultures containing mature, 
confluent PDL cells, an upregulation of TRAP and cathepsin K expression, an increase 
in the RANKL:OPG ratio, and higher resorptive activity was observed. However, with 
less mature, pre-confluent cells, the opposite was seen, with downregulation of 
resorptive genes and a decrease in the RANKL:OPG ratio and amount of resorption. 
Similar results were seen when treating RAW 264.7 with conditioned media from the 
PDL cells, indicating the PDL cells can produce sRANKL and their response to PTH 
is dependent on cell maturity [228].  
Serum is added to cell culture media as it contains a variety of proteins that help cells 
grow, divide and survive. However, its composition is not fully defined and therefore 
varies between batches [229]. This can give rise to inconsistencies in results due to the 
influence of unknown factors in the medium. Atkins, et al., attempted to develop a 
human-derived co-culture in a defined serum-free medium. They found that in serum-
replete medium that supported the formation of osteoclasts from hPBMCs in co-
culture with ST-2, osteoclastogenesis did not occur when the osteoblastic component 
was replaced with hOBs. However, when repeated in a defined, serum-free medium, 
co-culture of hOB with osteoclast precursors resulted in functional osteoclast 
formation, indicating some factor(s) may have been present in the serum that inhibited 
osteoclastogenesis [230].  
The concentration of calcium and phosphate in the media can also affect 
osteoclastogenesis. Co-culture of MC3T3-E1 murine pre-osteoblasts with murine 
bone marrow cells on segments of bovine tooth-roots with calcium concentrations 
ranging from 0 to 2.5 mM resulted in increased TRAP staining and resorption with 
decreased calcium [231]. The same group found that as MC3T3-E1 ALP activity and 
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therefore extracellular inorganic phosphate increases over time there is a decrease in 
osteoclast formation, and that increasing concentrations of β-glycerolphosphate (βGP) 
and exogenous ALP in the media has a similar effect [232]. Shin, et al., also 
investigated the effect of extracellular calcium on osteoclastogenesis, looking at a 
higher range of concentrations ranging from 1.8 mM to 10 mM on co-cultures of 
murine calvarial osteoblasts and murine bone marrow cells. They found that 
osteoclastogenesis increases with extracellular calcium in a dose-dependent manner 
when no other osteoclastogenic factors are added. However, in the presence of 
exogenous vitamin D3, sM-CSF and/or sRANKL, the opposite is seen and the number 
of TRAP positive, multinucleated osteoclasts decreases. This was likely due to the 
presence of calcium increasing the RANKL:OPG ratio by continuously upregulating 
RANKL expression but only transiently increasing OPG, whereas co-application of 
calcium and vitamin D3 decreased the ratio by not affecting RANKL and increasing 
OPG expression [233].  
In addition to chemical stimulus, environmental factors can also mediate 
osteoclastogenesis. Dandajena, et al., indirectly co-cultured hOBs from calvaria with 
hPBMCs using well inserts in either normoxic (21% O2) or hypoxic (2.5% O2) 
conditions, finding that low oxygen significantly upregulated RANKL production in 
comparison to normoxia, and that TRAP positive, resorptive osteoclasts only formed 
in hypoxic co-cultures [234]. 
Although the relationship between osteoblasts and osteoclasts is perhaps often 
considered to be one-sided, with the former producing factors that modulate the latter’s 
behaviour, there is evidence that osteoclasts can also effect osteoblasts. Garimella, et 
al., co-cultured primary murine calvarial osteoblasts with murine bone marrow cells 
in order to generate TRAP positive, multinucleated osteoclasts. Using in situ 
hybridisation and immunohistochemistry, they were able to detect bone 
morphogenetic protein (BMP) -2, -4, and -6 mRNA and protein, respectively, within 
the osteoclasts. Reverse transcriptase-polymerase chain reaction (RT-PCR) confirmed 
that the osteoclasts could synthesise mRNAs for BMP-2, -4, -6, and -7, with BMP-6 
having the highest expression [235]. Osteoclastic BMPs are possibly involved in the 
initiation of the anabolic phase of bone remodelling, recruiting and activating 
osteoprogenitor cells [236]. Further evidence for the influence of osteoclasts on 
osteoblasts comes from Luo, et al., who also co-cultured primary murine calvarial 
osteoblasts with murine bone marrow cells, albeit in a transwell configuration 
resulting in no direct osteoblast-osteoclast contact. Their findings demonstrated 
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greater ALP staining and activity in osteoblasts co-cultured with osteoclasts in 
comparison to monocultures. Furthermore, the osteogenesis related genes RUNX2, 
ALP and COL-1α1mRNA expression were all upregulated in the co-culture, 
indicating the anabolic role osteoclasts can have on osteoblasts [237]. 
A summary of the factors that can influence bone remodelling is given in figure 2.15. 
 
Figure 2.15: Schematic summarising the effects of different factors on bone balance. 
Factors that result in a positive bone balance shown on top, negative bone balance 
below. Legend: Osteoblast (OB) Osteoclast (OC) Differentiation (Diff) Intermittent 
(Int) Continuous (Cont). 
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2.3.3 Remodelling models 
The majority of the work done on the fundamentals of bone remodelling in vitro has 
been performed through the use of either conditioned media experiments, indirect co-
culture using well inserts that keep the osteoblasts and osteoclasts separate, or in direct 
2D co-culture, where osteoclasts are plated onto a monolayer of osteoblasts grown on 
tissue culture plastic. Whilst these studies have revealed a plethora of factors and 
molecules involved on bone remodelling, they fail to replicate the 3D architecture of 
native bone tissue. This results in differences in cell morphology, polarity and receptor 
expression, as well as a lack of diffusion gradients and unrepresentative substrate 
stiffness that in combination fail to represent the in vivo condition [238]. Therefore, to 
produce a viable model of bone remodelling in vitro, the co-culture should be 
performed in three dimensions. The development of the field of bone tissue 
engineering has resulted in a multitude of polymer, ceramic and metal scaffolds being 
produced that support the formation of mineralised extracellular matrix [239], [240]. 
These studies primarily focus on the action of osteoblasts, but can be adapted to create 
in vitro models of bone remodelling. 
Nakagawa, et al., appear to be the first to attempt to co-culture osteoblasts and 
osteoclasts in a scaffold in vitro. Collagen-coated porous PLGA scaffolds were 
precultured with porcine osteoblasts (pOBs) for two weeks before the addition of 
porcine osteoclast precursors and a further two weeks of culture in a rotational 
bioreactor. At the end of the culture, mature osteoclasts with ruffled borders and actin 
rings were visible on top of the mineralised surface synthesised by the osteoblasts, 
showing for the first time that studying remodelling in vitro is a realistic ambition 
[241]. 
Domaschke, et al., were the first to demonstrate remodelling in vitro and recognise its 
potential to reduce the need for animal studies. hPBMCs were cultured on mineralised 
collagen tapes containing hydroxyapatite for 24 hours before the addition of ST-2 and 
cultured in media supplemented with exogenous RANKL and M-CSF. Osteoclasts 
generated were able to resorb the scaffold-substrate and osteoblasts were able to 
deposit new mineralised matrix, a key element that distinguishes remodelling from 
resorption [164]. Further work by Bernhardt, et al., utilised the same substrate but 
replaced the murine ST-2 cells with primary hMSCs. However, here osteoblasts were 
seeded on one set of scaffolds and monocytes on another, keeping them separate from 
one another using well inserts. Osteoblasts proliferated at a faster rate and ALP mRNA 
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expression was higher in co-culture than monoculture. TRAP activity was lower on 
scaffolds and osteoclasts were smaller in size in the co-culture in comparison to 
monocyte monocultures, although there was no difference in cathepsin K and TRAP 
mRNA expression. Interestingly, across multiple donors, MSCs underwent less 
adipogenic differentiation in co-culture than in monoculture, as evidenced by fatty 
acid binding protein 4 expression and Oil Red O staining [242]. This indicates that 
without direct contact, the presence of osteoblasts can have an inhibitory effect on 
osteoclasts, perhaps via the increase in extracellular phosphate in the media as seen by 
Takeyama, et al. [232]. Furthermore, the presence of osteoclasts in indirect co-culture 
upregulated the proliferation and ALP activity of osteoblasts and inhibited 
adipogenesis, which agrees with the finding of Luo, et al. [237]. 
Following the initial work of Domaschke, Tortelli, et al., developed an in vitro 
remodelling model using primary murine cells. They used Skelite®, a commercial 
bone graft substitute, formed into discs to create a porous ceramic substrate and 
compared it to tissue culture plastic (TCP) using co-cultures that were seeded in a 1:1 
ratio of calvarial mOBs and osteoclast precursors from murine bone marrow. These 
cultures were maintained for 30 or 60 days, 2-4 times longer than Domaschke, without 
exogenous RANKL or M-CSF before analysis. Mature, TRAP positive, 
multinucleated osteoclasts and deposited, mineralised extracellular matrix were 
detectable after 60 days in 2D and 3D, with a more organised bone-like matrix 
deposited in 3D. Runx2, OSX and osteocalcin expression were analysed as markers 
of early, middle, and late osteoblast maturation, and cathepsin K and TRAP expression 
as markers of osteoclast differentiation. 3D cultures reached a maximal expression of 
Runx2 and OSX within ten days, whereas 2D cultures took 40, and osteocalcin 
expression was 19-fold higher in 3D by day 40, indicating osteogenesis started 
immediately in 3D but was delayed in 2D, and that osteoblasts fully differentiated in 
3D. Cathepsin K, TRAP and RANKL expression were significantly higher in 2D than 
3D, whereas OPG expression was lower [171]. These results combine to imply that 
osteoblasts in the earlier stages of osteoblastic differentiation have higher 
osteoclastogenic potential that more mature osteoblasts due to an increased 
RANKL:OPG ratio, and that 2D culture retains osteoblasts in an earlier phenotype due 
to a lack of physical stimuli, which agrees with the findings on Gori, et al., [210]. 
Although bone turnover at various time points can be analysed by histology, PCR and 
enzyme activity, it is difficult to determine exactly how a scaffold has been resorbed 
and remodelled by the cells, and it is impossible to see how bone tissue volume on the 
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same scaffold changes over time due to the destructive nature of these techniques. 
Ruggiu, et al., repeated the same co-culture as Tortelli, et al., on the same substrate 
but in addition to histological techniques, examined the scaffold before and after 
culture by synchrotron MicroCT to enable image registration. In comparison to mOB 
monocultures, co-cultures formed a more organised bone tissue with clear segregation 
between mineralised ECM and non-mineralised osteoid. Using MicroCT, increased 
mineralised and non-mineralised matrix deposition was seen in co-cultures, as well as 
scaffold degradation due to osteoclast activity which was not visible in mOB 
monocultures [243].  
The use of MicroCT as a non-invasive imaging technique to monitor bone remodelling 
in vitro has also been utilised by Rubert, et al., who co-cultured hMSCs and hPBMCs 
on previously mineralised and decellularised bone-like tissues in a spinner flask for 
up to 35 days in media supplemented with RANKL and M-CSF. By evaluating 
dynamic morphometric parameters using sequential MicroCT scans, co-cultures had 
a significantly decreased mineralising surface and almost 200% increase in bone 
resorption rate in comparison to hMSC mono-cultures. By registering images over 
time, regions of clear bone resorption and formation could be seen in the co-culture 
[244]. 
In addition to improving our understanding of the remodelling process, in vitro 
systems can also inform us how potential bone tissue engineering scaffolds will 
degrade and be remodelled in vivo prior to animal testing. Jones, et al., co-cultured 
MC3T3-E1 and primary mOC precursors on vapour or methanol stabilised silk fibroin, 
chitosan and poly(lactic acid) (PLLA) films to determine their suitability for bone 
tissue engineering. Cultures were seeded at a 1:100 (OB:OC) ratio and maintained in 
media containing exogenous RANKL for ten days. Silk and chitosan films supported 
the formation of greater numbers of TRAP positive osteoclasts in comparison to 
PLLA, and by comparing surface roughness using atomic force microscopy (AFM), 
the most resorption occurred on vapour stabilised silk films. This indicates their 
potential for remodelling studies and use in bone tissue engineering  [245].  
Hayden, et al., also utilised silk-based substrates in multiple studies attempting to 
develop an in vitro bone remodelling model. Initially, they used lentiviral transduction 
to tether ligands known to alter bone metabolism to hMSCS differentiated into hOBs; 
either PTH or glucose-dependent insulinotropic peptide (GIP). Green fluorescent 
protein (GFP) was used as a control.  
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Tethered osteoblasts were co-cultured with THP-1 in media with exogenous RANKL 
on silk films, porous silk sponges, or TCP for up to 5 weeks before surface roughness 
and calcium deposition quantification was performed to analyse resorption and matrix 
deposition.  Tethering of PTH increased mineral deposition in comparison to the GFP 
control in the TCP co-culture. This was possibly due to the feedback mechanism of 
osteoclasts to osteoblasts as their activity is raised. Increased surface roughness was 
seen on silk films with PTH-tethered co-cultures due to the production of larger 
mineral deposits, whilst GIP-tethered co-cultures decreased roughness, as GIP lowers 
osteoclast activity and as a result osteoclastic stimulation of matrix deposition by 
osteoblasts. Similar surface roughness trends were seen in the 3D sponges, but due to 
their more complex architecture it was harder to quantify [246].  
Following this, Hayden, et al., extended the duration of the co-culture with regular 
hMSCs and THP-1 and exogenous RANKL on the silk films to up to 32 weeks to 
characterise long term bone remodelling on the substrate. Films were characterised by 
SEM and MicroCT imaging prior to seeding. Mineralisation in co-culture in 
comparison to monoculture was continuous over the surface of the film, rather than in 
discrete patches. They also had higher surface roughness indicating more remodelling, 
as well as an increase in volume as quantified by MicroCT [247]. Finally, they looked 
to apply their in vitro model to a metabolic bone disease by investigating the effect of 
two bisphosphonates, a common therapeutic for patients with osteoporosis. Here the 
silk films were incorporated with hydroxyapatite and loaded with either clodronate or 
alendronate before co-culture of hMSCs and THP-1 with exogenous RANKL for up 
to 12 weeks. They identified concentrations of clodronate that could upregulate 
osteoblast ALP activity whilst diminishing osteoclast activity, a combination 
alendronate could not achieve [248]. Whilst this in vitro system can be used to evaluate 
potential osteoporosis therapeutics, it is a model of bone remodelling, not 
osteoporosis. 
Heinemann, et al., also developed an in vitro biomaterial testing system that utilised 
an all-human origin, direct contact, co-culture that compared TCP with a silica-
collagen-hydroxyapatite xerogel. hMSCs were first cultured for 13 days before the 
addition of hPBMCs and a further culture of up to 4 weeks without exogenous 
RANKL or M-CSF. Differentiation of MSCs into osteoblasts was confirmed by ALP 
activity. RANKL was synthesised as evidenced by RANKL mRNA expression and 
TRAP activity of the differentiated osteoclasts, which were also able to upregulate 
BSP-II gene expression in osteoblasts. In 3D, MSCs proliferated and differentiated, 
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forming layers of cells that covered the entire sample which had spherical, 
multinucleated osteoclasts with actin rings embedded within [249].  
A further in vitro bone model that only used human-origin cells co-cultured in direct 
contact was developed by Papadimitropoulos, et al. However, in contrast to 
Heinemann, they used human adipose tissue-derived stromal vascular fraction (SVF) 
cells that can commit to osteoblastic and endothelial lineages. These were co-cultured 
with hPBMCs on porous hydroxyapatite/β-tricalcium phosphate ceramic scaffolds in 
a perfusion bioreactor, with the SVF cells cultured for 5 days before the addition of 
the monocytes and the culture then maintained for 21 days in media supplemented 
with exogenous RANKL and M-CSF. After 21 days, osteoblastic, osteoclastic and 
endothelial cells were identifiable in the culture, with TRAP positive osteoclasts 
adhered to the deposited ECM. Culture supernatants were analysed to assess bone 
turnover, confirming matrix deposition by the presence of C-terminus procollagen-I, 
and resorption by the presence of N-telopeptides of collage type-I, changing phosphate 
levels and TRAP activity. When replacing exogenous supplementation of RANKL 
and M-CSF with Vitamin D3 co-cultures still underwent osteoclastogenesis, resulting 
in self-regulation of the model [250]. 
Although scaffolds provide a 3D environment and physical cues for cells, the natural 
and synthetic materials used to fabricate them are foreign to natural bone tissue and 
may obstruct the investigation of the actual sequence of cellular events that occurs in 
vivo during bone remodelling. This interference is greater if the scaffolds incorporate 
bioactive factors like BMPs. Therefore, Clarke, et al., attempted to create a scaffold-
free three-dimensional in vitro bone model by forming tissue aggregates in a rotational 
bioreactor. Tissue constructs were formed by culturing hOBs and hPBMCs at a 2:1 
ratio in media supplemented with exogenous RANKL and M-CSF with the rotational 
speed varied to alter initial aggregate size and keep the aggregate in free-fall for up to 
21 days. Mineralised, solid to the touch, aggregates up to 4 mm in diameter could be 
formed after 3 weeks. These contained a mineralised core with structures that resemble 
trabeculae which contained embedded cells that express sclerostin, indicating they 
may have become osteocytic. Surrounding the core a morphologically different 
perimeter that contained active osteoblasts and osteoclasts expressing osteocalcin and 
TRAP, respectively, was apparent that appeared to have resorption pits. BMP-2, -4, 
and -7 expression was also detectable [251]. A clear advantage of this in vitro model 
is the potential presence of the three main cell types; osteoblasts, osteocytes and 
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osteoclasts. However, it relies on exogenous supplementation to induce 
osteoclastogenesis rather than these factors being inherently produced.  
Penolazzi, et al., also utilised a rotational bioreactor in their in vitro remodelling 
system to simulate the jawbone microenvironment in the study of osteonecrosis of the 
jaw (ONJ), a very rare side effect associated with bisphosphonate therapy. They 
extracted hOBs from either healthy donors or patients undergoing treatment for ONJ 
and co-cultured them with hPBMCs either indirectly or directly without exogenous 
RANKL and M-CSF. Indirect cultures were performed using well inserts. Direct co-
cultures were either static or dynamic. Direct-static cultures were performed by 
generating spheroids of hOBs and hPBMCs in a 1:2 ratio on agarose-coated well 
plates. Direct-dynamic aggregates were formed in a rotational bioreactor at the same 
ratio. The indirect co-culture was capable of generating multinucleated, TRAP and 
cathepsin K positive osteoclasts, indicating the production of sRANKL. Static and 
dynamic direct cultures had no difference in cell viability. As with Clarke, et al., 
aggregates within the rotational reactor had a much more defined, better organised 
structure with three distinct regions. Osteoblast markers osteopontin (OPN), OSX, 
Runx2 and calcium staining by alizarin red S (ARS) were all higher in the dynamic 
culture, as were osteoclast markers TRAP and cathepsin K. Osteoblasts from ONJ 
patients were lower in quality but still able to from mineralising, TRAP positive 
aggregates [252]. 
The same group used this rotational bioreactor system to explore the effect of 
menaquinone-4 (MK-4), a member of the vitamin K2 family that can regulate calcium 
homeostasis and may have an anabolic effect on bone formation. Human amniotic 
fluid MSCs (hAFMSCs) were co-cultured with hPBMCs in a 2:1 ratio without 
exogenous RANKL and M-CSF. In conventional 2D and dynamic 3D monocultures 
of hAFMSCs, 10 µM of MK-4 significantly increased mineralisation, as well as ALP, 
RUNX2, osteocalcin, COL-1α1 and OPN mRNA expression without affecting cell 
viability. In dynamic 3D co-culture, hAFMSCs supported osteoclastogenesis without 
exogenous factors, again in the outer perimeter of the aggregate. In the presence of 
MK-4, there were significantly fewer TRAP positive osteoclasts formed and a 
significant increase in mineralised matrix deposition [253].   
Young, et al., explored how the surface features of the substrate can influence bone 
remodelling in vitro by performing co-cultures on a polycarbonate surface either with 
or without their previously developed ‘NSQ50’ nanotopography shown to increase 
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osteoblast differentiation.  Human bone marrow was aspirated and separated into BM- 
MSCs and BM-haematopoietic cells (BMHCs). BM-MSCs were cultured on the 
substrates for one week before the addition of BMHCs, and then cultures were 
maintained for a further three weeks with no exogenous osteoclastogenic supplements. 
After 21 days, large, TRAP positive, multinucleate osteoclasts with actin rings were 
visible on both substrates, as well as smaller TRAP positive mononuclear 
macrophages. There were no significant differences in osteoclastogenesis between 
planar and NSQ50 substrates, as quantified by microscopy and TRAP, OSCAR and 
cathepsin K mRNA expression. However, the patterned substrates stimulated 
increased bone mineral deposition over the planar surfaces as demonstrated by alizarin 
red s and osteopontin staining. RANKL, OPG and IL-6 expression were significantly 
increased on the NSQ50 surfaces but by equal amounts, maintaining the RANKL:OPG 
ratio [254]. Increasing osteoblast activity and mineral production without a subsequent 
increase in osteoclast activity suggests that certain nanotopographies can be 
selectively bioactive, influencing only one cell type. Furthermore, this work has 
potential applications in implant osseointegration and biomaterials that can stimulate 
bone restoration in patients with osteoporosis.  
Healthy bone remodelling requires a delicate balance between formation and 
resorption by BMUs. These are comprised of osteoblasts and osteoclasts, but also a 
blood supply which is essential for delivery of nutrients, precursors and waste 
removal. However, due to the complexity of replicating angiogenesis in vitro, this 
aspect of bone remodelling is often overlooked. We know that the microvascular cells 
at sites of bone turnover can influence osteoclastogenesis, and therefore including 
vascularisation is essential in the attempt to mimic bone remodelling in vitro [206]. 
To address this, Bongio, et al., tetra-cultured human umbilical vein endothelial cells 
(HUVECs), BM-MSCs, BM-MSCs differentiated into hOBs, and hPBMCs within 
collagen/fibrin hydrogels incorporated with calcium phosphate nanoparticles in media 
supplemented with exogenous RANKL and M-CSF. Formation of microvessels was 
confirmed in hydrogels in co-cultures of HUVECs and BM-MSCs. Monocultures of 
osteoblasts expressed increased proliferation, ALP activity and mineralisation over 
time, and monocultures of osteoclasts became TRAP positive and were able to resorb 
the matrix, releasing phosphate into the media. Comparing vascularisation in HUVEC-
BM-MSC co-cultures versus the tetra-culture, the presence of osteoblasts and 
osteoclasts appeared to diminish overall hydrogel vascularisation, with fewer but 
longer microvessels in the network. BM-MSC cells appeared to differentiate into 
mural cells to support the vascular network. Comparing osteoblast/osteoclast co-
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cultures to the tetra-culture, the latter increased osteoblast and osteoclast 
differentiation over co-cultures, as indicated by ALP and TRAP activity and phosphate 
release [255]. The presence of MSCs and HUVECs within the culture positively 
influenced osteogenic and osteoclastic differentiation, with all four cell types 
synergistically influencing each other.  
2.3.4 Pathological models 
Simpler, two-dimensional co-cultures of osteoblasts and osteoclasts can help us 
elucidate factors that regulate the remodelling process, and by moving to more 
physiologically relevant three-dimensional systems we have seen the creation of 
increasingly complex in vitro models of the entire process. These will become 
invaluable in understanding how this intricate process occurs as well as evaluating 
potential new therapeutics and implants. However, they also have the capacity to be 
adapted to study various pathologies, including cancer, osteoporosis, dental disorders 
and implant rejection.  
Multiple myeloma (MM) is a type of cancer characterised by accumulation of plasma 
cells in the bone marrow and formation of osteolytic lesions due to increased osteoclast 
activity and reduced osteoblast activity [256]. Bone remodelling compartments 
(BRCs) typically separate the BMU from the bone marrow to regulate the 
microenvironment and tightly control osteoblast-osteoclast coupling, ensuring 
balanced remodelling [55]. However, in biopsies from patients with MM, there are 
areas of uncoupled and therefore excessive resorption, which eventually results in the 
formation of osteolytic lesions. These lesions have compromised BRCs which permit 
the passage of MM cells.  Uncompromised areas had normal bone remodelling as the 
BRCs acted as a barrier to the cancerous cells [54]. To elucidate whether the formation 
of these lesions was indeed due to compromised BRCs, Anderson, et al., attempted to 
create an in vitro model of the scenario. They utilised a confluent G0-arrested 
monolayer of MC3T3-E1 to simulate the BRC. Direct contact with OPM2 MM cells 
decreased the surface area covered by the MC3T3-E1, whereas indirect co-culture 
using a well insert had no effect. Conversely, direct co-culture with hPBMC-derived 
osteoclasts increased the area covered [257]. This indicates that MM cells may be able 
to disrupt the BRC in direct cell contact. 
Prostate cancer (PCa) is one of the most common cancers and has a high mortality rate 
due to the development of hematogenous metastases. Approximately 90% of these 
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occur within bone, with 85-100% of patients who die from prostate cancer having 
bone metastases [258]–[260]. In order to better understand how PCa cells interact with 
the tissue, Nordstrand, et al., developed and in vitro co-culture model where 
monolayers of either PC-3, an osteolytic human PCa cell line, or LNCaP, a human 
PCa cell line with a mixed/osteoblastic phenotype, were cultivated beneath a freshly 
harvested murine calvarial bone that still contained osteoblasts and osteoclasts. PC-3 
upregulated cathepsin K, TRAP, MMP-9 and RANKL mRNA expression whilst 
inhibiting OPG, ALP and osteocalcin expression, causing a negative bone balance by 
increasing the RANKL:OPG ratio and decreasing osteoblast activity. In contrast to the 
osteolytic activity of PC-3, LNCaP increased ALP and osteocalcin expression and had 
no significant effect on the RANKL:OPG ratio in comparison to control calvarial 
cultures, indicating a small shift towards a positive bone balance [261]. By utilising 
ex vivo tissue in the co-culture the natural heterogeneity of the cell population in the 
bone tissue was maintained, allowing for an in vitro model that can study the 
interaction between PCa cells and bone to be produced. Lil, et al., also utilised PC-3 
and C4-2B, a subline of LNCaP, to examine how PCa metastases influence bone 
remodelling. In both cell lines, TGF-β increased RANKL expression and RAW264.7 
differentiation, indicating PCa cells can induce osteoclastogenesis [262]. 
Breast cancer (BCa) is another very common cancer that regularly metastasises to 
bone. These metastases cause a negative bone balance by increasing osteoclast 
activity. This releases cytokines and growth factors from the resorbed bone, which in 
turn stimulates cancer cell proliferation, further exacerbating the resorption. This 
vicious cycle results in significant bone loss, pain and morbidity [263], [264]. To 
investigate this, Krishnan, et al., introduced metastatic breast cancer cells to an in vitro 
bone remodelling model. Using a bioreactor they developed for long-term 
(<10 months) osteoblast culture, they maintained MC3T3-E1 for 60 days before the 
addition of pre-osteoclasts harvested from murine bone marrow [265]. MDA-MB-
231-GFP BCa cells were added to the co-culture after a further ten days. Cultures were 
maintained in media containing exogenous RANKL and M-CSF. After 60 days, the 
MC3T3-E1 had created and become embedded in a thick, collagenous ECM. After a 
further 21 days of osteoclast culture, multinucleated, TRAP positive osteoclasts that 
resorbed the ECM and formed pits were visible. Subsequent addition of new MC3T3-
E1 resulted in the refilling of the resorbed areas, completing the remodelling process. 
After the initial 60 days, the ECM was 20 µm thick. This was reduced to 16.5 µm by 
the addition of osteoclasts and 14.5 µm by osteoclasts and BCa cells. The metastatic 
cells penetrated the ECM and formed osteoclast-BCa aggregates, as well as increasing 
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osteoclastogenesis and downregulating osteoblast differentiation in comparison to co-
cultures [266], [267]. This model without the BCa cells includes the major processes 
of remodelling, albeit requiring the addition of new osteoblast pre-cursors, and 
provides a way of studying the process over long time periods. The addition of BCa 
cells provides a simplified platform for the study of how the major cellular constituents 
of breast cancer metastases interact. 
The cannabinoid type 2 (CB2) receptor has been implicated with regulating tumour 
growth and bone remodelling. By agonising this receptor with JWH133 or HU308, 
Sophocleous, et al., determined that the growth of three BCa cell lines could be 
inhibited, but that the agonists have no effect on the proliferation of murine calvarial 
osteoblasts or bone marrow-derived osteoclasts. In co-cultures of the bone cells, 
conditioned media from the cancer cells upregulated osteoclastogenesis in comparison 
to untreated controls; however, treatment with the CB2 agonists further increased 
osteoclast formation by increasing the RANKL:OPG ratio. Treatment of osteoclast 
monocultures with the agonists and conditioned media increased osteoclast formation, 
TRAP and cathepsin K expression and resorption in comparison to conditioned media 
alone [268]. These findings indicate that although CB-2 activation has been shown to 
suppress cancer cell proliferation and tumour growth at certain concentrations, ones 
lower than this enhanced osteolysis in this study. Therefore CB-2 inhibition may 
protect the skeleton in cases of BCa metastases [269].  
Trichostatin A (TSA) is an antibiotic that acts as an inhibitor of histone deacetylase 
enzymes that regulate chromatin remodelling and transcription activity, rendering it a 
potent anticancer drug. In co-cultures of primary calvarial mOBs and red blood cell 
(RBC) free murine bone marrow cells, 10 nM TSA significantly reduced osteoclast 
formation but it did not alter the RANKL:OPG ratio. Instead, it acts directly on 
osteoclast precursors by downregulating c-fos, a transcription factor essential in 
osteoclastogenesis. In vivo,  they found TSA can mitigate IL-1 induced bone loss, 
indicating this drug may also have potential in reducing inflammatory bone loss [270].  
Osteoporosis is the most common metabolic bone disorder, but as it stands there is no 
in vitro model of the disorder that can be used for the study of the disease. Despite 
this, in vitro models of remodelling can be used to study potential new anabolic 
therapeutics. Icariin is a flavonoid in Herba epimedii that can stimulate bone formation 
and inhibit osteoclastogenesis [271]. Liu, et al., investigated whether it can have a 
synchronised duel effect on osteoblasts and osteoclasts by performing a direct co-
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culture of murine BM-MSCs and RAW264.7 with exogenous RANKL and M-CSF, 
and indirectly culturing this with ovarian follicular granulosa cells (GC) in a well insert 
above. Co-cultures had increased ALP staining in comparison to mOB mono-cultures, 
indicating osteoclastic upregulation of osteoblasts. This was further increased when 
GC cells were present, and the co-culture increased the estradiol production of the GC 
cells. There was no increase in TRAP positive osteoclast formation in co-culture over 
osteoclast monoculture. Icariin was compared to common osteoporosis drugs to 
evaluate its efficacy. In co-culture, alendronate reduced both TRAP and ALP activity 
and PTH increased both TRAP and ALP activity. However, Icariin decreased TRAP 
and increased ALP activity, indicating its potential as an anabolic therapeutic for 
osteoporosis. A similar effect was seen when substituting RAW264.7 for murine 
peripheral blood monocytes [272]. 
Semaphorins are a class of membrane-bound or secreted proteins involved in 
osteoclast-osteoblast communication. Osteoclast-derived semaphorin 4D (sema4D) 
binds to its receptor Plexin-B1 on osteoblasts, inhibiting bone formation [273]. 
Therefore, it has the capability to regulate bone turnover, and overexpression of 
sema4D is observed in osteoporosis.  Zhang, et al., utilised siRNA to interfere with 
sema4D and create a targeted drug delivery system. By applying the siRNA to co-
cultures of mOBs with bone-marrow derived osteoclast precursors, they found that 
application of the siRNA does not influence osteoclast number or function, but ALP, 
COL-1α1 and osteocalcin mRNA expression and mineralised matrix formation are 
increased in silenced cultures. When used in vivo in OVX mice, regular administration 
of the siRNA significantly increased the number of active osteoblasts and total bone 
volume, indicating sema4D silencing as a potential therapeutic option for osteoporotic 
patients [274]. 
Remodelling models have also been used to study dental disorders. Cleidocranial 
dysplasia (CCD) is a congenital disorder that affects bone and tooth development due 
to mutations in the RUNX2 gene. For a tooth to erupt a path has to be cleared through 
the bone above via resorption. Eruption is delayed in patients with CCD, therefore 
Lossdörfer, et al., invesitgated whether this was due to PDL cells from CCD patients 
having reduced capability to induce osteoclastogenesis. Human PDL cells from 
healthy of CCD patients were co-cultured with RAW264.7 in a 1:1 ratio. Vitamin D3 
increased the RANKL:OPG ratio in both healthy and diseased PDL cells. Conditioned 
media from healthy PDL cells produced significantly more TRAP positive, 
multinucleated osteoclasts. In direct co-culture, PDL cells from CCD patients reduced 
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TRAP and cathepsin K expression in comparison to healthy PDL cells [275]. Yan, et 
al., also investigated the delayed eruption of teeth in CCD by co-cultruing primary 
human dental pulp cells (DPCs) from healthy or CCD patients with hPBMCs. ALP 
expression  and formation of mineralised nodules was reduced in CCD DPCs. In co-
culture, TRAP, cathepsin K and MMP-9 exression were all reduced in comaprison to 
healthy DPCs due to a 92% decrease in the RANKL:OPG ratio [276]. The findings of 
Wang, et al., agree with both these studies. They co-cultured healthy or CCD patient 
dental follicle cells (DFCs) with hPBMCs, finding that diseased cells had a reduced 
capability to induce osteoclast formation through a reduction in the RANKL:OPG 
ratio. However, vitamin D3 was only able to increase the RANKL:OPG ratio in DFCs 
from healthy donors as its stimulation of RANKL production is mediated prinicpally 
by a RUNX2 dependant pathway [277]. These data combine to indicate that the 
primary teeth retention associated with CCD may be due to a reduced capacity of 
osteoblast-like dental cells to induce osteoclastogenesis and create a path for teeth to 
emerge through.  
In vitro models of bone remodelling can also be used to predict how successfully 
implants will integrate into the bone tissue. Osteolysis can occur at the bone-cement 
interface resulting in loosening of the implant. Granchi, et al., found that PMMA bone 
cements increase the RANKL:OPG ratio in MG-63 [278]. This could increase 
osteoclastogenesis and exacerbate implant loosening. Calcitonin gene-related peptide 
(CGRP) is thought to have an inhibitory effect on the inflammation induced osteolysis 
that occurs around implants. Jablonski, et al., examined this by co-culturing MG-63 
with THP-1 without exogenous RANKL or M-CSF, aggravating the cultures with 
either ultra-high molecular weight polyethylene (UHMWPE) particles or bacterial 
lipopolysaccharides (LPS), then treating with CGRP. Both UHMWPE particles and 
LPS induce an inflammatory response by the THP-1 cells in the co-culture as indicated 
by the release of TNF-α. This response could be suppressed by the addition of CGRP. 
Interestingly, UHMWPE and LPS had no significant effect on the RANKL:OPG ratio 
or ALP activity [279]. This indicates that onset of inflammatory periprosthetic 
osteolysis is due to actions on osteoclastogenesis rather than osteoblast activity. 
Wu, et al., examined how magnesium based implants influence bone turnover by co-
culturing the human MSC cell line SCP-1 which had been differentiated into 
osteoblasts with hPBMCs and exposing them to varied concentrations of magnesium 
with no exogenous RANKL or M-CSF. The highest magnesium concentrations were 
toxic to hPBMC mono-cultures, but the presence of osteoblasts at the same 
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concentration played a protective role. High magnesium concentrations increased 
osteoblast proliferation, ALP activity and mineralisation whilst decreasing 
osteoclastogenesis [280]. This dual action on osteoblasts and osteoclasts highlights 
why in vitro assessment of potential implant materials should be performed using co-
cultures of osteoblasts and osteoclasts, not just osteoblast monocultures, as they are 
more representative of in vivo physiology. 
2.4 Summary 
Postmenopausal osteoporosis is a skeletal disorder caused by a decline in oestrogen 
that results in increased bone resorption. This occurs due to an increase in osteoclast 
activity and lifespan. To date, the progression of osteoporosis and potential new 
therapeutics for the disease have been predominantly studied in animals. Bone tissue 
engineering aims to combine the culture of osteoblasts with three-dimensional 
substrates to create a bone graft substitute that results in the restoration of the original 
tissue. Work in this area can be combined with the culture of osteoclasts to create an 
in vitro model of bone remodelling. Whilst this has been attempted for normal, healthy 
bone remodelling, an attempt to utilise this to study postmenopausal osteoporosis has 
not yet been performed. However, there have been studies into the response of various 
osteoblastic and osteoclastic cell lines to oestrogen. Development of such a model 
would reduce the reliance on animal models during drug development by providing a 
cheaper and more ethical approach.  
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2.5 Project aims and objectives 
The main aim of the work presented in this thesis was to determine to what extent an 
in vitro model of postmenopausal osteoporosis could be developed by utilising the 
principles of bone tissue engineering. This contributes to the long-term goal of 
reducing our reliance on rodent models for musculoskeletal research, as a human-
based in vitro model of postmenopausal osteoporosis has the potential to generate 
more relevant data through the use of human cells, as well as being cheaper and more 
ethical than the use of OVX animal models.  
To achieve this aim, the project was divided into the following objectives: 
1. Determine the response of various bone cell lines to oestrogen. 
a. Compare various osteoblast cell lines and their response to oestrogen, 
considering its effect on viability and mineral deposition. 
b. Investigate the response of RAW264.7 osteoclast precursors to 
oestrogen, considering its effect on viability and resorption. 
c. Select the most appropriate cell lines for the model based on the 
previously stated criteria. 
2. Select a suitable substrate for an in vitro model of osteoporosis. 
a. Confirm the amenability of a novel, emulsion templated scaffold to 
bone tissue engineering. 
b. Compare it to at least two other bone tissue engineering scaffolds, 
considering cell viability, bone-matrix deposition, fabrication method, 
reproducibility and cost. 
c. Select the most appropriate substrate for the in vitro model based on 
the previously stated criteria. 
3. Evaluate the feasibility of a tissue engineered in vitro model of osteoporosis. 
a. Confirm applicable markers of osteoblast and osteoclast activity in co-
culture. 
b. Utilise the findings of the previous two objectives to develop a two-
dimensional and three-dimensional co-culture of osteoblasts and 
osteoclasts. 
c. Evaluate the response of the co-culture to oestrogen exposure and 
subsequent withdrawal to mimic postmenopausal osteoporosis. 
d. Apply common therapeutics for osteoporosis to the model and compare 
the effects to those seen in vivo. 
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3. Materials and Methods 
This section contains the materials and methods necessary for the protocols common 
to the following chapters. Specific protocols relevant to only one section can be found 
in the respective chapter. 
3.1 Materials 
All reagents were purchased from Sigma-Aldrich (UK) unless otherwise stated. Tissue 
culture plastic was obtained from Thermo Fisher Scientific (UK). 
3.2 Methods 
3.2.1 Osteoblast cell lines 
Three different murine osteoblast cell lines were used in this thesis: MC3T3-
E1 subclone 4 (kindly donated by Dr. Peter Grabowski, University of Sheffield), IDG-
SW3 (purchased from Kerafast, USA) and MLOA5.  
MLOA5 were all originally from the laboratory of Dr Lynda Bonewald (University of 
Missouri) but were sourced from different locations: 
• MLOA5-S: kindly donated by Dr. Lynda Bonewald, University of Missouri 
• MLOA5-K: kindly donated by Prof. Alicia El Haj, University of Keele 
• MLOA5-A: purchased from Kerafast, USA 
MC3T3-E1 subclone 4 are derived from the clonal osteogenic cell line MC3T3-E1, 
which is a spontaneously immortalised osteoblast precursor cell lined generated using 
the 3T3 passaging protocol from the calvaria of newborn C57BL/6 mice by Kodama, 
et al. [177]. Although originally a clonal cell line, prolonged passaging resulted in a 
phenotypically heterogeneous population, and in 1999 Wang, et al., took advantage of 
this and isolated ten subclonal MC3T3-E1 cell lines, with subclone 4 exhibiting high 
levels of osteoblastic differentiation and mineralised extracellular matrix production 
when cultured with ascorbic acid and inorganic phosphate [281]. MC3T3-E1 have 
been used extensively since their creation due to being one of the most physiologically 
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relevant and convenient osteoblast cell lines, with a search for MC3T3-E1 limited to 
journal articles on PubMed yielding over 4,000 results [282]. However, the subclone 
used is not commonly reported, therefore differences in results may be due to 
investigators using different subclones and different stages of differentiation 
IDG-SW3 are a comparatively new cell line, developed in 2011 as an osteoblast-
osteocyte cell model [283]. They proliferate when cultured at 33 °C in the presence of 
IFN-γ due to the expression of a temperature-sensitive mutant of a tumour antigen that 
induces continuous proliferation and immortalisation. However, when returned to 
37 °C and IFN-γ is removed they resume their osteoblast/osteocyte behaviour and 
undergo osteocytogenesis. IDG-SW3 were isolated from 3-month-old transgenic mice 
that express green fluorescent protein (GFP) when DMP-1 is expressed, allowing 
observation of osteocyte differentiation by microscopy. Initially, they display typical 
late-osteoblastic characteristics, such as high ALP expression, collagen type 1 
deposition, and production of mineralised extracellular matrix. However, over time 
they undergo osteocytogenesis. During this process, their rate of mineralisation and 
ALP activity decreases, and as early osteocytes, they are capable of expressing the 
osteocyte specific proteins E11/gp38, DMP-1 MEPE and Phex. As they progress to 
late osteocytes they develop a dendritic, stellate morphology and express sclerostin 
and FGF-23.  
MLOA5 represent a post-osteoblast/pre-osteocyte cell type and are capable of rapidly 
depositing mineralised extracellular matrix in sheets rather than nodules [284]. They 
have very high expression of bone sialoprotein, osteocalcin and ALP (higher than 
IDG-SW3) all hallmarks of the post-osteoblast phenotype [285]. Unlike IDG-SW3, 
during culture they do not continue to differentiate into osteocytes, meaning that their 
ALP activity and mineralisation capability remains high.  
Human embryonic stem-cell derived mesenchymal progenitors 002.5 (hES-MPs), a 
human cell line capable of undergoing osteogenic differentiation, were also used for 
some studies. They are a cell line developed from human embryonic stem cell lines by 
consecutive enzymatic passaging that is able to undergo osteogenic, chondrogenic and 
adipogenic differentiation. Phenotypically, they resemble mesenchymal stem cells, 
with a fibroblast-like morphology [286]. 
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3.2.2 Osteoclast cell lines 
The osteoclast pre-cursor cell line RAW264.7 (ATCC® TIB-71™) used in this thesis 
was kindly donated by Dr. Peter Grabowski, University of Sheffield, and was used for 
all osteoclast experiments. 
RAW264.7 is a murine leukemic monocyte macrophage cell line that can be induced 
to undergo osteoclastic differentiation by exposure to RANKL. A key advantage they 
have over other osteoclast precursors is that they do not require co-stimulation with 
M-CSF to induce osteoclastogenesis as they express both M-CSF and the c-fms 
receptor [166], [167]. Osteoclasts generated from RAW264.7 are multinucleate, 
TRAP positive, express cathepsin K and are capable of resorbing a matrix [287]. 
3.2.3 Culture media preparation 
Cell lines and their respective culture media are presented in table 3.1. Basal media 
(BM) refers to the simplest formulation of medium each cell line is cultured in and 
consists of a minimum essential medium (MEM), foetal bovine serum (FBS), 
glutamine, and antibiotics. Two types of MEM are used in this thesis; minimum alpha 
medium without l-glutamine (α-MEM, Lonza, UK, cat# BE02-002F) and minimum 
alpha medium with ultraglutamine and nucleosides (α-MEM+nuc, Lonza, UK, 
cat# BE12-169F). 
For the MC3T3-E1, MLOA5 and RAW264.7 cell lines, BM is used during passage to 
expand cell number. However, when IDG-SW3 cell number is being expanded at 
33 °C, they are cultured in expansion media (EM), which is their BM supplemented 
with IFN-γ. hES-MPs also require an expansion media during passage, which is their 
BM supplemented with human fibroblastic growth factor (hFGF). 
Differentiation media is referred to as supplemented media (SM), which is BM with 
additives that promote mineralised extracellular matrix formation (beta-glycerol 
phosphate (βGP) and ascorbic acid 2-phosphate (AA-2P)), or osteogenesis induction 
media (OIM) which is the same as SM but also contains the corticosteroid 
dexamethasone (Dex) to stimulate osteogenic differentiation. 
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Table 3.1: Cell lines used in this thesis and their respective culture media. 
Cell Line Basal Media (BM) Expansion 
Media 
(EM) 
Differentiation 
Media 
MC3T3-E1 
Subclone 4 
(Osteoblast) 
α-MEM, 10% FBS, 2 mM 
L-glutamine, 100 U/mL 
penicillin, 100 µg/mL 
streptomycin 
N/A OIM (BM + 5 mM 
βGP, 50 µg/mL AA-
2P, 10 nM Dex) 
MLOA5-S 
(Osteoblast) 
α-MEM, 10% FBS, 2 mM 
L-glutamine, 100 U/mL 
penicillin, 100 µg/mL 
streptomycin 
N/A SM (BM + 5 mM 
βGP, 50 µg/mL AA-
2P) 
MLOA5-K 
(Osteoblast) 
α-MEM, 10% FBS, 2 mM 
L-glutamine, 100 U/mL 
penicillin, 100 µg/mL 
streptomycin 
N/A SM (BM + 5 mM 
βGP, 50 µg/mL AA-
2P) 
MLOA5-A 
(Osteoblast) 
α-MEM+nuc, 5% iron 
supplemented bovine calf 
serum (cat# 11551831, 
Fisher Scientific), 5% heat 
inactivated FBS (cat# 
12350273, Fisher 
Scientific), 100 U/mL 
penicillin, 100 µg/mL 
streptomycin 
N/A SM (BM + 5 mM 
βGP, 50 µg/mL AA-
2P) 
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IDG-SW3 
(Osteoblast) 
α-MEM+nuc, 10% FBS, 
100 U/mL penicillin, 100 
µg/mL streptomycin 
BM +  
50 U/mL 
INF-γ 
SM (BM + 5 mM 
βGP, 50 µg/mL AA-
2P) 
hES-MP 
(Osteoblast) 
α-MEM, 10% FBS, 2 mM 
L-glutamine, 100 U/mL 
penicillin, 100 µg/mL 
streptomycin 
BM + 4 nM 
hFGF 
OIM (BM + 5 mM 
βGP, 50 µg/mL AA-
2P, 100 nM Dex) 
RAW264.7 
(Osteoclast) 
α-MEM, 10% FBS, 2 mM 
L-glutamine, 100 U/mL 
penicillin, 100 µg/mL 
streptomycin 
N/A BM + 25-50 ng/mL 
RANKL 
3.2.4 General osteoblast culture 
MC3T3-E1 were expanded in T75 flasks, MLOA5-S, MLOA5-K and IDG-SW3 in 
gelatine coated T75 flasks, and MLOA5-A in collagen coated T75 flasks in BM. All 
were cultured until ~90% confluent with media changes every 2-3 days.  
To detach cells for passage or seeding, media was removed from the T75 flasks which 
were then washed two times with PBS. 2.5 mL of trypsin (Trypsin-EDTA solution) 
was then added and incubated under standard conditions for 5 minutes to detach the 
cells. Flasks were checked under the microscope before adding 5 mL of BM to inhibit 
the enzyme, and then the suspension was centrifuged for 5 minutes at 1,000 rpm. The 
supernatant was then removed and the remaining cell pellet resuspended in a known 
volume of BM. 20 µL of the suspension was combined with 20 µL of Trypan Blue® 
in a 1.5 mL tube to selectively dye dead cells so that only viable cells appear bright 
when viewed under a microscope. This was then added to a haemocytometer and 
counted under a light microscope. From this, the viable cell density was determined.   
Cell storage over long time periods was performed in liquid nitrogen at -196°C. When 
freezing down, after counting, the cell density of the cell suspension was adjusted to 
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1 × 106 cells/mL of freezing medium (10% DMSO, 90% FBS). 1 mL aliquots were 
transferred to freezing vials and placed into an isopropanol-jacketed freezing container 
at -80°C for 24 hours before transferring to liquid nitrogen. 
To reanimate cells, partially thawed cells were immediately placed into 20 mL of 
warm medium and mixed before adding to a T75. After 24h, a full media change was 
performed to remove any residual DMSO.  
3.2.5 General osteoclast culture 
RAW264.7 were expanded in T75 flasks in 25 mL of BM and grown until 70-80% 
confluent. It is essential cultures do not overgrow as the cell line contains a sub-
population of strongly adherent motile cells amongst a main population of semi-
adherent static cells. Overgrowth can result in the dilution and removal of the motile 
sub-population within only a few passages. Similarly, splitting too early can also alter 
the balance between the two. 
To detach cells for passage, all but 10 mL of BM was removed from the flask. A cell 
scraper was then used to detach the cells and the suspension aspirated and returned to 
the flask multiple times to disperse clumps of cells. 2 to 4 mL of suspension was then 
transferred to a new T75 flask and BM added to a total volume of 25 mL. Media was 
changed every 2-3 days by removing 75% of the BM and replacing with fresh to 
conserve factors produced by the cells. To detach for seeding, all but 5 mL of BM was 
removed from the flask, which was subsequently scraped and aspirated the same way. 
20 µL of the suspension was combined with 20 µL of Trypan Blue® and a 
haemocytomer used to determine viable cell density. 
To freeze down, the same protocol as that in §3.2.4 was used, except cells were frozen 
at a density of 5 × 106 cells/mL. 
After seeding, RAW264.7 were maintained in media containing RANKL to induce 
osteoclastogenesis. Human RANKL was purchased from R&D Systems, UK 
(cat# 390-TN-010). A stock solution was created by dissolving 10 µg RANKL in PBS 
containing 0.1 wt/vol% bovine serum albumin.  The stock solution was aliquoted and 
stored at -20°C.  
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3.2.6 Resazurin reduction assay 
In order to evaluate cell viability, RR assays were performed. Resazurin sodium salt 
is reduced to resorufin by metabolically active cells, changing the colour of the media 
from a non-fluorescent blue to a highly fluorescent pink. The intensity of the 
fluorescence is correlated with metabolic activity [288]. 
A RR working solution was made by dissolving 10 vol% resazurin stock solution 
(1 mM resazurin sodium salt in diH2O) in BM. To perform the assay on 2D 
experiments, media was removed from each well and replaced with a known volume 
of the working solution. The well plate was then wrapped in aluminium foil and 
incubated for 4 hours under standard conditions. For 3D experiments, scaffolds were 
transferred to a new well plate before adding the working solution so only cells 
adhered to the scaffold were analysed. In both protocols, after 4 hours 200 µL of the 
reduced solution was transferred in triplicate to a 96-well plate and read on a plate 
reader (Tecan infinite 200-pro) at  λex : 540 nm and λem : 590 nm.  Finally, wells and 
scaffolds were washed once with PBS before media was replaced.   
3.2.7 Cell digestion 
To produce lysates for ALP activity, TRAP activity and DNA assays, cells were 
digested. For 2D samples, media was removed and the cells washed twice in PBS. 1 
mL of CDB (10 vol% CAB (1.5 M Tris-HCL, 1 mM ZnCl2, 1 mM MgCl2 in diH2O) 
in diH2O with 1 vol% Triton-X100) was added to the well and incubated for 30 
minutes. Wells were then scraped and the lysates transferred to 1.5 mL tubes. These 
were vortexed briefly and refrigerated overnight. For scaffolds, media was removed 
and the scaffolds washed twice with PBS. 1 mL of CDB was added to a 1.5 mL tube 
and the scaffold drained and transferred to the CDB. These were then incubated for 30 
minutes and refrigerated overnight. The following day, lysates underwent a freeze-
thaw cycle (-80oC 10 mins, 37oC 15 mins) three times, vortexing for 15 seconds and 
the end of each cycle. Samples were then centrifuged at 10,000 rpm for 5 minutes 
before vortexing again. If evaluation was not done on the same day then samples were 
stored at -80˚C directly after overnight refrigeration. 
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3.2.8 Alkaline phosphatase activity 
To quantify ALP activity, a Pierce™ pNPP Substrate Kit (Thermo Scientific) was used 
according to manufacturer’s instructions. Briefly, one tablet containing 5 mg para-
nitrophenol phosphate (pNPP) was dissolved per 5 mL of 20 vol% diethanolamine 
buffer in diH2O to form the assay substrate. 20 µL of cell lysate (§3.2.7) was added in 
triplicate to a 96 well plate. To this, 180 µL of ALP substrate was added. The well 
plate is then incubated at 37oC until a colour change from colourless to yellow is 
observed or 30 minutes has passed. The absorbance of each well was measured at 
405 nm every minute for 30 minutes in a plate reader (Tecan infinite 200-pro). Activity 
is expressed as nmol para-nitrophenol (PNP) per minute (nmol PNP/min), where one 
absorbance value equals 19.75 nmol of product (K, standard curve in Appendix §10.1), 
the volume of the sample is the volume of digestion buffer added (VSample) and the 
measured volume is the volume combined with the pNPP phosphatase solution 
(VMeasured) (Eqn. 1).  
𝐴𝐿𝑃 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =  
𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝑠𝑙𝑜𝑝𝑒 ×𝐾 × 𝑉𝑆𝑎𝑚𝑝𝑙𝑒 
𝑉𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑑
     (1) 
3.2.9 DNA quantification 
ALP activities were always determined in parallel with DNA quantities to allow 
normalisation to cell number using the same lysate. DNA was quantified using a 
Quant-iT® high sensitivity dsDNA assay kit according to manufacturer instructions. 
Briefly, the Quant-iT® reagent was diluted 1:200 in the Quant-iT® assay buffer to 
create a working solution. 90 µL of the working solution was added in triplicate to a 
black 96 well plate. 10 µL of the lysate was then added to this. The well plate was then 
shaken for 15 seconds with a linear amplitude of 1 mm, left for 10 minutes at room 
temperature to allow the DNA and reagent to conjugate and shaken again before the 
fluorescence was measured (𝜆𝑒𝑥: 485 nm,  𝜆𝑒𝑚: 535 nm). Shaking and fluorescence 
was performed and measured using a plate reader (Tecan infinite 200-pro). 
Fluorescence was converted to ng of DNA using a standard curve (Appendix §10.1), 
then similarly to ALP activity, whole sample DNA was calculated (Eqn. 2). 
𝑇𝑜𝑡𝑎𝑙 𝐷𝑁𝐴 (𝑛𝑔) =  
𝐷𝑁𝐴 𝑖𝑛 20 µ𝐿 (𝑛𝑔) × 𝑉𝑆𝑎𝑚𝑝𝑙𝑒 
𝑉𝑀𝑒𝑎𝑠𝑢𝑟𝑒𝑑
    (2) 
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3.2.10 Cell fixing 
To fix samples for histological evaluation, media was removed and the samples 
washed twice with PBS. Samples were then submerged in 3.7% formaldehyde for 
either 20 minutes for 2D cultures or 30 minutes for scaffolds. The fixative was then 
removed and the samples washed twice in PBS and then refrigerated in PBS until 
needed.  
3.2.11 Alizarin Red S staining 
Alizarin red S (ARS) is an organic dye that has a high affinity for calcium, and 
therefore can be used to stain mineral deposited by osteoblasts. A key advantage of 
this technique is that the dye can be extracted and assayed colourimetrically, allowing 
quantification of how much stain, and therefore calcium, is present [289].  
To prepare the stain, ARS was dissolved at 1 w/v% in diH2O. The solution was filtered 
using a 0.45 µm filter to remove undissolved particulates and the pH adjusted to 4.1. 
Fixed samples were rinsed twice with diH2O before submerging in a known volume 
of ARS stain and leaving for 30 minutes. The stain was then removed and the samples 
washed with diH2O every five minutes whilst orbitally shaking at 100 rpm until the 
wash-water remained clear. A known volume of 5% perchloric acid was then added 
to destain the samples and left on the orbital shaker at 100 rpm for 15 minutes. 150 µL 
was then added in triplicate to a 96 well plate and read at an absorbance of 405 nm. 
(Tecan infinite 200-pro). The concentration of ARS was determined via a standard 
curve (Appendix §10.1) created by serially diluting the staining solution in the destain. 
From this, the absorbance units can be converted to a quantity of ARS. 
3.2.12 Direct Red 80 staining 
To determine collagen production, DR80 staining was performed. To prepare the stain, 
DR80 was dissolved in saturated picric acid at 1 w/v%. The solution was filtered using 
a 0.45 µm filter to remove undissolved particulates. Depending on whether samples 
were being stained after fixing or ARS staining, samples were washed twice or thrice, 
respectively. After washing, samples were submerged in a known volume of DR80 
stain and left for 18 hours on an orbital shaker at 100 rpm. The staining solution was 
then removed and the samples washed with diH2O every five minutes whilst orbitally 
shaking at 100 rpm until the wash-water remained clear. A known volume of 
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0.2 M NaOH and MeOH in a 1:1 ratio was then added to destain the samples and left 
on the orbital shaker at 100 rpm for 20 minutes. 150 µL was then added in triplicate 
to a 96 well plate and read at an absorbance of 405 nm. (Tecan infinite 200-pro). The 
concentration of DR80 was determined via a standard curve (Appendix §10.1) created 
by serially diluting the staining solution in the destain. From this, the absorbance units 
can be converted to a quantity of DR80. 
3.2.13 TRAP staining 
2D cultures were stained for TRAP using the Acid Phosphatase Leukocyte (TRAP) 
Kit (387A), adapting the manufacturer’s instructions for in vitro staining. Cells were 
fixed by submersion if the fixative solution (citrate solution, 37% formaldehyde and 
acetone in a 25:8:65 ratio) for 30 seconds. They were then rinsed in diH2O before 
adding the staining solution (diH2O, diazotized Fast Garnet GBC solution, 
Naphthol AS-BI Phosphate solution, acetate solution and tartrate solution in a 
45:1:0.5:2:1 ratio) and incubating at 37oC protected from light for 1 hour. Samples 
were then rinsed in diH2O and counterstained in Haematoxylin solution, Gill No. 3, 
before blueing the nuclei in alkaline tap water. Samples were air-dried before imaging. 
3.2.14 TRAP activity  
TRAP staining is a qualitative measure of TRAP production and is not suitable for 3D 
cultures. Therefore, an assay to measure its activity in a sample is also necessary. For 
2D samples, a modified protocol of that outlined by Dugard, et al. was used [290]. 
Media was removed from the wells and a known volume of the assay substrate 
(2.5 mM Naphthol AS-BI phosphate in 100 mM sodium acetate buffer containing 
50 mM potassium hydrogen (+) tartrate, 2% IGEPAL and 1% ethylene glycol 
monomethyl ether (EGME) buffered to pH 5.6) was added. This was incubated for 35 
minutes at 37oC before adding the stop solution (0.3 M NaOH). The volume of stop 
solution is half the volume of assay substrate. The solution was then transferred in 
triplicate to a 96 well plate and read at an absorbance of 405 nm (Tecan infinite 200-
pro).   
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3.2.15 Scanning electron microscopy 
Samples were mounted on a carbon tab, sputter coated with gold (SC500, emscope) 
and imaged using a Philips XL-20 SEM with a beam energy of 15 kV. To prepare 
scaffolds with cells for SEM, cells were fixed in accordance with §3.2.10, then 
dehydrated in ethanol at increasing concentrations (50/70/80/90/100/100 vol% in 
diH2O) with a 10 minute exposure at each concentration. Finally, cells were immersed 
in 100% hexamethyldisilazane (HMDS) for 3 minutes before air drying overnight. 
Samples were then mounted, coated and imaged using the above protocol. 
3.2.16 Statistical analysis 
All statistical analysis was undertaken in Graphpad Prism (version 7.00). Data was 
tested for normality (D’Agostino-Pearson omnibus normality test) and outliers 
removed (ROUT method, Q = 1%). Normally distributed data was analysed by 
analysis of variance (ANOVA). Depending on whether a response was affected by one 
or two factors, either one or two-way ANOVA was performed with Tukey’s multiple 
comparisons test to evaluate significant differences. Data which did not fit a Gaussian 
distribution was analysed by a Kruskal-Wallis non-parametric test with Dunn’s 
multiple comparisons test to evaluate significant differences. Differences were 
considered significant when p<0.05. All graphs are presented as mean ± standard 
deviation unless otherwise stated and notable significant differences are indicated on 
the graphs or in the legends. All experiments were performed a minimum of two times 
in triplicate for each condition where possible. The total number of replicates (n) is 
stated in the figure legend.  
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4. Response of bone cells to oestrogen 
4.1 Introduction 
Decline in oestrogen levels following the onset of postmenopausal osteoporosis is 
associated with increased bone turnover and a loss of bone, resulting in weaker whole 
bone mechanical properties [131], [291]. However, although whole bone mass and 
strength is clearly reduced, it has been shown that the remaining tissue has increased 
stiffness and strength in comparison to normal tissue in OVX rats due to an increase 
in tissue-level mineral content [292]. Subsequent work studying mineral distribution 
in proximal femurs from OVX sheep and human female vertebrae found that the 
distribution of tissue-level mineral is altered during osteoporosis, with it becoming 
more heterogeneous, which in turn may affect the mechanics of the tissue [144], [293]. 
The mechanism by which this increase in mineralisation is initiated is unknown, but it 
may occur in an attempt to compensate for the overall loss of bone [294]. Although 
this compensation may increase the stiffness of the bone, it does not necessarily 
increase the toughness and therefore does not reduce the risk of fracture. 
Bisphosphonates can reduce fracture risk by up to 50%; however, their use is also 
associated with atypical femoral fractures due to increased mineralisation and 
therefore brittleness. It has been shown that the fracture toughness and crack-initiation 
toughness are lower in bisphosphonate treated patients in comparison to untreated 
patients [295].  
The changes in osteoclast activity after the onset of menopause are well documented, 
but the effects of menopause on osteoblasts are less well known. There is evidence to 
suggest that following the decline in oestrogen at the onset of menopause, the first cell 
type affected is the osteoblast, with changes in osteoclast activity and increased 
resorption being later events [296], [297]. 17β-estradiol is the primary type of 
oestrogen produced by the ovaries; therefore, it this form of oestrogen that is typically 
used in scientific studies. Oestrogen receptor α (ERα), rather than ERβ, is the key 
receptor for oestrogen in bone [298]. Investigations into the response of osteoblasts to 
oestrogen have yielded contradictory results. For example, it has been shown to both 
accelerate [299], [300] and slow down [301] cell proliferation, upregulate ALP 
activity [299], [301], [302] but suppress osteocalcin production [299], [301], and both 
enhance [303] and not affect [304] mineralisation. In contrast to its effect on 
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osteoclasts, oestrogen is an anti-apoptotic factor for osteoblasts [305]. Interestingly, 
Rao, et al., found only intermittent, not continuous, exposure to oestrogen increased 
mineralisation in comparison to untreated controls [300], and Park, et al., found 
blocking oestrogen receptors with the oestrogen agonist fulvestrant reduces 
mineralisation [306].  
Significantly for this project, it has been shown that osteoblasts cultured in vitro with 
oestrogen that subsequently undergo withdrawal respond in a similar way to cells from 
OVX mice, as indicated by an increase in IL-6 production [307]. From this, Brennan, 
et al., performed a subsequent study investigating whether altered mineral production 
occurs as a result of withdrawal, finding that MC3T3-E1 osteoblasts exposed to 
oestrogen for two weeks before withdrawal had significantly higher ALP activity and 
mineralisation than cultures with maintained oestrogen, and that this effect could be 
abrogated by fulvestrant [308]. 
The pathogenesis of postmenopausal osteoporosis is primarily due to the decline in 
oestrogen caused by the cessation of ovarian function. Although bone formation by 
osteoblasts may be increased slightly, the increase in resorption by osteoclasts is the 
most prominent change in bone cell activity postmenopause. This causes resorption to 
greatly exceed formation resulting in a strongly negative bone balance which impairs 
bone quality [93], [94]. Once oestrogen was identified as having a central role in the 
progression of osteoporosis, the mechanisms by which it affects bone turnover were 
investigated in order to understand the disorder better and develop treatments. 
Several cytokines, such as IL-1, IL-6, TNF and M-CSF, can regulate 
osteoclastogenesis. IL-1 and TNF stimulate resorption and inhibit formation by 
enhancing osteoclast formation. This occurs by stimulating proliferation of precursors 
and inducing other cytokines, such as IL-6, that in turn regulate maturation of 
precursors into osteoclasts [95]. Oestrogen is an inhibitor of these cytokines, 
performing a protective role by modulating their production. 
The RANK/RANKL/OPG axis is important in understanding the effect of oestrogen 
on osteoclasts [63]. RANKL binds to its receptor, RANK, but OPG can competitively 
bind to RANKL, antagonising its function [96]. In normal bone remodelling, cells 
from the osteoblast lineage express RANKL and M-CSF which conjugate with their 
receptors, RANK and c-fms, on osteoclast precursors, stimulating their maturation. 
Oestrogen increases OPG and decreases RANKL production by osteoblastic cells, as 
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well as modulating osteoclast lifespan by activating apoptosis. In addition to its action 
on the production of osteoclastogenic factors by osteoblasts and its effects on 
osteoclast lifespan, oestrogen also directly affects protein transcription downstream of 
the RANK receptor, directly inhibiting osteoclastogenesis [309], [310]. Therefore, 
reduced oestrogen results in less inhibition of osteoclastogenesis, meaning more 
mature osteoclasts are generated that in turn live longer due to a reduction in apoptosis. 
The result is the large increase in bone resorption seen in osteoporosis [97]–[99]. 
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4.2 Aims and objectives  
Oestrogen has an anabolic effect on bone in vivo by increasing osteoblast and 
decreasing osteoclast activity. The aim of this chapter was to explore the response of 
different osteoblast and osteoclast cell lines to oestrogen in vitro. From this, an 
appropriate osteoblast and osteoclast cell line can be selected for use in the in vitro 
model of postmenopausal osteoporosis developed in chapter 6. To achieve this, the 
following objectives were addressed: 
1. Assess whether 17β-estradiol affects osteoblast proliferation, differentiation 
and matrix production in vitro. 
2. Assess whether 17β-estradiol affects the RANKL:OPG ratio in vitro. 
3. Determine the effects of 17β-estradiol on osteoclastogenesis and osteoclast 
activity in vitro. 
4. Identify a suitable osteoblast and osteoclast cell lines for the in vitro model. 
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4.3 Materials and Methods 
Further to the materials and methods outlined in §3, the following are used in this 
chapter. 
4.3.1 Preparation of oestrogen supplement 
17β-estradiol (cat# E2257) was purchased from Sigma Aldrich, UK. A 100 µM stock 
solution was created by dissolving 1 mg 17β-estradiol in 1 mL of absolute ethanol then 
diluting in 35.7 mL of α-MEM. The stock solution was aliquoted and stored at -20°C. 
The same amount of vehicle was added to all wells regardless of the drug 
concentration used. 
4.3.2 Alternative cell digestion protocols 
To compare to the protocol used in §3.2.7, cells were also digested in the following 
ways: 
To digest in PBS, media was removed and the cells washed twice in PBS. 1 mL of 
PBS with 1 vol% Triton-X100 was added to the well and the well plate refrigerated 
overnight. The following day, whole well plates underwent a freeze-thaw cycle (-80oC 
10 mins, 37oC 15 mins) three times, before scraping and the lysates transferred to 1.5 
mL tubes. These were vortexed briefly, then centrifuged at 10,000 rpm for 5 minutes 
before vortexing again. Samples were stored at -80 °C until use. 
For enhanced digestion, cells were scraped in their culture media and the suspension 
transferred to microcentrifuge tubes. These were spun at 300 g for 7 minutes, the 
supernatant aspirated and the pellet resuspended in ice-cold PBS. This was centrifuged 
at 300 g for 7 minutes, the supernatant removed and the pellet resuspended in cell 
extraction buffer (CEB, Thermo Fisher Scientific, UK, cat# FNN0011) supplemented 
with 1 mM Phenylmethylsulfonyl fluoride (PMSF, 0.3 M stock solution in DMSO 
stored at -20 °C) and 5 vol% protease inhibitor cocktail (Sigma, UK, cat# P-2714). 
The suspension was then transferred to a new microcentrifuge tube and kept on ice for 
30 minutes, vortexing every ten minutes. The lysate was then spun at 13,000g for ten 
minutes to clarify the extract, which was transferred again to a new clean tube. 
Samples were stored at -80 °C until use.  
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4.3.3 Polyurethane scaffold preparation 
Polyether polyurethane foam (Caligen Foam Ltd) was cut into 5 × 5 mm (diameter × 
height) cylinders using a hole punch and scalpel in a similar method to 
Sittichockechaiwut , et al. [9]. Once cut, they were submerged in 0.1 w/v% gelatine 
solution and autoclaved at 121 oC for 30 minutes to sterilise and improve cell 
attachment.  
4.3.4 Polyurethane scaffold seeding 
Before seeding, scaffolds were soaked in BM for 30 minutes. To seed, the BM was 
aspirated and replaced with a seeding suspension of 600 cells/0.31 µL BM per mm3. 
Cells were left for 45 minutes to attach for 45 minutes before submerging in BM 
overnight. The following day, scaffolds were transferred to a new well plate and 
cultured in the appropriate medium for the remainder of the experiment. Media was 
changed every 2-3 days. 
4.3.5 RANKL and OPG ELISA 
RANKL and OPG enzyme-linked immunosorbent assay (ELISA) kits were purchased 
from R&D Systems (Cat# MTR00 and MOP00, respectively) and performed 
according to manufacturer instructions. Samples analysed were either cell culture 
supernatant for soluble isoforms of the cytokines or lysates produced using enhanced 
cell digestion for the membrane-bound variants (§4.4.2). Cell-culture supernatant was 
stored at -20°C until use. For the assay, supernatants or lysates were thawed and added 
to microplates with an affinity purified polyclonal antibody specific for RANKL or 
OPG coated onto the wells which binds the respective cytokine. Unbound substances 
are washed away before adding an enzyme-linked polyclonal antibody for either 
RANKL or OPG. After washing again, a substrate solution is then added which yields 
a blue product that turns blue upon addition of the stop solution. The intensity of the 
stopped reaction is compared to a standard curve to determine the quantity present. 
Both kits are supplied with a control concentration of the appropriate cytokine that is 
also tested during the ELISA to ensure that the assay is performed correctly. 
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4.3.6 Preparation of Vitamin D3 supplement 
1α,25-dihydroxyvitamin D3 (vitamin D3) was purchased from Sigma Aldrich, UK. A 
10 µM stock solution was created by dissolving 10 µg vitamin D3 in 2.4 mL of 
absolute ethanol. The stock solution was aliquoted and stored at -80 °C. The same 
amount of vehicle was added to all wells regardless of the drug concentration used. 
4.3.7 Assessment of osteocytogenesis 
DMP-1-GFP is a marker for osteocyte differentiation in IDG-SW3 [311]. To assess its 
production and therefore osteocytogenesis, GFP fluorescence was quantified in live 
cells using a microplate reader (Tecan infinite 200-pro). To take the measurements, 
media was removed, cells washed with PBS, and Hank’s Balanced Salt Solution 
(HBSS) added to cover the cells. Multiple measurements were taken (𝜆𝑒𝑥: 485 nm, 
𝜆𝑒𝑚: 535 nm) in the central region of experimental wells as well as wells containing 
just HBSS in order to subtract the background.  
4.3.8 Fluorescence microscopy 
Fluorescent images were obtained with a Ti-E Nikon inverted microscope (Nikon, 
Japan). Image capture and stage control were performed with MetaMorph® 
Microscopy Automation & Image Analysis Software (Molecular Devices LLC). 
To stain live cell nuclei, Hoechst 33342 stock solution was created at 10 mg/mL in 
PBS and stored at -20 °C. Media was removed and the wells washed twice with PBS. 
The stock solution was diluted 1:2,000 in PBS to create a working solution, which was 
added for five minutes before aspirating and washing two further times in PBS. Cells 
were imaged (𝜆𝑒𝑥: 360 nm, 𝜆𝑒𝑚: 460 nm) in PBS before replacing with fresh media.   
Fixed cell nuclei were stained with 4’, 6-diamidino-2- phenylindole dihydrochloride 
(DAPI, Sigma Aldrich, UK). A DAPI stock solution was created at 4 mg/mL in PBS 
and stored at 4 °C. After fixing, cells were permeabilised and stained in a solution 
containing 0.1 vol% Triton X-100 in PBS and 400 ng/mL DAPI for five minutes. This 
solution was aspirated and replaced with PBS before imaging (𝜆𝑒𝑥: 360 nm, 
𝜆𝑒𝑚: 460 nm). GFP synthesised by the IDG-SW3 did not require exogenous staining 
to image (𝜆𝑒𝑥: 470 nm, 𝜆𝑒𝑚: 525 nm) 
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4.3.9 Resorption pit quantification 
To assess the resorptive capability of the osteoclasts, cultures were performed on the 
Corning® Osteo Assay Surface under standard conditions. At the end of the 
experiment, cells were removed by bleaching (1.2 g sodium hypochlorite/100 mL) for 
5 minutes before rinsing twice with diH20 and leaving to air dry for three hours. 
To enhance contrast, the remaining phosphate in the wells was stained with either 1% 
toluidine blue in water for 2 minutes before washing until clear, or by using Von Kossa 
staining. Here, 2% silver nitrate solution was added and exposed to strong UV for 30 
minutes before rinsing with water and adding 5% sodium thiosulphate for 5 minutes 
before rinsing again. Images were then captured using brightfield on a Ti-E Nikon 
inverted microscope (Nikon, Japan). 
4.3.10 TRAP activity – lysates 
In addition to the TRAP activity protocol detailed in §3.2.14, TRAP activity was also 
quantified from lysates. Here, 250 µL of lysate was combined with 250 µL of assay 
substrate (2.5 mM Naphthol AS-BI phosphate in 100 mM sodium acetate buffer 
containing 50 mM potassium hydrogen (+) tartrate, 2% IGEPAL and 1% EGME 
buffered to pH 5.6) and incubated for 35 minutes at 37oC before adding the 250 µL of 
stop solution (0.3 M NaOH). The solution was then transferred in triplicate to a 96 
well plate and read at an absorbance of 405 nm (Tecan infinite 200-pro).   
4.3.11 Preparation of trabecular bone and dentine substrates 
3 mm diameter bovine trabecular bone or dentine cylinders were kindly provided by 
Dr. Enrico Dall’Ara, University of Sheffield. To prepare the bone samples for 
osteoclast culture, any marrow or debris was removed via ultrasonication for 15 
minutes in deionised water before insertion into a 200 µL pipette tip and cleaning with 
a dental water jet. Discs were then removed from the tip and ultrasonicated for a 
further 15 minutes. Dentine discs were ultrasonicated for 15 minutes in deionised 
water. Both discs were then sterilised in 70% ethanol for 90 minutes before washing 
three times in sterile PBS before seeding with 20,000 RAW264.7 in 75 µL of BM in 
a 96 well plate. After 30 minutes, a further 125 µL of BM containing 50 ng/mL 
RANKL was added and the cultures maintained for 16 days before SEM analysis, with 
half the media changed every 2-3 days.  
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4.4 Results 
4.4.1 Phenol red only affects oestrogen responsiveness at low concentrations 
Phenol red is a pH indicator used in most culture media. However, it has a structural 
resemblance to some oestrogens and has been shown to affect oestrogen responsive 
cell lines [312]. To see whether the presence of phenol red was affecting the 
responsiveness of MC3T3-E1 to oestrogen, cultures were performed in phenol free 
media. There is no phenol free equivalent of the α-MEM produced by Lonza; 
therefore, a phenol-containing (PC) and phenol free (PF) version of a different α-MEM 
were used (Gibco, cat# 12571063 & 41061029, respectively). The effects of oestrogen 
added at different concentrations to OIM composed of these two media and the regular 
α-MEM were investigated over 21 days in MC3T3-E1. Cell viability, ALP activity 
and ARS were measured (Fig. 4.1). 
MC3T3-E1 proliferated in all three media formulations at all time timepoints. 
Proliferation was significantly faster in the PF and PC media than the Lonza. There 
was no significant difference in metabolic activity at any time point between the PC 
and PF for any oestrogen concentration.  
In all three media, normalised ALP activity increased with oestrogen concentration. 
ALP activities and total DNA were significantly higher in the PC and PF media in 
comparison to Lonza (data not shown), as expected from the metabolic activity; 
however, the normalised ratios remained similar. At 0.1 nM, normalised ALP activity 
was significantly higher in the PF media than PC and Lonza, but not at 10 or 100 nM. 
Furthermore, the difference between 0 and 0.1 nM was greatest in the PF group. 
Therefore, it appears that phenol red can mask the effect of very low concentrations 
of oestrogen, but at higher concentrations this effect is lost. Mineralisation was also 
higher in the PC and PF formulations, but oestrogen had no significant effect in any 
media type. Therefore, the Lonza α-MEM was used for all subsequent work. 
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Figure 4.1: Effect of phenol and oestrogen on MC3T3-E1. Comparison of Lonza, 
phenol containing (PC) and phenol free (PF) media with different concentrations of 
oestrogen, examining (A) metabolic activity (B) day 21 ALP activity (C) day 21 ARS. 
For clarity, a legend for each individual growth curve is not given, instead each media 
type is coloured differently (n=6). 
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4.4.2 Oestrogen withdrawal does not further enhance MC3T3-E1 activity 
It has been shown in the literature that exposing MC3T3-E1 osteoblasts to oestrogen 
for a prolonged period then withdrawing it results in a greater increase in ALP activity 
and mineralisation than exposure alone [308]. Here, cells were passaged in the 
presence of 10 nM oestrogen (17β-estradiol) for 14 days. They were then seeded and 
the oestrogen level either maintained at 10 nM (E2), reduced to 0.1 nM (E1), or 
withdrawn (E-) (Fig. 4.2). 
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Figure 4.2: Effect of oestrogen withdrawal on MC3T3-E1. Day 14 (A) ALP (all groups 
significantly different to each other (p<0.01)) (B) ARS (maintained, reduced 
withdrawn not significantly different to each other but all significantly higher than 
untreated control (p<0.001) (n=6). 
All oestrogen exposed groups had higher ALP activity and mineralisation than the 
untreated control. Maintained oestrogen had the highest normalised ALP activity and 
withdrawn was still significantly higher than untreated. There was no significant 
difference in mineral between oestrogen exposed groups, possibly due to the very low 
levels of mineralisation.  
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4.4.3 Mineralisation capacity of MC3T3-E1 can be increased with varied 
supplementation 
The mineralisation capacity of MC3T3-E1 is far lower than other cell lines, such as 
MLOA5 [284]. As production of resorbable mineral is essential in an osteoporosis 
model, it is imperative that sufficient levels are deposited. Although the concentrations 
of βGP and AA2P added to OIM here are in line with that reported in the literature, 
higher levels are used by some groups. Therefore, the effect of increasing the 
concentrations typically used were examined by adding either normal (1X) or double 
(2X) concentrations of βGP and AA2P (Fig. 4.3). 
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Figure 4.3: Effect of varied osteogenic supplementation of MC3T3-E1. Day 21 ARS 
staining for varied supplementation in OIM on MC3T3-E1 cells. 1X is normal 
supplementation, 2X is doubled. * = p<0.05, **=p<0.01, ***=p<0.0001 (n=6). 
Doubling the BGP concentration led to significantly higher mineralisation whereas 
doubling only AA2P did not. The combination of two times BGP and AA2P caused 
four times the amount of mineralisation in a three-week period in comparison to 
regular OIM.  
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4.4.4 Oestrogen withdrawal has no effect of MLOA5 
To the author’s knowledge, the oestrogen responsiveness of MLOA5 has not 
previously been tested. Initially, the withdrawal experiment in §4.4.2 was repeated 
with MLOA5-S (Fig. 4.4). 
No effect of oestrogen was seen on MLOA5-S, with no significant difference in ALP 
activity or mineralisation for any of the oestrogen exposed groups in comparison to 
the untreated control. The MLOA5-S cell line was prone to cell sheet detachment once 
confluent. This meant that mineral deposition in the reduced group could not be 
quantified. 
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Figure 4.4: Effect of oestrogen withdrawal on MLOA5. Mean ± SD on day 14 for (A) 
ALP (no significant different between groups) (B) ARS (no significant difference 
between groups with the exception of reduced vs. all others) (n=6). 
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4.4.5 Oestrogen exposure has no effect on MLOA5 even at extreme 
concentrations 
Due to MLOA5 being much more metabolically active that MC3T3-E1, it was 
possible that 10 nM was not a sufficiently high concentration of oestrogen to have an 
effect. Therefore, their response to concentrations ranging from 0 nM to 10,000 nM 
was studied over seven days on MLOA5-S (Fig. 4.5) and 14 days on MLOA5-K 
(Fig. 4.6). 
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Figure 4.5: Effect of oestrogen exposure on MLOA5-S. Mean ± SD on day 7 for (A) 
ALP (no significant difference between groups) (B) ARS (no significant difference 
between groups with the exception of 0 nM vs 10,000 nM (p<0.01) for MLOA5-S 
(n=6). 
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Figure 4.6: Effect of oestrogen exposure on MLOA5-K. Mean ± SD on day 14 for (A) 
ALP (no significant difference between groups) (B) ARS (no oestrogen exposed group 
was significantly higher than the 0 nM group) for MLOA5-K (n=6). 
Oestrogen had no effect on the ALP activity or calcium production of MLOA5-S or 
MLOA5-K. Detachment of the cell line once confluent again meant that mineral 
quantification could not be performed for all groups. Due to both MLOA5-S and 
MLOA5-K not behaving as described in the original literature about the creation of 
the MLOA5 cell line, a new source of MLOA5 (MLOA5-A) was purchased. However, 
these also did not function as described in literature and although there were still 
metabolically active cells after seven days, it was clear that a large proportion of the 
MLOA5-A cells were dying in comparison to MLOA5-K; therefore, the experiment 
was ended and oestrogen responsiveness not assessed (Fig. 4.7). 
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Figure 4.7: Comparison of MLOA5-K and MLOA5-A. Cell metabolic activity of 
MLOA5-A compared to MLOA5-K over eight days (n=6). 
Despite seeding at a density just below confluent as stated by Kerafast, it seems that 
the MLOA5-A cells begin to die once confluent. Therefore, cells were seeded at a 
lower density (100,000 per well vs. 335,000 per well) initially to see whether this 
influenced how well they survived. Cells were discernibly dead before day 7 therefore 
the growth curve is not included. 
4.4.6 Oestrogen exposure has no effect on IDG-SW3 
Due to the low mineralisation capacity of MC3T3-E1 and the lack of reproducibility 
of MLOA5, an alternative cell line was sought. IDG-SW3 was identified as an 
appropriate cell line for these studies. Its oestrogen responsiveness was assessed by 
exposure to 0 – 100 nM for three weeks and quantifying ALP activity, total DNA, 
mineralisation and osteocytogenesis by measuring GFP expression (Fig. 4.8).  
As with MLOA-5, there was no significant effect of oestrogen on the proliferation, 
ALP activity or mineralisation of IDG-SW3. Furthermore, there was no significant 
effect of oestrogen on osteocytogenesis, as indicated by GFP expression. However, 
the mineralisation capacity of IDG-SW3 is far superior to MC3T3-E1, and the 
behaviour of the cell line appeared to be more consistent than MLOA5.  
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Figure 4.8: Response of IDG-SW3 to oestrogen. (A) GFP expression indicating 
osteocytogenesis (no significant difference) (B) total DNA (no significant difference) 
(B) Normalised ALP (no significant difference) (C) ARS (no significant difference) 
(n=6). 
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4.4.7 Varied temperature and media type can hold IDG-SW3 as osteoblasts 
IDG-SW3 have been designed to proliferate at 33 °C in EM and undergo 
osteocytogenesis at 37 °C in SM. At 33 °C in the presence of IFN-γ, they express a 
temperature-sensitive mutant of a tumour antigen that induces continuous proliferation 
and immortalisation, but at 37 °C without IFN-γ they resume their normal proliferative 
ability [283]. To examine the effects of temperature and media supplementation, IDG-
SW3 were seeded at 25,000 cells per well in a 48 well plate and cultured at 33 °C in 
EM for three days until confluent. They were then maintained for a further 28 days at 
either: 33 °C in EM (33-EM), at 33 °C in SM (33-SM), at 37 °C in EM (37-EM), or at 
37 °C in SM (37-SM). Metabolic activity, ALP activity, DNA, GFP expression and 
calcium deposition were analysed at various time points (Fig. 4.9) 
As expected, the highest metabolic activities and total DNA were found in cultures 
maintained in EM, with the highest total DNA in the 33-EM group at all time points. 
Interestingly, the highest ALP activities were found in the 33-SM group, rather than 
the 37-SM group. This pattern occurs even after normalising to total DNA. GFP 
expression is highest in the 33-SM group by day 14, but normalising to total DNA to 
account for variation in cell number shows that the condition that stimulated the 
highest amount of osteocytogenesis was 37-SM. By 28, cultures maintained in 37-SM 
had GFP expression approximately 4 times higher than 33-SM, indicating that 
osteocytogenesis occurs at the highest rate in week four. Cultures maintained in EM 
have no significant change in GFP expression. 
Mineralisation was significantly higher in the 33-SM group at day 21 and day 28, 
although substantial mineralisation still occurred at 37-SM. Cultures maintained in 
EM did not mineralise. These results indicate that SM is clearly needed for mineralised 
matrix production and osteocytogenesis. However, at 33 °C in SM the osteoblast 
phenotype capable of mineralising with high ALP activities is maintained, whereas at 
37-SM, IDG-SW3 become osteocytes, decreasing ALP and increasing GFP 
expression.  
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Figure 4.9: Effect of varied temperature and media composition on IDG-SW3. (A) 
metabolic activity (B) ALP activity (C) total DNA (D) normalised ALP activity (E) 
GFP expression and (F) normalised GFP expression (H) photograph of ARS staining 
before quantification in IDG-SW3 (n=4). 
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4.4.8 RANKL:OPG Ratio 
The ratio of RANKL to OPG is an important determinant of whether 
osteoclastogenesis will occur. To compare the ratios of the three cell lines, all three 
were seeded either as a monolayer in a well plate at 200,000 per well in a six well plate 
or in a 5 × 5 PU scaffold at 60,000 per scaffold and maintained for seven days in their 
differentiation media. 1 mL of the media was then taken for ELISA analysis 
(Fig. 4.10).  
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Figure 4.10: Day 7 RANKL and OPG production in various osteoblastic cell lines. 
Concentrations of (A) sRANKL and (B) OPG as determined by ELISA on day 7. No 
detectable sRANKL in any condition. OPG not significantly different in monolayer, 
MLOA5-K significantly higher in scaffolds than MC3T3-E1 and IDG-SW3 (n=3). 
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No RANKL was detectable from any cell line in monolayer or scaffolds culture. The 
ELISA was performed correctly as evidenced by the standard curve produced and the 
control kit standard provided being in the correct range. OPG production was not 
significantly different for any cell line in 2D; however, levels were significantly lower 
in 3D for MC3T3-E1 and IDG-SW3 in comparison to MLOA5-K.  
Performing ELISAs on cell culture media can only evaluate the presence of 
soluble/secreted isoforms of the cytokines. Vitamin D3 has been shown to induce 
RANKL production. Therefore, MC3T3-E1 and IDG-SW3 were cultured with or 
without 10 nM vitamin D3 for seven days and media samples taken prior to digestion 
using the cell extraction protocol in §4.3.2. ELISAs were then performed on the media 
and lysates for RANKL. Normalised ALP activities were also determined from the 
lysates. The addition of vitamin D3 was found to cause cell death in the IDG-SW3, 
whereas the addition of the vehicle control did not. From changes in media colour this 
appeared to be due to a pH change; therefore, the effect of the addition of 10 mM of 
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) pH buffer was also 
evaluated (Fig. 4.11). 
Neither cell type produced a detectable amount of RANKL in either the media or 
lysate whether vitamin D3 was present or not, indicating that neither cell type produces 
either the soluble or membrane-bound isoform. The addition of vitamin D3 had no 
effect of the ALP activity of MC3T3-E1. However, the presence of vitamin D3 
significantly reduced the ALP activity of IDG-SW3 (p<0.01). The presence of HEPES 
had no significant effect on ALP activity whether vitamin D3 was present or not. 
Media containing vitamin D3 was visibly more orange 24 hours after addition in 
comparison to vehicle-only controls, indicating a more acidic pH. By comparing the 
cell phenotype using an optical microscope, there were clearly dead or dying cells in 
wells treated with vitamin D3. Total DNA values on day 7 were approximately 50% 
lower by day 7 in treated wells. No such effect was seen on MC3T3-E1.  
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Figure 4.11: Effect of Vitamin D on RANKL production in MC3T3-E1 and IDG-SW3. 
(A) sRANKL and mRANKL concentrations of MC3T3-E1 and IDG-SW3 with and 
without vitamin D3 and (B) effect of vitamin D3 on normalised ALP activity of 
MC3T3-E1 and IDG-SW3 on day 7 (n=3) (C) Photo culture medium and cell 
phenotype after addition of vehicle and 10 nM vitamin D3. 
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The expression and ratio of RANKL and OPG expressed by osteoblastic cells changes 
as they progress from progenitor to osteocyte. Osteoblast precursors typically have a 
high RANKL:OPG ratio (high RANKL and low OPG), which decreases as they 
differentiate and produce osteoid (RANKL decreases, OPG increases), reducing their 
ability to induce osteoclastogenesis [210]. However, osteoblasts that become 
embedded in the bone and terminally differentiate into osteocytes are capable of 
inducing osteoclast differentiation through RANKL expression, showing that the 
RANKL:OPG ratio does not continually decline. MLO-Y4 osteocytes have been 
shown to induce osteoclastogenesis in direct cell-cell contact as they produce 
mRANKL [211].  
The ELISAs performed thus far have tested the supernatants and cell extracts of 
osteoblasts which are thought to have the lowest RANKL expression in comparison 
to the rest of the osteoblast lineage. IDG-SW3 are capable of undergoing 
osteocytogenesis. To determine whether this differentiation results in a change in their 
ability to synthesise RANKL, the experiment exploring the effect of oestrogen on 
IDG-SW3 in §4.4.6 was continued to fully allow osteocytogenesis to occur [283].  
GFP expression was measured and media supernatants collected each week for 
RANKL and OPG ELISA. On day 35, cells were digested using the enhanced 
digestion technique, allowing mRANKL to be determined.  
The greatest increase in osteocytogenesis occurred in the fourth and fifth weeks of 
culture (Fig. 4.12). In the first four weeks of culture there was no significant effect of 
oestrogen on osteocytogenesis However, at day 35, 100 nM of oestrogen had 
significantly higher GFP expression than 0 nM (p<0.01). Through fluorescence 
microscopy, GFP expression was found to localise to areas of mineralisation 
(Fig. 4.13). 
No sRANKL was detectable at any time point. OPG expression  increased at each time 
point, and was over the detection limit of the ELISA on days 28 and 35. mRANKL 
was only detectable on day 35 in cultures containing oestrogen, with 100 nM oestrogen 
having the highest mRANKL expression of approximately 0.75 ng/mL.  
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Figure 4.12: The effect of oestrogen and osteocytogenesis on RANKL expression. 
(A) oestrogen had no significant effect on GFP expression at any time point, except 
D35 where 100 nM was significantly greater than 0 nM (p<0.01) (n=6) (B) OPG 
expression increased at each time point and was above the detection limit on D28 and 
35. No sRANKL detectable at any time point (n=3) (C) Oestrogen exposure was 
necessary for mRANKL detection on day 35 (n=3). 
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Figure 4.13: Composite images of IDG-SW3 GFP fluorescence. GFP fluorescence 
localises to regions of mineralisation. Left column: mineral in centre, Right column: 
mineral at top and bottom only. (A&B) Brightfield images (C&D) GFP fluorescence 
(E&F) Composite of brightfield, GFP and DAPI nuclei staining. All at 10× 
magnification, same exposure for each wavelength. Scale bar 200 µm. 
 
146 
 
4.4.9 RAW264.7 mature in the presence of sRANKL 
To mature osteoclast precursors into osteoclasts they need to be stimulated with M-
CSF and RANKL. RAW264.7 inherently produces M-CSF; therefore, only exogenous 
supplementation with RANKL is necessary to stimulate osteoclastogenesis. Mature 
was defined as a large, multinucleated, TRAP positive osteoclast capable of resorbing 
a substrate.   
To ensure that the source of RAW264.7 used was capable of undergoing 
osteoclastogenesis they were initially seeded at 20,000 cells/well in a 6 well plate and 
cultured with 25 ng/mL RANKL for six days (Fig. 4.14A-C). Clear purple staining for 
TRAP was only visible in cultures with RANKL. In cultures with RANKL, large, 
multinucleated osteoclasts were visible and well as smaller, TRAP positive 
macrophages. To confirm multinucleation, cultures were stained with Hoechst 33342 
and imaged on day 6. Overlays of brightfield and fluorescent images show that 
multinucleation only occurs with RANKL (Fig. 4.14D-F). From the position of the 
nuclei around the perimeter of the large osteoclasts, it is possible to see the typical ring 
shape formed by actin, another marker of osteoclast maturity.  
Osteo Assay Surface plates have a thin film of inorganic crystalline calcium phosphate 
on the culture surface to mimic bone material. In the presence of mature osteoclasts, 
areas of this film will be removed, leaving visible pits in the surface. RAW264.7 were 
seeded onto Osteo Assay Surfaces at 20,000 cells per well and cultured in either 0, 25 
or 50 ng/mL of RANKL for 12 days before bleaching. Wells were either left unstained, 
or stained with toluidine blue or Von Kossa (Fig. 4.15). Whole wells were imaged at 
10 × magnification using automated stage control software (MetaMorph®, Molecular 
Devices LLC). Images could not be stitched to create a composite image due to a lack 
of discernible features in each image for an algorithm to identify. Therefore, ten 
images were selected at random for each well using a random number generator to 
assess resorption pit formation. Cultures without RANKL did not mature and no 
resorption pits were detectable. Cultures with 25 ng/mL RANKL formed 
multinucleated osteoclasts, but resorption pits were small and sparse. 50 ng/mL 
RANKL resulted in frequent, large resorption pits over the entire culture surface. Due 
to the film being only microns thick, staining was not found to enhance contrast. 
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Figure 4.14: Effect of RANKL on RAW264.7. TRAP staining of RAW264.7 (A) 
cultured with 25 ng/mL RANKL at high magnification (B) whole well plate view 
showing clear positive staining with RANKL (C) without RANKL at the same 
magnification as (A). Hoechst 33342 staining day 6 (D) 6 × magnification with 
RANKL (E) 15 × magnification with RANKL (F) 6 × magnification without RANKL. 
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Figure 4.15: Analysis of RAW264.7 resorption. Brightfield images of randomly 
selected well regions. Resorption pits circled in red. (A-C) 0 ng/mL RANKL, no pits 
detected. (D-F) 25 ng/mL RANKL. Some pits, sparse, small. (G-L) 50 ng/mL RANKL, 
multiple pits, often in groups, range of sizes from very small to large. Present 
throughout well.  
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4.4.10 TRAP activity is dose dependent and is significantly reduced by digestion  
As with ALP activity, it is also possible to quantify TRAP activity from cell lysates, 
rather than qualitatively staining. The advantage of this is that ALP and TRAP activity 
and total DNA can be quantified for the same sample, which reduces the number of 
experimental wells/scaffolds needed as a separate one is not needed for each assay. To 
determine the most efficacious method of quantifying TRAP activity, RAW264.7 
were seeded at 5,000 cells per well in a 24 well plate in 25 ng/mL of RANKL and 
cultured for ten days. TRAP activity was then determined by either direct application 
of the assay substrate, as outlined in §3.2, or by digesting using the standard, PBS or 
enhanced method and combing the lysates with the assay substrate, as outlined in §4.3 
(Fig. 4.15A&B). To determine the effect of RANKL on TRAP activity, RAW264.7 
were seeded at 5,000 cells per well in a 24 well plate in either 0, 25 or 50 ng/mL of 
RANKL and cultured for six days before digesting using the PBS method and 
determining TRAP activity (Fig. 4.16).  
There were no significant differences in the TRAP activities of the normal, PBS or 
enhanced digestion protocols. Direct measurement of TRAP yielded a significantly 
higher apparent TRAP activity than any of the digestion protocols. Cells were digested 
in 1 mL of digestion buffer and 250 µL was analysed, therefore it was anticipated that 
the TRAP activity would be one quarter of the direct method. However, direct 
measurement is 8 times higher than the highest digestion method (direct mean 0.19 vs 
PBS mean 0.02375). Therefore, half of the apparent TRAP activity is lost by digesting. 
This could be due to loss of the amount of enzyme during the digestion process or a 
loss of enzyme efficacy because of the digestion process. Visually, no discernible 
yellow colour change is observed for the lysate activities after adding the stop solution.  
TRAP activity increases with RANKL concentration. Due to the significant reduction 
in apparent TRAP activity in cell lysates, all TRAP activity described in the rest of 
this thesis was performed using the direct method. 
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Figure 4.16: Comparison of digestion protocol on apparent TRAP activity. Mean ± 
SD of (A) TRAP and (B) Normalised TRAP activity for different digestion methods. 
DIRECT TRAP normalised to NORMAL digestion DNA. DIRECT significantly higher 
(p<0.0001) that all other methods. No significant difference between any digestion 
method. (C) TRAP activity at 0, 25, or 50 ng/mL RANKL. Activity significantly 
increases RANKL concentration (n=6). 
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4.4.11 Seeding density affects osteoclastogenesis 
To assess the effect of seeding density on the ability of osteoclast precursors to mature, 
RAW264.7 were seeded at either 400 to 5,000 cells per well in a 96 well plate and 
cultured for six days in either 0, 25, or 50 ng/mL of RANKL before determining TRAP 
activity (Fig. 4.17). 
As seen in when using digestion, response to RANKL is dose-dependent. No TRAP 
activity was present without RANKL and 50 ng/mL RANKL resulted in significantly 
higher TRAP activity at every seeding number than 25 ng/mL. For both RANKL 
exposures, there was no significant difference between 400 and 1,000 cells and 
between 2,500 and 5,000 cells. For both concentrations, 400 and 1,000 were 
significantly higher than 2,500 and 5,000 cells. The culture surface area of a 96 well 
plate is 0.32 cm2; therefore, the optimal seeding density is approximately 3,000 
cells/cm2. 
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Figure 4.17: TRAP activity in response to varied RANKL concentrations and seeding 
number. 50 ng/mL significantly higher than 25 ng/mL for every seeding number. No 
significant difference between 400 and 1,000 cells at 25 or 50 ng/mL. 400 and 1,000 
significantly higher than 2,500 and 5,000 at 25 and 50 ng/mL (n=4). 
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4.4.12 Oestrogen inhibits osteoclast viability and activity 
Oestrogen inhibits the RANK/RANKL pathway and upregulates osteoclast apoptosis. 
To determine its effects on RAW264.7, cells were seeded at 20,000 cells per well in a 
six well plate and cultured with 50 ng/mL RANKL and either 0, 10 or 100 nM 17β-
estradiol for sixteen days. Metabolic activity was assessed by RR on days 1, 5, 12, and 
16 and TRAP activity and total DNA quantified on day 7 (Fig. 4.18). 
10 nM oestrogen had no significant effect on metabolic activity at any time point. 
100 nM significantly lowered metabolic activity from day 5 onwards, with a dramatic 
decrease on day 16. 10 nM did lower the total DNA in comparison to 0 nM, but not 
significantly, whereas the reduction at 100 nM was significant. 100 nM oestrogen also 
significantly reduced the total TRAP activity. Interestingly, the reduction in DNA and 
TRAP activity at day 7 was 28% and 27%, respectively, meaning that normalised 
TRAP activities were similar and indicating that the reduced activity may be due to 
the effect on cell lifespan.  
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Figure 4.18: Effect of oestrogen on RAW264.7. (A) metabolic activity - significantly 
lower at 100 nM from day 5 onwards, no difference between 0 and 10 nM (B) DNA – 
only 100 nM significantly lower (C) TRAP activity – 100 nM significantly lower (n=3-
6). 
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4.4.13 IDG-SW3 support osteoclastogenesis in direct co-culture 
As seen by the RANKL ELISA, none of the potential osteoblast cell lines secrete 
detectable sRANKL or mRANKL. This means that in the co-cultures performed in the 
in vitro model of postmenopausal osteoporosis developed in chapter 6, exogenous 
RANKL will have to be added to induce osteoclastogenesis. However, they do 
produce OPG, an antagonist for RANKL. This means that the RANKL:OPG ratio will 
still be affected by the presence of osteoblasts.  
As OPG has the potential to completely negate the effects of RANKL at high enough 
concentrations, co-cultures of MLOA5-K or IDG-SW3 with RAW264.7 were 
performed to determine which cell line has a RANKL:OPG ratio amenable to 
osteoclastogenesis. MC3T3-E1 were not used due to their low level of mineralisation. 
Osteoblasts were seeded at 1,500 cells/cm2 in a 12 well plate before the addition of 
3,000 RAW264.7/cm2 24 hours later. The cultures were maintained for 7 days with 
either 0 or 50 ng/mL RANKL and compared to monocultures of osteoblasts or 
RAW264.7 (Fig. 4.19).  
For both co-cultures, no TRAP activity was present without exogenous RANKL 
addition, confirming that neither mRANKL or sRANKL are being produced by the 
osteoblasts. In co-culture with MLOA5-K, osteoclastogenesis did not occur as the 
TRAP activity was not significantly different to the MLOA5-K monoculture. 
Exogenous RANKL did not increase the co-culture activity, potentially due to 
overwhelming OPG production. In co-culture with IDG-SW3, TRAP activity was 
significantly higher when exogenous RANKL was added but significantly lower than 
the RAW264.7 monoculture. This could be due to OPG production by the osteoblasts, 
but in smaller quantities than MLOA5-K.  
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Figure 4.19: Day 7 TRAP activity for co-cultures of (A) MLOA5-K and RAW264.7 
and (B) IDG-SW3 and RAW264.7. Neither osteoblast could stimulate 
osteoclastogenesis without exogenous RANKL. MLOA5-K inhibited 
osteoclastogenesis in co-culture. TRAP activity was lower in co-culture with IDG-
SW3 than mono-culture, but still substantial (n=6). 
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4.4.14 RAW264.7 failed to resorb ex vivo tissue 
In addition to quantifying resorption on the Osteo Assay Surface, RAW264.7 were 
also cultured on bovine trabecular bone and dentine to see whether resorption pits 
could be identified. Cultures were maintained for 16 days with 50 ng/mL (bone) or 
100 ng/mL (dentine) RANKL before SEM examination (Fig. 4.20).  
From the SEM images, it is clear that osteoclasts were able to adhere, mature and 
grow. However, it was not possible to identify clear resorption pits on either substrate.  
 
 
Figure 4.20: Composite of multiple SEM images of RAW264.7 on trabecular bone and 
dentine (bottom right). 
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4.5 Discussion 
The work performed in this chapter primarily aimed to determine the effects of 
oestrogen on a range of bone cell lines with the aim of selecting an osteoblast and 
osteoclast cell line suitable for an in vitro model of postmenopausal osteoporosis. First, 
the effect of potentially oestrogenic factors in culture media was considered, then a 
range of common osteoblast cell lines were exposed to various oestrogen 
concentrations and treatment regimens and the effects on their activity evaluated. The 
effect of oestrogen and varied seeding density on RAW264.7 osteoclastogenesis was 
then examined, and finally, preliminary co-cultures of osteoblasts and osteoclasts were 
performed to allow the most suitable cell lines to be selected.  
Initially the effect of phenol red in the media was assessed. Phenol red is a pH indicator 
commonly found in cell culture media. It has structural similarities to some non-
steroidal oestrogens and can have oestrogenic effects, for example strongly promoting 
cell proliferation, progesterone receptor expression and susceptibility to chemotherapy 
in MCF-7 breast cancer cells [312]–[314]. Additionally, it has been found to have 
oestrogenic effects on bone cells in vitro [315]. However, other work suggests that its 
concentration in culture media is not sufficient to cause oestrogenic effects [316]. The 
PC and PF media used here both resulted in a higher proliferation rate of MC3T3-E1 
than the regular BM. This is likely due to them being more ‘complete’ compositions 
of α-MEM as they contain ribonucleosides and deoxynucleosides. ALP activity is 
normalised to DNA, therefore the differences in cell number due to differences in 
proliferation rate are accounted for. It can be seen that there is no significant difference 
in ALP activity per cell between media types at 0 nM and 100 nM oestrogen. 
Mineralisation is higher in the PC and PF media due to the greater cell number. 
However, there is no significant difference in mineralisation at different oestrogen 
concentrations. Although the absolute values differ between PC and PF for ALP 
activity and mineralisation, the same response to oestrogen is seen whether phenol red 
is present or not, even at 0.1 nM. Therefore, it does not seem necessary to use phenol 
free culture medium. In addition to the oestrogen added to the cultures, it is likely that 
it is also present in the FBS added to the media. This effect could be removed by 
charcoal stripping FBS, removing hormones, growth factors and cytokines from the 
serum [317]. However, this process will cause differences in cellular performance in 
comparison to non-stripped FBS due to the removal of these factors, and as an effect 
of oestrogen can be seen without charcoal stripping, it seems unnecessary in this work. 
A better alternative to charcoal-stripping would be to use a serum-free or chemically 
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defined medium. This allows confidence that none of the factors being studied are 
already present in the culture medium and that no unknown factors are masking effects 
that would otherwise be observed. However, due to the high comparative cost and 
difficulties in identifying suitable media, it was instead decided to use a single batch 
of FBS for all experiments to maintain the same concentration of factors within the 
serum.  
Although the effects of oestrogen withdrawal on MC3T3-E1 are not in full agreement 
with the work by Brennan et al., who showed that withdrawal significantly increased 
activity [308], the response seen here would still be applicable for the in vitro model. 
It is believed that postmenopause, osteoblast activity increases. However, due to the 
much greater increase in osteoclast activity, the net result is bone loss and therefore 
the increase is not evident, with the possible exception of increased mineral content in 
certain regions of the skeleton [144], [292], [293]. Therefore, if in the model to be 
developed oestrogen withdrawal does not promote osteoblast activity, the net effect 
will be similar as the amount of bone will reduce. This means that MC3T3-E1 could 
have been applicable for the model if they were able to mineralise sufficiently. 
Although mineralisation can be increased by doubling the osteogenic 
supplementation, these high phosphate concentrations have been related to detection 
of non-cell produced mineralisation as a result of spontaneous precipitation of calcium 
phosphate [318]. These deposits have a reduced ratio of calcium and phosphate ions 
in the mineral deposited in comparison to hydroxyapatite in vivo, where the ratio is 
approximately 1:1.63 [319]. As this spontaneous mineralisation does not represent 
what happens physiologically, where the mineral deposition is performed by 
osteoblasts, it would be more suitable to use an osteoblast cell line that had a higher 
mineralisation capacity at 5 mM βGP. 
MLOA5 are capable of rapidly depositing mineralised extracellular matrix in sheets 
and have a typical post-osteoblast phenotype [284]. However, both MLOA5-S and 
MLOA5-K were found to not respond to oestrogen withdrawal or oestrogen exposure 
in the same way as MC3T3-E1, with no significant effect on ALP activity or ARS 
staining). This could have been due to much higher metabolic activity than MC3T3-
E1; however, as a response was not seen at a concentration 100,000× greater than that 
used to stimulate MC3T3-E1 this seems unlikely. Furthermore, this concentration of 
17β-estradiol is many orders of magnitude higher than the levels found in serum in 
mice, whereas 10 – 100 nM is more physiologically relevant [320]. It seems more 
likely that this cell line is already producing ALP and mineralising at its maximum 
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capacity, and therefore cannot be further stimulated using oestrogen. This  inability to 
further upregulate ALP activity and mineral deposition in the MLOA5 cell lines agrees 
with the findings of Wittkowske during a parallel project, who found that mechanical 
stimulation was unable to upregulate these processes, despite published results 
showing their responsiveness [321], [322].  
It is possible that the detachment observed in some MLOA5 cultures was due to an 
increase in cell proliferation in response to oestrogen exposure. At the start of puberty 
when oestrogen levels begin to increase, epiphyseal growth is promoted causing the 
characteristic ‘growth spurt’, indicating the effects it can have on osteoblast-lineage 
cell proliferation [323]. Furthermore, in vitro, oestrogen has been shown to accelerate 
cell proliferation [299], [300]. However, it does not always promote proliferation, as 
high oestrogen levels towards the end of puberty promote bone maturation and 
epiphyseal fusion, and there are also in vitro studies that show it can slow down cell 
proliferation [301]. Therefore, due to the conflicting effects of oestrogen on cell 
proliferation, the sporadic nature of MLOA5 detachment, and the very high 
proliferation rate of the cell line even prior to treatment, it seems more likely that the 
detachment overserved was due to the inherent tendency of the cell line to overgrow 
in monolayer cultures regardless of any treatment applied. 
One potential reason for MLOA5 being unable to respond to oestrogen is that they 
may lack ERα. To date, no study has explored whether this cell line responds to 
oestrogen or has oestrogen receptors, and it was not mentioned in the original literature 
detailing its development [284]. However, as the cell line was developed from a mouse 
and there is no good reason that the protocol used would have removed ERα, it seems 
unlikely that the original MLOA5 would have lacked the receptor. 
Three different sources of MLOA5 were assessed in this work. MLOA5-K seem to be 
the variant most similar to that originally described by Kato, et al. [284].  However, in 
comparison to the original literature, none of the MLOA5 variants, including that 
purchased directly from the original developer, behave as originally described. All of 
the variants were provided at a high passage (minimum 20); therefore, differences may 
be explained by careless passaging where the fastest proliferating cells have 
unintentionally been selected for, similar to how multiple subclones of MC3T3-E1 
were developed [281]. Furthermore, passage number is a poor description of a cell 
lines age as it does not take into account splitting at different ratios or confluences. 
Where possible, all work done in this thesis was from cell banks created before 
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experiments began to ensure that all cells seeded for experiments were the same age. 
Where new cell lines were purchased, passage doubling level rather than passage 
number was recorded so that an accurate record of the cell ‘age’ could be kept. 
IDG-SW3 is a relatively newly developed cell line. As with MLOA5, to date the effect 
of oestrogen on their activity has not been explored. Here it has been found that 
oestrogen has no significant effect on proliferation, ALP activity or mineralisation. 
However, the findings that only one out of three osteoblast cell lines responded 
positively to oestrogen is not unthinkable. Reports on the effects of 17β-estradiol on 
osteoblast behaviour are varied and contradictory [299]–[304], and reports on 
response to oestrogen withdrawal in vitro are sparse. Furthermore, although there is 
evidence for increased tissue mineralisation in a heterogeneous manner to counteract 
whole bone weakening post-OVX, this is not a well-established response and does not 
occur in all bone tissues. This change in tissue-level mineral distribution was seen in 
ovine proximal femurs and human vertebrae, both of which undergo high 
physiological loads, whereas cultures here were performed under static, unloaded 
conditions [144], [293], [294].  
IDG-SW3 are designed to proliferate at 33 °C in EM and undergo osteocytogenesis at 
37 °C in SM. At 33 °C in the presence of IFN-γ they undergo continuous proliferation 
and are immortalised due to the presence of a temperature-sensitive mutant of the 
SV40 large tumour antigen that is controlled by an IFN-γ inducible promotor [283]. 
Once they are transferred to 37 °C and cultured in media without IFN-γ that is 
supplemented with βGP and AA2P they resume their normal proliferative ability and 
undergo osteocytogenesis. Here it was found that the control of the proliferation was 
predominantly due to temperature rather than the presence of IFN-γ due to the relative 
differences in total DNA and metabolic activity between 33-EM and 33-SM compared 
to 33-EM and 37-EM. ALP activity and mineralisation were an order of magnitude 
greater when cultured at 33-SM in comparison to 37-SM on day 21, even after 
normalising to account for differences in cell number. By day 28, 33-SM is still 
highest, but 37-SM deposited a substantial amount of mineral. As expected, the 
presence of osteogenic supplements, not the change in temperature, is the driving 
factor for their osteoblastic activity. Conversely, the highest number of osteoblasts 
undergoing osteocytogenesis occurred at 37 °C in SM, although SM at any 
temperature did induce some osteocytogenesis. This indicates that the lower 
temperature in combination with SM appears to hold IDG-SW3 in their osteoblast 
phenotype, whereas the higher temperature in combination with SM promotes 
161 
 
osteocytogenesis as a lower ALP activity and less mineralisation is observed. This is 
likely due to the cells production of sclerostin as they become osteocytes, a known 
inhibitor of bone formation [324]. 
It was observed that the most mineralised areas had the highest proportion of GFP 
positive IDG-SW3, indicating that there were also the most osteocytes. This finding 
agrees with the work of Wittkowske, who also noted that osteocytogenesis 
predominantly occurred in mineralised regions in IDG-SW3 cultures [322]. This 
finding may seem surprising as osteocytes produce sclerostin, an inhibitor of 
mineralisation. However, the mineralisation and osteocytogenesis processes are 
thought to be linked as in vivo osteocytes differentiate when osteoblasts become 
embedded in the bone matrix [325]–[327]. Therefore, it seems likely that these mineral 
deposits are necessary for osteocytogenesis to occur.  
RANKL was not detectable in the cell culture supernatants of MLOA5-K, MC3T3-E1 
or IDG-SW3 in 2D or 3D cultures at day 7. At this time point all three of these cell 
lines have an osteoblastic phenotype. As the expression and ratio of RANKL and OPG 
expressed by osteoblastic cells changes as they progress from progenitor to osteocyte, 
it was thought that this lack of detection may have been due the differentiative state of 
the cell line [210]. Therefore, the cell culture supernatants of IDG-SW3 cultures 
differentiated into osteocytes were tested for RANKL. As MLO-Y4 osteocytes have 
previously been shown to only express mRANKL, cell extracts were also analysed 
[211]. From GFP measurements and fluorescent images it was clear that numerous 
osteocytes were present after 35 days of culture; however, sRANKL and mRANKL 
were not detectable at any time point. However, cultures maintained in 10 nM and 
100 nM oestrogen were positive for very low levels of mRANKL, indicating that the 
hormone may have induced its synthesis. Oestrogen is a hormone that is viewed as 
protecting bone; therefore, its ability to upregulate RANKL synthesis seems unlikely. 
It has previously been shown to upregulate OPG [328] and decrease M-CSF [95] and 
RANK [309] expression, but found to have no effect on RANKL production [329], 
[330]. It is worth noting that although it was detected, the concentration was only 25-
50 pg/mL, over 100 times lower than the OPG detectable at the same time point, and 
1,000 times less than the exogenous RANKL added to the media during RAW264.7 
cultures. Therefore, in terms of RANKL:OPG ratios, it was not a quantity that could 
be utilised to induce osteoclast differentiation without exogenous additions, as the 
RANKL:OPG ratio would have been only 1:100, rather than 10:1.  
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Other studies have looked into the RANKL expression of the cell lines investigated 
here. MLOA5 have previously been shown to express RANKL mRNA [331]. 
Delgado-Calle, et al., reported detecting both RANKL mRNA and sRANKL 
production from MLOA5 using the same ELISA kit used here. However, their 
reported values are below 5 pg/mL which is the minimum detectable dose of the 
ELISA kit used, meaning that this may be a false positive [332]. MLO-Y4, an 
osteocyte cell line developed by the same group as MLOA5 and IDG-SW3, has also 
been shown to express RANKL mRNA and have RANKL on their cell surface and 
dendritic processes [211]. Sufficient amounts of RANKL are present on MLO-Y4 to 
stimulate TRAP positive osteoclast formation on RAW264.7 [333]. However, this cell 
line is unable to mineralise and therefore was not considered for the in vitro model. 
As with MLOA5, RANKL mRNA expression has also been reported in IDG-SW3 
[334]–[336]. However, to the author’s knowledge, confirmation that the protein is 
successfully produced has not been performed. MC3T3-E1 have previously been 
shown to express both RANKL mRNA and produce sRANKL via ELISA, both with 
and without vitamin D3 in MC3T3-E1.  
1α,25-dihydroxyvitamin D3 is the active form of vitamin D3 and is metabolised from 
25-hydroxyvitamin D3 by the 1α-hydroxylase enzyme [337]. It has previously been 
shown to stimulate RANKL expression in osteoblasts and osteocytes, and therefore 
increase osteoclast formation [193]–[195]. This is likely due to the role of vitamin D 
in maintaining normocalcaemia, as increased osteoclast activity can raise serum 
calcium through bone resorption. Paradoxically, vitamin D is administered as a 
therapeutic for osteoporosis due to its protective effects on BMD through suppressing 
bone resorption. The reasons why the opposite effects are seen in vitro and in vivo are 
not clear, but possible explanations include alteration of the calcium endocrine system 
when active vitamin D compounds are repeatedly administered, direct action on 
osteoblasts to suppress RANKL expression, or though action on osteoclast precursors 
[338]. 
Here the presence of vitamin D3 did not induce the production of sRANKL or 
mRANKL in MC3T3-E1 or IDG-SW3. It has previously been shown that all three cell 
types have the vitamin D3 receptor (VDR) [339], [340]. MLOA5 have been shown to 
be able to metabolise 25-hydroxyvitamin D3 to the active form [331] and that the 
presence of this can increase their mineralisation [341]. In MC3T3-E1, Song, et al., 
demonstrated that vitamin D3 could augment the effects of 17β-estradiol. Here 
oestrogen enhanced cell proliferation, viability, differentiation and matrix production, 
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and these were further promoted when vitamin D3 was also added. However, it had 
no effect when added by itself [342]. St. John, et al., examined the effects of 
vitamin D3 exposure on IDG-SW3, finding that concentrations of 1 – 100 nM strongly 
inhibited mineralisation of IDG-SW3 by day 14. Furthermore, a 24h hour application 
on day 35 had a different effect on the transcriptome to when it is applied on day 3, 
indicating that osteoblasts were responding differently to osteocytes [340]. However, 
they did not report any negative effect on cell viability of vitamin D3 on IDG-SW3. 
The effect that vitamin D3 can have on cells of the osteoblast lineage is clearly 
variable. It has been shown to regulate transcription, proliferation, differentiation and 
mineralisation, as well as increasing the RANKL:OPG ratio by altering the production 
of both cytokines [343]. Furthermore, it can also facilitate the adhesion of osteoclast 
precursors to osteoblasts by upregulating ICAM-1 expression [344]. Although 
RANKL is produced by most cells in the osteoblast lineage, it has been reported that 
it is expressed preferentially in immature osteoblasts and that levels decrease as they 
mature [345]. However, it seems that expression may increase again as they become 
osteocytes as it has been shown that they are better-able to support osteoclastogenesis 
in co-culture with osteoclast precursors that mature osteoblasts [346]. Furthermore, it 
has been shown to both negatively and positively influence matrix formation. 
Therefore, whether vitamin D3 affects RANKL and matrix synthesis seems dependant 
on the maturity of the cell type.  
Vitamin D has also been shown to affect osteoclast precursors and is one potential 
reason it may have an anti-resorptive effect on osteoclasts in vivo. For example, 
monocyte precursors possess the enzyme required to metabolise vitamin D into the 
active form. Kogawa, et al., found that during RANKL-induced osteoclastogenesis, 
production of this enzyme is increased, and that the active metabolite increased 
osteoclast formation [337]. Vincent, et al., also demonstrated that when vitamin D3 is 
administered to RAW264.7 with RANKL, TRAP positive osteoclast formation is 
enhanced in comparison to RANKL-only osteoclastogenesis between concentrations 
of 1 and 20 nM [347]. During this thesis, the effect of vitamin D3 on RAW264.7 was 
also investigated; however, there were no significant difference in TRAP activity 
between 0 nM and 10 nM vitamin D3 by day 10 (n=6, data not shown).  
The apparent lack of response to vitamin D3 in this study could have been due to a 
variety of reasons. It could have been that the cell types could have lacked VDR, either 
due to it not being present or cell line degradation. This seems unlikely as all four cell 
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lines have been reported to respond to vitamin D in the literature and, with the 
exception of MLOA5-K, all cell lines were sourced relatively recently from a supplier. 
Therefore, perhaps the most likely reason is the interference of factors in the FBS used 
during the experiments. Vincent, et al., studied the effect of vitamin D3 on RAW264.7 
performed in serum-replete and serum-free conditions. They found vitamin D3, 
fibronectin, various growth factors and hormones within FBS, all of which can 
influence osteoclastogenesis [347]. The concentrations and presence of these factors 
varies between batches, and although only one batch was used during these 
experiments, it was not possible to accurately define its composition and analyse 
potential competing factors to the ones added exogenously [229].  
There was no significant difference in OPG production in monolayer culture between 
the three cell types. By day 7 all cell types were confluent and therefore had similar 
cell numbers. In contrast, OPG levels were significantly higher in MLOA5-K than 
MC3T3-E1 and IDG-SW3 when cultured in scaffolds. Due to the higher proliferation 
rate of the MLOA5 cells than MC3T3-E1 and IDG-SW3, the higher OPG 
concentration in the media is most likely due to increased cell number. However, it 
could also be due to the phenotypic changes in cells when cultured in scaffolds in 
comparison to a monolayer, as 3D culture has been shown to increase expression of 
OPG and lower expression of RANKL [171]. It is important to know the total OPG, 
rather than the OPG per cell, as it is this concentration in the media that will affect the 
RANKL:OPG ratio.  
It is well established that RANKL induces osteoclastogenesis in RAW264.7, indeed 
one of their main advantages for studying osteoclastogenesis is that you only need 
RANKL instead of both RANKL and M-CSF to induce osteoclastogenesis [166]. 
Osteoclast formation was confirmed by microscopy to view multinucleation, TRAP 
activity and resorption, the three essential characteristics of a mature osteoclast. Due 
to the difficulties with counting nuclei of individual cells in co-culture, especially in 
3D, TRAP activity and resorption were used to quantify osteoclast activity in all 
successive experiments. TRAP activity correlates very strongly with counts of 
multinucleated osteoclasts and therefore is a valid substitution for manual counts 
[348].  
TRAP activity is intrinsically linked with osteoclast activity, but its precise role is 
unknown. In vivo, TRAP activity strongly correlates with the rate bone resorption and 
TRAP knockout mice develop osteopetrosis [186]. It is a non-specific enzyme, 
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meaning it can act on a wide range of substrates, which has both intra- and 
extracellular functions. Outside the cell, it is able to cleave phosphate groups from 
bone matrix proteins such as osteopontin, bone sialoprotein and osteonectin [349]. 
Osteopontin allows osteoclasts to adhere to the bone surface by binding with integrins, 
therefore its disruption by TRAP implies a possible regulatory role for osteoclast 
adhesion, possible enabling migration of the osteoclasts to sites adjacent to where is 
currently being resorbed. Furthermore, TRAP can release inorganic pyrophosphate 
from the matrix, an inhibitor of bone formation [23], [24], [40]. Intracellular TRAP is 
localised to transport vesicles within the osteoclast that move the organic products of 
bone resorption from the ruffled border to the functional secretory domain where they 
can both be removed [350]. This results in the increased concentration of TRAP seen 
in the serum with increased bone resorption. In addition to this, TRAP appears to 
catalyse the formation of free radicals that actively resorb the matrix and can degrade 
the proteins within the transcytotic vesicle [350], [351]. These observations combine 
to indicate that TRAP may have an indirect role on bone resorption, rather than a direct 
ability to degrade the tissue.  
When analysing TRAP activity, it is important to ensure that your conditions and 
substrate are specific to the osteoclastic TRAP enzyme. There are many different acid 
phosphatases in vivo that can be generated by almost all cell types in the body [40]. 
Acid phosphatase 5b, more commonly known as TRAP5b, is specific to osteoclast 
activity, but another isoform, TRAP5a, predominantly produced by immune cells also 
exists. When using TRAP concentration in the serum as a marker of bone turnover, 
the 5b isoform can be preferentially selected for by increasing the pH to 6.1 as the 
optimum pH for 5a is 4.9-5.2. In vitro, where no immune cells are present, the 
optimum pH of 5b (5.5-6.0) can be used to maximise hydrolysis of the substrate [352], 
[353].  
Relying on changing pH alone is not sufficient to ensure you are only measuring 
TRAP5b activity; the substrate must also be carefully selected. One of the most 
common substrates to assess acid phosphatase activity is para-nitrophenol phosphate 
(pNPP), the same substrate as that used when quantifying ALP, an alkaline 
phosphatase. pNPP is hydrolysed to produce para-nitrophenol (pNP), a yellow 
chromogen that can be analysed colourimetrically. However, this can be hydrolysed 
by non-TRAP5b acid phosphatases; therefore, it is better to use naphthol-ASBI-
phosphate, a substrate specific to TRAP5a and 5b. When hydrolysed naphthol-ASBI 
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is produced which can also be quantified colourimetrically, and in serum 
quantification 5b can be preferentially selected for by increasing the pH [354].  
Seeding density of osteoclast precursors affects their ability to mature and rate of 
maturation. However, when the seeding density of RAW264.7 is stated in the 
literature, it varies extensively from 1562.5/cm2 [355] to 15,000/cm2 [356], [357], 
20,000/cm2 [310], even up to 35,000/cm2 [358]. Osdoby, et al., found that in the range 
of 100-500/cm2 osteoclast formation is delayed due to a lack of precursors, and that 
above 450,000/cm2 the density is so high that osteoclastogenesis is inhibited [167]. 
Although they recommend using 1,000-30,000/cm2 for evaluating the effects of 
various agents on osteoclast formation, it has been found here that even increasing 
from 1,250-15,625/cm2 affects this. This is because when precursors are too sparse, 
they cannot fuse readily, but as they become denser maturation occurs more quickly, 
generating osteoclasts sooner. However, these then undergo apoptosis at an earlier 
time point than those seeded at lower densities. This makes it difficult compare results 
between studies if different seeding densities are used as the peak osteoclast activity 
shifts, meaning it may have already happened, be happening, or be yet to occur (Fig. 
4.21).   
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Figure 4.21: A hypothetical diagram showing how seeding density affects when 
osteoclastogenesis occurs in RAW264.7. At the lowest seeding density, fusing of 
precursors is delayed, as the density increases the peak shift to the left as 
multinucleation occurs sooner. At the highest density, precursors are too dense to be 
able to fuse.  
The primary role of oestrogen in bone remodelling is its action on osteoblasts and the 
RANKL:OPG ratio; however, it can also act directly on osteoclasts. Palacios, et al., 
confirmed the expression of ERα but not ERβ on RAW264.7, finding that 
osteoclastogenesis could be reduced by ER agonists. 17β-estradiol and two non-
steroidal ER agonists all reduced proliferation and TRAP expression of RAW264.7, 
with 10 nM estradiol being the most potent [310]. In contrast to this study, here 10 nM 
oestrogen did not have an effect on proliferation or osteoclastogenesis, requiring 
100 nM for a significant reduction to occur. As the method for preparing and storing 
the stock solution is not given it is difficult to discern the reasons for the discrepancy, 
but it is likely due to differences in cell line age or in the potency of the oestrogen 
solution.   
Both MLOA5 and IDG-SW3 were unable to promote osteoclast formation without 
exogenous RANKL. This is unsurprising considering that the ELISA indicated that 
neither cell line produced the cytokine. When RANKL was added, MLOA5 
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completely inhibited osteoclast formation. This could be due to the large amount of 
OPG produced by the cell line completely overwhelming the concentration of RANKL 
added. Alternatively, the very high metabolic activity and proliferation rate of 
MLOA5 could have resulted in RAW264.7 either being unable to have sufficient space 
and/or nutrients to proliferate and fuse. IDG-SW3 did support osteoclastogenesis; 
however, the TRAP activity of the co-culture was significantly lower than the 
RAW264.7 monoculture. As a substantial TRAP activity was still present, this 
inhibition is likely due to the OPG produced by the IDG-SW3 reducing the effective 
concentration of sRANKL.  
Interestingly, it was not possible to identify resorption pits on trabecular bone and 
dentine slices. The ability of RAW264.7 to resorb a substrate does diminish with 
extended passaging; however, the cells used were only recently acquired from the 
ATCC and were capable of resorbing calcium phosphate films. RAW264.7 have 
previously been shown to resorb both bone and dentine [359], [360] at concentrations 
of RANKL ranging from 25 – 100 ng/mL. Here, 50-100 ng/mL RANKL was added 
and mature osteoclasts were generated; therefore, the lack of resorption pits may have 
been due to the osteoclasts being unable to form a sealed zone over the substrate, 
prohibiting resorption, possibly due to an unamenable surface roughness from the 
striations left by the saw when cutting the samples.  
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4.6 Summary 
• Phenol red at the levels available in the culture media did not act as an 
oestrogen receptor agonist. 
• Oestrogen only has an effect on MC3T3-E1, no changes are seen with MLOA5 
or IDG-SW3. 
• Different phenotypes of IDG-SW3 can be achieved by modulating temperature 
and media supplementation. 
• None of the potential cell lines produced RANKL, meaning it will have to be 
added exogenously. 
• MC3T3-E1 and IDG-SW3 have the lowest OPG production, giving them the 
highest RANKL:OPG ratio. 
• RAW264.7 can be matured into multinucleated, TRAP positive, bone 
resorbing osteoclasts. 
• The maturation of RAW264.7 into osteoclasts is highly dependent on seeding 
density. 
• Oestrogen inhibits RAW264.7 proliferation and osteoclastogenesis. 
• IDG-SW3 permit osteoclastogenesis in co-culture. 
• IDG-SW3 and RAW264.7 are the most suitable osteoblast and osteoclast cell 
lines for the in vitro model aimed to be developed in chapter 6. 
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5. Development of a suitable substrate 
for an in vitro model of osteoporosis 
5.1 Introduction 
5.1.1 Scaffold requirements 
In tissue engineering, 3D scaffolds are used to guide cell growth and tissue formation 
[82]. Scaffold properties and performance are dependent on material selection, 
architecture, and fabrication technique; factors that can be altered to fulfil scaffold 
requirements. First, the general requirements for implantable bone tissue engineering 
scaffolds are discussed, before considering whether all these properties are desirable 
for an in vitro model of osteoporosis, as well as any specific additional requirements.  
Perhaps the single most important requirement of an implantable scaffold is 
biocompatibility, as without this cell growth and tissue integration cannot occur. 
Biodegradability is also a requisite property for tissue engineering scaffolds as ideally 
they biodegrade into biocompatible products at a similar rate to tissue formation, 
allowing complete tissue regeneration [19]. Porosity, which can be subdivided into 
percentage porosity, pore size, and pore interconnectivity, is important for cell 
attachment, cell growth and penetration into the scaffold, nutrient diffusion and 
metabolic waste removal, matrix production and vascularisation [361]. Each of these 
processes require different types of porosity. For example, nutrient and waste diffusion 
and tissue integration need a highly interconnected porosity, whereas it is 
recommended to incorporate pore sizes of at least 50 μm but ideally greater than 300 
μm for osseous tissue deposition as this also permits vascularisation [362]–[365]. 
Therefore, the ideal scaffolds contain porosities on multiple length scales (hierarchical 
porosity), ranging from micron to millimetre, as well as a high level of 
interconnectivity. 
Porosity also influences mechanical properties, another key characteristic. There is a 
trade-off between these two, as increased porosity and pore size are detrimental to 
mechanical strength. Mechanical properties of bone tissue engineering scaffolds are 
important as they must not fail during normal patient activities [366]. Additionally, as 
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bone formation is force dependent [16], scaffolds need to retain their strength until 
remodelling is complete. Finally, the surface properties of the material are important 
to permit cell attachment and proliferation. 
The requirements outlined for implantable bone tissue engineering scaffolds are 
similar to those needed for scaffolds used  in an in vitro model of osteoporosis, but 
there are some key differences (Table 5.1). Clearly, biocompatibility, a suitable 
surface chemistry and porosity are still essential for creating an appropriate scaffold 
as cell must be able to attach, survive and proliferate over the structure. Appropriate 
mechanical properties are also still important; however, ‘appropriate’ now refers to 
properties that permit dynamic culture through the use of bioreactors without 
undergoing irreversible, plastic deformation. However, biodegradability is no longer 
a necessary or desirable feature as it is with implantable scaffolds. This is because it 
is important to have a high level of control over related properties such as scaffold 
surface area to ensure that variation due to cell number or scaffold size between repeats 
are minimised. Furthermore, there are additional properties for an in vitro model 
scaffold that are not required for clinical applications. Perhaps the most important of 
these is reproducibility of their architecture, again to minimise variation between 
scaffolds. Although implantable scaffolds do need to be reproducible to an extent, due 
to the variation in defect sizes they will be used to treat as bone graft substitutes, there 
is no need for scaffolds to be identical on the micro-scale. Related to this is the 
desirability of an in vitro model scaffold to be easily modelled computationally. It is 
well known that fluid flow shear stress can be used to modulate bone cell activity 
[322]. To predict the stresses applied in complex structures it is necessary to use 
computational fluid dynamics; therefore, an architecture that is easily replicated in 
silico is advantageous [367], [368].  
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Table 5.1: The difference in requirements for a tissue engineering scaffold and in vitro 
model scaffold. 
Property Tissue Engineering In Vitro Model 
Biocompatible ✓ ✓ 
Biodegradable ✓  
Porous ✓ ✓ 
Regular architecture Not essential ✓ 
Approved materials ✓ Not essential 
Reproducible architecture Not essential ✓ 
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5.1.2 Fabrication techniques 
3D scaffold fabrication techniques can be divided into two categories depending on 
whether they produce a random or user-controlled microstructure [82]. Random 
structures, produced using techniques such as solvent casting and particulate leaching, 
are generally easier to produce in bulk; however, there is less control over their 
microarchitecture and properties [369]. Additive manufacturing techniques (AMTs), 
such as stereolithography and fused deposition modelling, have an architecture 
defined by computer aided design and manufacture (CAD/CAM), which allows 
investigation into the effects of topology on cells by altering geometrical parameters 
[361]. AMTs create 3D structures by repeatedly depositing 2D cross sections. This 
results in a tightly controlled, reproducible architecture that has high levels of pore 
interconnectivity without the use of solvents. 
Scaffolds produced by a casting or leaching approach that have a random 
microarchitecture can have limited pore interconnectivity and varied pore size [370], 
[371]. The low pore interconnectivity arises at lower porosities when there are not 
sufficient porogens to have a continuous porosity, and are the result of a ‘skin’ forming 
around the pores during solvent evaporation. In an attempt to alleviate this, samples 
are often thin to ensure even pore dispersal and adequate porogen removal [369]. 
Polymerised High Internal Phase Emulsions (PolyHIPEs) have a random porous 
microarchitecture and excellent interconnectivity without the use of solvents. 
However, thin monoliths can still only be produced as cellular penetration is dependent 
on pore size (~50 µm) and thickness, with penetration rarely seen beyond 1 mm [372], 
[373].  
5.1.3 Microstereolithography  
Microstereolithography (μSL) is an AMT that was first explored in the 1980s [374]. 
It creates structures from photocurable monomers by use of a laser. Common 
approaches for this technique are projection μSL, direct-write μSL and scanning µSL. 
Projection μSL can create scaffolds with a resolution of 1 to 25 μm by reflecting laser 
light off a digital micromirror device which is set to only permit the reflection of an 
image of the cross-section of the scaffold. This image is focused onto a z-stage within 
a receptacle containing a photocurable prepolymer. The stage slowly moves 
downwards within the receptacle, allowing a 3D structure to be formed from the 
bottom up [375]. A direct-write approach uses a computer-controlled stage that can 
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travel in all three planes to move a photocurable liquid whilst a laser is focussed into 
a single focal spot that crosslinks the prepolymer. This creates a complex architecture 
one layer at a time [376]. This can be done using two-photon polymerisation, where 
resolutions of 120 nm can be achieved [377], or using a single-photon polymerisation, 
which trades resolution for fabrication speed allowing writing to occur one to two 
orders of magnitude faster [378]. Scanning µSL is similar to direct-write, except the 
focal spot of the laser is translated rather than the prepolymer [379]. In order to create 
3D structures, consecutive layers of polymer are cured through either manual or 
automated addition. Once fabrication is complete, any uncured prepolymer is washed 
away to reveal the structure.  
5.1.4 PolyHIPE materials for tissue engineering 
Emulsions form when water and oil are mixed in the presence of an emulsifier or 
surface active agent (surfactant). They consist of an internal and continuous phase, 
where the internal phase forms droplets within the continuous. Whether an emulsion 
is oil-in-water (O/W) or water-in-oil (W/O) can generally be determined using the 
Bancroft rule which states that whichever phase the surfactant is more soluble in is the 
continuous phase [380]. Surfactants lower the interfacial tension between the two 
phases by being amphiphilic, consisting of both hydrophilic and lipophilic groups. 
This enables them to adsorb at the oil-water interface and stabilise the emulsion, 
preventing the phases from separating. As surfactants are amphiphilic, they can be 
water or oil soluble. Their solubility is calculated by determining the hydrophilic-
lipophilic balance (HLB) which is expressed on a scale of 0 to 20, where 3 – 6 
represents hydrophobic, oil soluble W/O surfactants, and 12 – 16 represents 
hydrophilic, water soluble O/W surfactants [381]. As inversion for O/W to W/O or 
vice versa can occur at high internal phase volumes, it is important to carefully select 
an appropriate surfactant [382]. 
A high internal phase emulsion (HIPE) is an emulsion where the internal phase volume 
ratio (Φ) exceeds 0.7405. This is because at this Φ, droplets are forced to interact. If 
the most efficient manner of packing monodisperse rigid spheres into a cube is 
considered, they will occupy 74.05% of the volume. As monodisperse internal phase 
droplets are not rigid bodies, when this Φ is exceeded droplets are forced to change, 
becoming either polydisperse or polyhedral in shape [383]. When the continuous 
phase of a HIPE contains one or more monomers and polymerisation is initiated, a 
PolyHIPE is formed. This preserves the internal shape and structure of the emulsion 
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as a porous polymer (Fig. 5.1). The internal phase forms pores within the polymer, 
and the nominal percentage porosity is simply Φ multiplied by 100%. Depending on 
the level of surfactant present, PolyHIPEs have either a closed or open pore structure, 
where closed pores are completely contained trapping the internal phase, and open 
pores fully interconnect with each other allowing the internal phase to be removed 
[384]. Open porosity PolyHIPEs are permeable polymers with a highly interconnected 
microarchitecture and a low bulk density. Interestingly, this effect of surfactant on 
pore openness occurs even at internal phase volume ratios as high as 0.97. From this, 
it would appear that increased surfactant thins the internal-continuous phase interface, 
and at a threshold concentration this causes interconnects to appear between droplets 
during polymerisation. In an attempt to elucidate the mechanism by which this occurs, 
scanning electron microscopy has been used to view PolyHIPEs that have been frozen 
at different stages of polymerisation. These images indicated that the contraction of 
the continuous phase during conversion from monomer to polymer causes 
interconnects to occur [385]. However, an alternate theory proposed is that the cured 
PolyHIPEs still have thin films covering the interconnects after polymerisation which 
then rupture during washing, as evidenced by images of partially sealed interconnects 
[386].  
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Figure 5.1: SEM of an acrylate-based PolyHIPE demonstrating the interconnected 
porous network. Image captured by author. 
HIPEs are typically cured from acrylates or methacrylates via a radical initiated 
addition reaction. This process can be activated either thermally or photochemically 
by introducing a photoinitiator into the continuous phase. Photocurable HIPEs lend 
themselves to structuring via µSL [375]. This combination allows the formation of 
scaffolds with multi-scale porosity that combine a bottom-up and top-down approach 
to introducing porosity, where the microstructure of the scaffold struts have an 
inherent porosity controlled by emulsion templating and the macrostructure is 
governed by AMT. Combining AMTs and emulsion templating has previously been 
used to create hierarchically porous structures, both through projection µSL 
fabrication of HIPEs [375], [387] and Digital Light Process printing of O/W emulsions 
[388].  
During previous work by the author, twenty acrylate-based PolyHIPE formulations 
were mechanically characterised and selected compositions structured using single-
photon direct-write µSL to fabricate hierarchically porous scaffolds [389]. The 
proportions of two monomers; 2-ethylhexyl acrylate (EHA), an elastomer, and 
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isobornyl acrylate (IBOA), which gives brittle characteristics, were varied from 100% 
EHA to 100% IBOA at 25% intervals. At each of these five compositions, HIPEs with 
Φ of 0.75, 0.80, 0.85, and 0.90 were synthesised [240]. Further work investigated 
introducing hydroxyapatite into these structures to determine its effects on 
osteogenesis [390]. These scaffolds will be evaluated and developed during this thesis. 
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5.2 Aims and objectives 
The aim of this chapter was to compare multiple scaffolds, evaluating their ability to 
support extracellular matrix deposition, reproducibility and ease of manufacture. From 
this, an appropriate substrate can be selected for use in the in vitro model of 
postmenopausal osteoporosis to  be developed in chapter 6. To achieve this, the 
following objectives were addressed: 
1. Continue to improve and develop the PolyHIPE scaffolds previously designed 
by evaluating their ability support bone matrix deposition, examining the 
effects of substrate stiffness and surface coating, and improving its 
architecture. 
2. Compare the cellular performance and physical characteristics of the 
PolyHIPE scaffold with two alternatives; a polyurethane foam and a 
polycaprolactone scaffold produced by fused deposition modelling. 
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5.3 Materials and methods 
Further to the materials and methods outlined in §3, the following are used in this 
chapter. 
5.3.1 PolyHIPE nomenclature 
PolyHIPEs will be referred to by their monomer composition and porosity. All 
PolyHIPEs produced use only two monomers, EHA and IBOA; therefore, these will 
be referred to by their weight percentage of EHA and nominal porosity. For example, 
a 100% EHA composition at 85% porosity will be referred to as EHA100P85 and a 
15% EHA composition at 80% porosity will be referred to as EHA15P80. If any 
further additions are made to the composition, this will be added to the end of the 
description. 
5.3.2 HIPE synthesis 
The proportions of the constituent materials to synthesise the HIPE are summarised in 
table 5.2. Briefly, the continuous phase is synthesised first before adding the internal 
phase. The continuous phase has an organic component consisting of the monomers 
EHA and IBOA and the crosslinker trimethylolpropane triacrylate  (TMPTA) at 
26.96 wt% of the monomers. A surfactant (Hypermer B246-SO-(MV), Croda, UK) 
was added at 3 wt% of the organic mass and left to dissolve in a sonic water bath. 
Finally, a photoinitiator (2,4,6-trimethylbenzoyl)-phosphine oxide/2-hydroxy-2-
methylpropiophenone, 50/50,) was added at 5 wt% of the organic mass. When the UV 
light absorber Tinuvin® 234 (2-(2H-Benzotriazol-2-yl)-4,6-bis(1-methyl-1-
phenylethyl)phenol)  was included in the HIPE, it was introduced to the continuous 
phase of the emulsion at 0.1 wt% of the organic component.  
To create the HIPE, the internal phase (deionised water) was added dropwise at a 
constant rate to the continuous phase whilst stirring at 350 rpm using a paddle stirrer 
(Pro40, SciQuip, UK) in a 50 mL beaker. Once added, the HIPE was stirred for a 
further five minutes before transferring to a foil wrapped tube. If HIPEs were not used 
on the day of synthesis, they were respun at 350 rpm for five minutes before use.  
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Table 5.2: Proportions of the HIPE constituent materials. 
Phase Material Proportion 
Continuous  Monomer(s)  N/A 
Continuous Crosslinker 26.96 wt% of monomers 
Continuous Surfactant 3 wt% of monomers and 
crosslinker 
Continuous Photoinitiator 5 wt% of monomers and 
crosslinker 
Continuous Light absorber 0.1 wt% of the monomers 
and crosslinker 
Internal Deionised water 75-90 vol% 
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5.3.3 Coverslip functionalisation 
When the PolyHIPE was required to bind to a glass coverslip they were functionalised. 
Initially, coverslips were submerged in piranha solution (80 vol% H2SO4, 20 vol% 
H2O2 (30 wt% in water)) for thirty minutes. This powerful oxidiser removes any 
organic matter or residue and exposes surface hydroxyl groups. Coverslips were then 
rinsed in deionised water before washing in methanol and drying. Once dry, they were 
submerged in a solution of 10 wt% 3-methylacryloxypropyltrimethoxysilane 
(MAPTMS, Polysciences Inc) in toluene to add methacrylate groups to the surface and 
left overnight. Before use these were washed in methanol and dried. 
5.3.4 Bulk HIPE polymerisation 
To create sheets of the PolyHIPE material, bulk polymerisation was performed using 
a UV belt curer (GEW Mini Laboratory, GEW engineering UV). A Teflon sheet was 
added to the base of a glass petri dish before filling with HIPE. This was passed 
multiple times under the UV lamp at 10 m/min until cured. The resulting sheets were 
washed in acetone for 24 hours before drying until constant mass.  
5.3.5 Mechanical characterisation 
To create tensile specimens, PolyHIPE monoliths were laser cut (Mini 19 Laser, 
Epilog Laser) at a power of 8%, speed of 70% and frequency of 2,500 Hz in 
accordance with ASTM D638-10. However, the length of the specimens was reduced 
by a factor of 3.83 due to the maximum sample size of the testing machine. 
Samples were tested on a BOSE ElectroForce 3200 mechanical testing machine using 
a 450 N load cell, an extension rate of 0.02 mm/sec, a grip distance of 10 mm, and a 
maximum extension of 6 mm. Young’s modulus was determined using the linear 
region of the force-displacement curve. The initial point was always at an extension 
of 0.02 mm and the final point taken at yield.  
 
 
 
183 
 
5.3.6 Physical characterisation 
In order to physically characterise the PolyHIPEs, SEM images of the 20 compositions 
were analysed and the degree of openness (DOO) of each determined [391]. For 
imaging, each sample was mounted on a carbon tab, sputter coated with gold (SC500, 
emscope) and imaged using a Philips XL-20 SEM with a beam energy of 20 kV. 
Images were taken at 400× and analysed using Image J [392].  
DOO is the ratio of open surfaces (So) within a pore/cavity of the PolyHIPE to the 
total surface of the cavity (Sc). Sc is calculated from the measured diameter of the pore 
(Dm). However, as it is unknown where the pore has been bisected, this is multiplied 
by a statistical correction factor to give the equatorial pore diameter (De) (Eqn. 3) 
[393]. 
 𝑆𝑐 = 𝜋(
2𝐷𝑚
√3
)2                    (3) 
In order to determine the area of So, the diameters of visible interconnects within the 
pore are averaged (Di) and this value used to calculate the average area. This is 
multiplied by the number of visible interconnects (N), then by 2 as the pore has been 
bisected, then by the statistical correction factor as we do not know where this has 
occurred. From these two values, the DOO can be calculated (Eqn. 4).  
𝐷𝑒𝑔𝑟𝑒𝑒 𝑜𝑓 𝑂𝑝𝑒𝑛𝑛𝑒𝑠𝑠 (𝐷𝑂𝑂) =
𝑂𝑝𝑒𝑛 𝑆𝑢𝑟𝑓𝑎𝑐𝑒 𝑜𝑓 𝐶𝑎𝑣𝑖𝑡𝑦
𝑇𝑜𝑡𝑎𝑙 𝑆𝑢𝑟𝑓𝑎𝑐𝑒 𝑜𝑓 𝐶𝑎𝑣𝑖𝑡𝑦
=
𝑁∗2∗
2
√3
∗𝜋(
𝐷𝑖
2
)2
𝜋𝐷𝑒
2  (4) 
For each of the twenty PolyHIPE compositions, ten pores were analysed and the 
average DOO for each composition calculated.  
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5.3.7 PolyHIPE scaffold fabrication 
Scaffolds were manufactured using single-photon direct write microstereolithography. 
Regardless of the HIPE composition, the following method was used; a 
subnanosecond pulse duration passively Q-switched DPSS microchip laser 
(PULSELAS-P355-300, ALPHALAS, Germany) controlled using a laser diode and 
thermoelectric cooler driver (LDD1-1BT-D, ALPHALAS, Germany) emitting 
wavelengths of 1064, 532 and 355nm was used as a source, with a Pellin-Broca prism 
(ADB-10, THORLABS, UK) used to separate a single wavelength of 355nm. Beam 
delivery was controlled with a shutter (UNIBLITZ LS6, VincentAssociates, Canada) 
linked to a shutter driver (VCM-D1, VincentAssociates, Canada), and a pinhole was 
used to modulate the beam intensity. Finally, the beam was focused through a 
microscope objective (EC-Plan NEOFLUAR 10x, Carl Zeiss Ltd, UK), and a high 
precision stage with the ability to move in all three planes (ANT130-XY, Aerotech, 
UK, for xy translation & PRO115, Aerotech, UK, for z translation) commanded by a 
motion controller and software (A3200 Software-Based Machine Controlled, 
Aerotech, UK) was used to translate the focal spot. To fabricate the scaffold, a known 
volume of HIPE was pipetted onto the coverslip which was placed onto the stage. The 
first layer was then written, followed by the addition of additional HIPE and the 
writing of the next layer after adjusting the z height accordingly. This was repeated 
until the scaffold was completed. The laser was focused just above the coverslip-HIPE 
interface for the bottom layer and the fibre-HIPE interface for each subsequent layer 
in order to write the scaffold.  
For HIPE compositions without Tinuvin, a current of 2.20 μA and a pinhole size of 
3.1 mm was used, resulting in a scaffold with ~350 µm fibres and ~650 µm spacing. 
For HIPE compositions with Tinuvin, a current of 2.65 μA and a pinhole size of 4.0 
mm was used, resulting in a scaffold with ~325 µm fibres and ~325 µm spacing.  
For clarity, the development of the PolyHIPE scaffold resulted in experiments with 
three separate ‘generations’ of scaffold. The first-generation scaffold is a four layer 
woodpile scaffold attached to a functionalised coverslip. The second generation is a 
four-layer scaffold with the incorporation of Tinuvin that has improved architecture 
and can be removed from the coverslip making it free standing. The third generation 
is a 6 to 12-layer scaffold with further improved architecture and reproducibility.  
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5.3.8 Plasma modification of scaffolds 
As the continuous phase of the HIPEs is inherently hydrophobic in order to form an 
emulsion with water, it is necessary to alter the surface chemistry to promote cell 
attachment, spreading, and proliferation. This is achieved through plasma 
modification of the scaffold either using an air plasma clean (pcAir) or air plasma 
clean followed by plasma deposited acrylic acid (pdAAc).   
Treatments were applied to the scaffolds by placing them on an aluminium foil 
wrapped platform in the centre of a cylindrical plasma chamber with stainless steel 
endplates wrapped with a coiled wire connected to a 13.56 MHz frequency generator 
(Coaxial Power Systems Ltd, UK. The gas/monomer inlet is controlled by a needle 
valve (LV10K, Edwards, UK) and a gauge (APG100 Active Pirani Vacuum Gauge, 
Edwards, UK) with a gauge controller (AGC Active Gauge Controller, Edwards, UK) 
used to monitor the pressure. An isolation valve (Speedivalve, Edwards, UK) is 
present between the plasma chamber and vacuum pump. 
To apply the pcAir treatment, the pressure was lowered to 1.8×10-1 mbar and the power 
set to 50 W to generate the plasma. Samples were treated for 5 minutes. To apply the 
pdAAc treatment, samples were kept in the chamber after air plasma exposure and 
liquid nitrogen added to the cold trap. The pressure was lowered to 3.0×10-3 mbar, and 
then a flask (JY Sample Flask with O-Ring and Plain Arm, GPE Scientific, UK) of 
acrylic acid (Sigma Aldrich, UK) attached to the inlet. The pressure was then stabilised 
at 3.0x10-2 mbar and the flow rate (F) calculated by closing the isolation valve and 
recording the initial pressure (ρi) and the pressure after 30 seconds (ρf) (Eqn. 5). Δ is 
a constant specific to the plasma rig and always equals 6.2. 
𝐹 = 𝛥(𝜌𝑓 − 𝜌𝑖)        (5) 
For all pdAAc treatments, a flow rate of 2.4-2.5 sccm-1 was used by adjusting the 
initial pressure until the flow rate was within this range. Once achieved, this process 
was repeated a further two times to ensure stability, and then acrylic acid was 
deposited for 10 minutes at a power of 15 W. Samples were used for cell culture on 
the same day the plasma treatment was applied.  
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5.3.9 General hES-MP culture 
hES-MPs (Cellartis, Sweden) were passaged at 37oC, 5% CO2 in expansion media 
(EM), consisting of BM (α-MEM, 10% FBS, 2 mM L-glutamine, 100 mg/mL 
penicillin/streptomycin supplemented with 4 ng/mL of human fibroblastic growth 
factor (hFGF, Life Technologies, UK) in gelatine-coated T75 flasks. Media was 
changed every 2-3 days. Passaging, counting, freezing down and reanimating was 
performed using the general osteoblast culture protocol (§3.2.4). 
Experiments with hES-MPs were seeded in BM. The following day media was 
exchanged for OIM (BM supplemented with 5 mM βGP, 50 µg/mL AA-2P and 
100 nM dexamethasone), with the exception of experiments where the influence of 
substrate stiffness on osteogenic differentiation was evaluated. Here, experiments 
were maintained in SM (BM supplemented with 5 mM βGP and 50 µg/mL AA-2P), 
as it does not contain dexamethasone, a steroid which induces osteogenesis, but still 
has the osteogenic supplements required for mineralisation.  
5.3.10 PolyHIPE scaffold sterilisation 
Scaffolds were sterilised for use in cell culture experiments. They were soaked in 
70 vol% ethanol under vacuum for 1.5 hours before rinsing three times with sterile 
PBS. Scaffolds were never stored, plasma treatment, sterilisation and seeding was 
always performed on the same day. Scaffolds which do not sink during sterilisation 
are discarded due to their hydrophobicity.  
 
 
 
5.3.11 PolyHIPE scaffold seeding 
To seed, generation 1 and 2 scaffolds were transferred to a non-treated 24 well plate 
and 75,000 cells at a density of 1,500,000 cells/mL were added and left for 45 minutes 
to attach. Scaffolds were then submerged in 1 mL BM and incubated overnight. The 
following day, scaffolds were transferred to a 12 well plate and cultured in 2 mL of 
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the appropriate medium for the remainder of the experiment. Medium was changed 
every 2-3 days. 
Generation 3 scaffolds were seeded with 100,000 cells in 100 µL of basal media (BM) 
in a bespoke 3D printed grid to maximise seeding efficiency. Grids were deigned in 
Solidworks and printed using an Ultimaker 2 go using Acrylonitrile butadiene styrene 
(ABS) plastic. Cells were left to attach for 2 hours before transferring scaffolds to a 
well plate and submerging with BM overnight. The following day, appropriate 
medium was added for the remainder of the experiment. Medium was changed every 
2-3 days. 
5.3.12 Polyurethane scaffold preparation 
Polyether polyurethane foam (Caligen Foam Ltd) was cut into 6 × 10 mm or 5 × 5 mm 
(diameter × height) cylinders using a hole punch and scalpel in a similar method to 
Sittichockechaiwut , et al [9]. Once cut, they were submerged in 0.1 w/v% gelatine 
solution and autoclaved at 121 oC for 30 minutes to sterilise and improve cell 
attachment.  
5.3.13 Polyurethane scaffold seeding 
Before seeding, scaffolds were soaked in BM for 30 minutes. To seed, the BM was 
aspirated and replaced with a seeding suspension of 600 cells/0.31 µL BM per mm3. 
Cells were left for 45 minutes to attach for 45 minutes before submerging in BM 
overnight. The following day, scaffolds were transferred to a new well plate and 
cultured in the appropriate medium for the remainder of the experiment. Media was 
changed every 2-3 days. 
 
 
5.3.14 Biotek scaffold seeding 
For comparison to the PolyHIPE and polyurethane scaffolds, osteoblasts were also 
cultured on the 24 well compatible 3D InsertTM-PCL, a commercial poly(ε-
caprolactone) (PCL) woodpile scaffold produced by 3D Biotek. It has fibre diameter 
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and spacing of 300 µm, a diameter of 14 mm and a height of 1.5 mm, making it 6 
layers in height. Biotek scaffolds were seeded according to manufacturer instructions. 
Briefly, 75,000 cells were added in a volume of 270 µL and left to attach for 3 hours. 
Scaffolds were then submerged in a further 370 µL of BM and left overnight. The 
following day, scaffolds were transferred to a new well plate and cultured in the 
appropriate medium for the remainder of the experiment. Media was changed every 
2-3 days. 
5.3.15 Micro-computed tomography 
To evaluate the 3D architecture of the scaffold and mineralised matrix deposition, 
micro-computed tomography (MicroCT) was performed on a Skyscan 1172 (Bruker, 
Belgium). A polystyrene foam cube with a hole milled to the shape of the scaffold and 
glued to a brass platform supplied with the MicroCT was used to stop any artefacts 
associated with sample movement during scanning. Scanning parameters for the three 
different scaffolds are given below (table 5.3) 
 
 
 
 
 
 
 
 
Table 5.3: MicroCT scanning parameters for the three different scaffolds. 
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Scanning Parameter PolyHIPE Polyurethane Biotek 
Voltage (kV) 38 51 59 
Amperage (µA) 173 165 167 
Power (W) 7 8 10 
Rotational step (°) 0.7 0.7 0.7 
Averaging 2 2 2 
Total sample rotation 
(°) 
180 180 180 
Voxel size (µm3) 10 10 10 
Filter No filter No filter No filter 
Camera size Medium Medium Medium 
 
All scans were reconstructed using Nrecon (v.1.6.10.2, Bruker, Belgium). 
Reconstructions were then aligned to counter any tilt present in the scan and a region 
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of interest that contained the entire scaffold was saved using DataViewer (v.1.5.2.4, 
Bruker, Belgium). These were analysed using CTAn (v.1.15.4.0, Bruker, Belgium) by 
selecting a volume of interest (VOI) within the centre of the scaffold, thresholding, 
and exporting the grayscale index histogram for the entire VOI. Analysis parameters 
are given in table 5.4. This histogram can be used to analyse differences in density. 
Reconstructions and VOIs were visualised using CTvox (v.3.0.0r114, Bruker, 
Belgium). To minimise reconstruction artefacts, samples underwent misalignment 
compensation, ring artefact reduction and beam-hardening correction. These settings 
are only relevant to the particular MicroCT scanner used and were kept consistent for 
each scanning session. Where comparisons are made, samples were scanned 
concurrently in the same session to allow accurate, quantitative comparisons.  
 
 
 
 
 
 
 
 
 
 
 
Table 5.4:  MicroCT analysis parameters for the three different scaffolds. GSI is 
greyscale index. 
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Analysis Parameter PolyHIPE Polyurethane Biotek 
Volume of interest 
(diameter × height, 
mm) 
5 × 0.5 5× 5 scaffold: 
2 × 2 
8 × 1 
6 × 10 scaffold: 
3 × 3 
Thresholding with 
scaffold (GSI) 
45 - 255 50 - 255 40 – 255 
Thresholding without 
scaffold (GSI) 
120 - 255 155 - 255 80 - 255 
 
 
 
 
 
 
5.3.16 Tissue sectioning and staining 
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For histological analysis, some scaffolds were sectioned using a microtome. Samples 
were fixed in formaldehyde in accordance with §3.2.10 before being submerged in 
tissue freezing medium (Leica) and frozen by submerging in liquid nitrogen. Samples 
were then stored in a -80 °C freezer for a minimum of 24 hours before sectioning. 
Sections were obtained using a cryostat (Leica CM1860 UV) at -24 °C at 8 µm 
thickness.  
Sections were mounted onto a glass slide and stained with haematoxylin and eosin 
(H&E) by rinsing in diH2O to dissolve residual freezing medium, submerging in 
haematoxylin solution for 1 minute, washing in gentle running tap water for 4 minutes, 
counterstaining in 1% eosin solution for 5 minutes, briefly rinsing in diH2O, 
dehydrating in 70%, 90% and 100% ethanol for 2 minutes at each stage before finally 
clearing in xylene for 1 minute. Sections were preserved by mounting with a coverslip 
attached using DPX mountant.  
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5.4 Results 
Results in §5.5.1 to §5.5.5 have been published [240]. A full copy of this publication 
is available in the appendix, §10.3. Where the same figures have used, they are 
reprinted under the Creative Commons Attribution licence. 
5.4.1 Wet mechanical properties are the same as dry 
Previous work fully mechanically characterised 20 EHA/IBOA PolyHIPE 
compositions. Young’s moduli between 63.01±9.13 (EHA0P75) and 0.36±0.04 
(EHA100P90) MPa, Ultimate tensile stress (UTS) between 2.03±0.33 (EHA25P75) 
and 0.11±0.01 (EHA75P90) MPa, and percentage elongation at failure between 
21.86±2.87 (EHA50P90) and 2.60±.61 (EHA0P85) % were measured [389]. From 
this, three compositions, EHA0P80, EHA50P80, and EHA100P80, were selected for 
cell culture. To determine whether cell culture conditions affect the mechanical 
properties, wet mechanical testing was performed on these compositions to determine 
whether this would affect the stiffness by soaking the tensile specimens in BM for one 
hour prior to testing (Fig. 5.2).  
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Figure 5.2: Young’s moduli under dry and wet conditions of the three PolyHIPE 
compositions selected for cell culture. No significant difference for dry vs. wet for any 
composition (n=13). 
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The dry Young’s moduli for the three compositions were 48.13±7.25 MPa 
(EHA0P80), 6.85±0.97 MPa (EHA50P80), and 1.00±0.09 MPa (EHA100P80. The 
corresponding ‘wet’ moduli were 51.80±9.45 MPa, 8.43±1.52 MPa, and 1.09±0.08 
MPa, respectively. There was no significant difference between dry and wet moduli 
for any of the three compositions. 
5.4.2 The degree of openness in linearly related to the internal phase proportion 
The DOO of each of the 20 PolyHIPE compositions was calculated to determine 
whether the physical characteristics of the PolyHIPEs was affected by the monomer 
composition as well as the percentage porosity (Fig. 5.3). 
DOO increased with porosity for all compositions. At a given porosity comparing 
monomer proportions, there was no significant difference between 0.75, 0.80, and 
0.90 Φ (p<0.05). For 0.85 Φ, only EHA25P85 vs. EHA50P85 and EHA50P85 vs. 
EHA75P85 were significantly different (p<0.05). At every monomer composition, the 
largest increase in DOO was seen when increasing nominal porosity from 0.75 to 
0.80 Φ. The lowest DOO at 0.75 Φ is because an emulsion is only classed as high 
internal phase at 0.7405 Φ, below this it is a medium internal phase emulsion (MIPE). 
Here, water droplets are not forced to interact resulting in negligible pore 
interconnectivity and therefore, a DOO of zero. The increase in DOO is not linearly 
correlated with the increase in nominal porosity. However, this is because the required 
internal phase addition exponentially increases with nominal porosity. If nominal 
porosity is not viewed as Φ, but rather the volume of internal phase addition required 
per 1 mL of continuous phase to achieve Φ, a linear relationship is seen. This is 
because the porosity of the HIPE is reciprocal to the amount of polymer.  
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Figure 5.3: Effect of composition and porosity on degree of openness. (A) Mean ± SD 
of the DOO for each of the 20 compositions (* = p<0.05). (B) Average DOO vs. Φ 
expressed as the volume of internal phase per 1 mL of continuous phase. Nominal 
porosities combined for compositions. R2 calculated using linear regression, slope is 
significantly non-zero (p<0.0001). 
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5.4.3 Batch production significantly reduces manufacture time 
Generation 1 scaffolds were fabricated from three HIPE compositions (EHA0P80, 
EHA50P80, EHA100P80). These four-layer scaffolds had an approximate fibre 
diameter of 350 µm and spacing of 650 µm. The third and fourth layers were offset by 
500 µm so that the fibres lay directly above the gaps of the first and second layer 
(Fig. 5.4). Due to the large number of scaffolds required, batch production was 
investigated before production commenced. Rather than producing individual 
scaffolds with a manufacture time of approximately 15 minutes, a 3×3 grid of scaffolds 
was initially attempted. This would produce 9 scaffolds in approximately 105 minutes, 
reducing the equivalent manufacture time per scaffold to 11.5 minutes. However, due 
to the long time periods between layers it was found that water from the internal phase 
evaporated. This results in scaffolds that did not have the correct composition and 
adversely affected the architecture. Therefore, a 2×2 grid was attempted. Each layer 
was sufficiently fast for the HIPE to not be affected and the per scaffold manufacture 
time was reduced to 13 minutes. A saving per scaffold of 2 minutes per scaffold seems 
minimal, but in total 336 generation 1 scaffolds were produced to evaluate the effect 
of stiffness and plasma modification, reducing the total manufacture time by 
approximately 11 hours.  
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Figure 5.4: SEM images of an EHA0P80 4-layer ‘woodpile’ scaffold. (A-E) 
Magnification of the same point from 22× to 400×, showing the inherent macroscopic 
and microscopic porosity of the structure. (F - Main) A side view of one of the fibres 
showing the offset of the upper two layers. (F-Insert) Photograph of a single scaffold 
(13 mm diameter). 
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5.4.4 Air and acrylic acid plasma treatments are equally effective at supporting 
cells 
Initially, the effects of plasma treatment, media composition and substrate stiffness on 
cell growth were examined over 15 days in all possible combinations (Table. 5.5).  
Table 5.5: Conditions to be examined to determine the effects of plasma treatment, 
media composition and substrate stiffness on hES-MPs. All compositions are treated 
with each plasma and cultured with both media types. 
PolyHIPE Compositions Plasma Treatments Media Compositions 
EHA0P80 – ‘Stiff’ Untreated Osteogenesis Induction 
Media (OIM) 
EHA50P80 – ‘Medium’ pcAir Supplemented Media 
(SM) 
EHA100P80 0 ‘Soft’ pdAAc - 
 
 
 
 
 
 
199 
 
Untreated scaffolds were unable to support cell attachment and growth (Fig. 5.5A). 
Both pcAir and pdAAc plasma treatments clearly enhanced the viable cell number on 
all scaffolds (Fig. 5.5B,C,D). The metabolic activity on plasma modified scaffolds was 
significantly higher on days 8 and 15 regardless of PolyHIPE composition or media 
type (p<0.05). Interestingly, there was no significant difference at any time point and 
composition between pcAir and pdAAc scaffolds, showing that both treatments 
supported similar levels of metabolic activity. As previously described by Delaine-
Smith, et al., there is no significant difference observed between the two cell culture 
media (SM and OIM) [321]. ). Comparisons between scaffolds with the same plasma 
treatment but different wt% EHA indicated that EHA0 scaffolds supported the lowest 
metabolic activity, with the highest metabolic activity achieved on pcAir-treated 
EHA100 scaffolds and pdAAc-modified EHA50 substrates. There were no significant 
differences between compositions at day 8, but by day 15 significant differences with 
regards to composition were observed between EHA0P80 pcAir vs. EHA100P80 
pcAir and EHA0P80. 
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Figure 5.5: Effect of PolyHIPE composition, media and plasma treatment on cell 
proliferation.  RR assay fluorescence for (A) untreated (B) pcAir (C) pdAAc OIM (D) 
pdAAc SM samples. Untreated scaffold did not support cell attachment and growth. 
pcAir and pdAAc had similar increases in metabolic activity. The highest metabolic 
activity appeared to occur in compositions containing EHA. Metabolic activity was 
not affected by differences in media composition (OIM vs. SM) (n=6). 
 
 
 
 
 
 
201 
 
5.4.5 Substrate stiffness only affects differentiation under certain conditions 
In addition to determining the effects on metabolic activity, ALP activity was 
quantified on day 8 and 15 Fig. 5.6).  
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Figure 5.6: Effect of PolyHIPE composition, media and plasma treatment on 
osteoblastic differentiation. ALP activity normalised to DNA fluorescence. hES-MPs 
cultured in OCM had higher ALP activity than their NOCM counterpoints at all time 
points (* = p<0.05). None of the substrates or plasma treatments were seen to 
significantly induce higher osteogenic differentiation, with the exception of pdAAc 
modified EHA0 scaffolds, which by day 15 were found to be significantly higher than 
all other groups (*** = p<0.001). 
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In OIM, normalised ALP activity increased over time . On day 8, normalised ALP 
activity was similar for both plasma treatments at each composition, with pcAir only 
being significantly higher on EHA0 scaffolds (p<0.05). On day 15, there was no 
significant difference between pcAir and pdAAc for EHA50 and EHA100 scaffolds. 
However, normalised activity on pdAAc EHA0 scaffolds was significantly higher than 
pcAir for the same composition (p<0.001), as well as significantly higher than both 
pdAAc and pcAir EHA50 and EHA100 scaffolds (p<0.001). Normalised activity in 
SM was lower than in OIM in all instances and did not increase over time. This 
indicates that the stiffness of the substrate did not affect osteogenic differentiation 
when dexamethasone was not present in the media. 
5.4.6 Stiffer PolyHIPE scaffolds retain their architecture without a glass base 
The functionalised glass coverslip base of the generation 1 PolyHIPE scaffolds 
provided a useful platform for developing the manufacturing technique and 
investigating the effects of the polymer composition. However, this design is not 
suitable for tissue engineering as the glass is not implantable and it acts as a barrier, 
limiting nutrient diffusion and flow through the scaffold.  
Initially, attempts to fabricate scaffolds using the same method but with a normal, non-
functionalised coverslip were performed. Without the MAPTMS on the surface, the 
PolyHIPE cannot bond to the surface so the scaffold can be removed afterwards. A 
summary of these attempts is given below (Table 5.6). 
EHA0P75 free standing scaffolds were analysed by SEM (Fig. 5.7). The bottom layer 
of fibres did not lie parallel as there was no anchoring to hold them in position. By 
looking at fibre cross sections, the interconnected porous network within the fibre can 
be seen, as well as a skin that forms around the edge of the fibres. This results in only 
the top surface of the fibre having open pores. This is due to the HIPE curing with an 
air interface on the top surface, with the side and underside of the fibres curing with a 
HIPE-polymer or HIPE-glass interface.   
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Table 5.6: Summary of the different attempts to create a free standing PolyHIPE 
scaffold. 
PolyHIPE Composition Reasoning Result 
EHA50P80 Able to undergo high 
strains (~20%) before 
failure, a useful property 
in dynamic culture 
Unable to hold its 
structure, forms a ball 
during washing due to 
low stiffness 
EHA50P30-60 Lower porosity (medium 
internal phase emulsion - 
MIPE) increases stiffness 
with minimal effect on 
strain at failure 
Although a stiffer 
material, still unable to 
retain its architecture. 
MIPEs have closed 
porosity, which stops 
effective washing 
EHA25P75 Higher proportion of 
IBOA increases stiffness 
of the PolyHIPE 
Increased stiffness 
improves architecture, but 
the scaffold warps during 
drying  
EHA0P75 Highest stiffness of 
PolyHIPE fabricated 
Successfully formed free 
standing scaffolds with 
the same architecture as 
generation 1.  
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Figure 5.7: SEM images of an EHA0P75 free standing scaffold. (A-C) magnification 
of the same point from 25× to 100× (D) underside of the scaffold (E) fibre cross-
section (F) side skin. 
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To confirm that these generation 2 PolyHIPE scaffolds could support cell growth over 
extended time periods, they were seeded using the same protocol as generation 1 
scaffolds and maintained for 28 days, assessing metabolic and ALP activity (Fig. 5.8). 
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Figure 5.8: Growth and differentiation of hES-MPs on generation 2 scaffolds. 
Mean ±SD for (A) RR fluorescence and (B) normalised ALP activity. * indicates 
p<0.05 (n=3). 
hES-MPs adhered and remained viable on the generation 2 scaffolds over the 28 day 
period although no time point was significantly different to any other. In comparison 
to generation 1, seeding efficiency was 60% lower as cells were not retained within 
the scaffold by a glass base. This low initial viability limited proliferation throughout 
the scaffold. ALP activity increased, showing that hES-MPs were still undergoing 
osteoblastic differentiation, with a peak between day 14 and 21.  
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5.4.7 Printing resolution is improved using a UV light absorber 
The fibre spacing in generation 1 and 2 PolyHIPE scaffolds is ~650 µm. When it is 
set to less than this, polymerisation occurs between the fibres resulting in a sheet being 
formed. A 355 nm laser beam in the UV wavelength is used to initiate polymerisation. 
Therefore Tinuvin, a UV light absorber, in the continuous phase should reduce or 
eliminate the polymerisation of material outside the focal spot of the laser. 
Furthermore, by reducing this partial polymerisation, the surface skin on the scaffold 
fibres should be reduced.  
To determine the concentration of Tinuvin required, attempts to fabricate scaffolds 
with concentrations ranging from 0.1 to 4 wt% were added to EHA0P80 PolyHIPEs . 
A summary of these attempts is given below (Table 5.7). 
Fibres with a depth similar to PolyHIPEs without UV light absorbers was attainable 
when using 0.1 wt% Tinuvin. In order to achieve this, the write speed was reduced to 
1.50 mm/sec from 1.75 mm/sec, and the laser current increased to 2.65 μA which 
increases the power. The pinhole diameter remained at 3.1 mm. Fibre spacing was 
reduced from 650 μm to 450 μm, with a fibre diameter of 400 μm. The incorporation 
of Tinuvin also affected the side skin formation, as open pores can be seen on a higher 
percentage of the fibre surface area. However, it did not appear to reduce the thickness 
of the skin in the regions where it was still present (Fig. 5.9).  
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Table 5.7: Summary of the effects of different Tinuvin concentrations on EHA0P80 
scaffolds. 
Tinuvin 
Concentration 
Effect 
4 wt% Unable to polymerise with maximum laser power and 
pinhole size 
2 wt% Unable to polymerise with maximum laser power and 
pinhole size 
0.5 wt% 
Polymerised, but formed thin ribbons rather than 
cylindrical fibres 
 
0.1 wt% Polymerised and formed cylindrical fibres 
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Figure 5.9: SEM images of an EHA0P80-0.1wt% Tinuvin scaffold. (A-D) 
magnification of the same point from 50× to 400× (E) fibre cross section (F) side skin. 
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 5.4.8 Tinuvin is not cytotoxic in an EHA/IBOA PolyHIPE 
Tinuvin is assumed to be cytotoxic and therefore would not be suitable in a 
biodegradable scaffold. However, the EHA/IBOA PolyHIPEs are non-degradable and 
therefore this effect may be mitigated. To assess cytotoxicity, MLOA5-S cells were 
seeded onto EHA0P80 scaffolds fabricated with either 0 or 0.1 wt% Tinuvin. To 
control for differences in surface area, fabrication parameters were changed for the 
composition with Tinuvin to match the fibre diameter and spacing of that without the 
light absorber. Metabolic activity was measured weekly for 18 weeks (Fig. 5.10). No 
loss of viability was seen with the incorporation of Tinuvin, even over extended time 
periods, indicating it is not cytotoxic in this polymer and does not leach out over time. 
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Figure 5.10: Metabolic activity on EHA0P80 scaffolds with or without Tinuvin for (A) 
21 days or (B) 18 weeks. No significant difference with the light absorber (n=6). 
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5.4.9 PolyHIPE and polyurethane scaffolds are equally suitable for the model 
To determine the most suitable scaffold for the in vitro model, multiple bone tissue 
engineering scaffolds were compared that fitted the requirements outlined in §5.1.1. 
Since the advent of bone tissue engineering a plethora of scaffolds have been 
developed from materials including ceramics, natural and synthetic polymers, glasses, 
metals and composites of combinations of these using a wide range of fabrication 
techniques [239], [394]. Clearly this gives a wide range of potential substrates; 
however, as the main scope of this thesis was the application of the scaffold rather 
than its development, comparisons were limited to three prospective scaffolds; the 
generation 2 PolyHIPE, a polyurethane scaffold, and the Biotek 3D InsertTM-PCL 
(Biotek). Unlike some other scaffolds materials, for example electrospun PCL [395],  
the PolyHIPE and polyurethane scaffolds require a surface treatment before use which 
increases the processing time. Despite this, these materials were still pursued as the 
pcAir plasma treatment for the PolyHIPEs is relatively high throughput and the 
resulting hydrophilicity aids the sterilisation process, whilst the gelatine coating stage 
for the polyurethane scaffolds is combined with the autoclave sterilisation, making it 
a facile step. 
The PolyHIPE scaffold developed thus far was selected due to the promise these 
emerging emulsion templated materials have shown in the field of bone tissue 
engineering to date [240], [389], [390], [396], [397]. The Biotek scaffold was chosen 
as it has a similar macroarchitecture to the PolyHIPE scaffold but lacks the inherent 
microporosity of the PolyHIPE material in the fibres, allowing its influence to be 
assessed. The Biotek scaffold has previously been used for bone tissue engineering 
studies [398], [399], as well as many other cell types including haematopoietic [400] 
and adipose-derived [401] stem cells. Finally, the polyurethane scaffold was selected 
due to its previous use in bone tissue engineering studies [9], [402], [403], as well as 
the use of other polyurethane scaffolds in the field [404]–[407]. A summary of their 
key properties and differences is given in table 5.8. Representative SEM images are 
shown in figure 5.11. 
In order to determine which scaffold supports the most mineralised matrix deposition, 
each scaffold was seeded with 25,000 MLOA5-S and maintained for 28 days. Cell 
metabolic activity, calcium staining and collagen production were assessed (Fig. 5.12). 
 
212 
 
Table 5.8: Comparison of key features and properties of the three scaffolds compared 
for the model. 
Parameter PolyHIPE Biotek 3D InsertTM - 
PCL 
Commercial 
Polyurethane 
Fibre Diameter 300 µm 300 µm 43 - 96 µm 
Fibre Spacing/ 
Pore Size 
350 µm 300 µm 150 – 1000 µm 
Number of 
Layers/ 
Height 
4 6 10 mm 
Diameter 13 mm 14 mm 6 mm 
Micro-porosity Yes No No 
Material Acrylate 
PolyHIPE 
Polycaprolactone Polyurethane foam 
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Figure 5.11: SEM images of the macrostructure of the three scaffold types evaluated. 
(A) PolyHIPE (B) Biotek (C) polyurethane. Images not to the same scale. 
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Figure 5.12: Comparison of proliferation and matrix deposition on the three scaffold 
types. Mean ± SD for (A) viability (B) ARS staining (C) DR80 staining. *** indicates 
p<0.001. PolyHIPE vs PU DR80 not significant at D21 or D28. (n=6). 
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PolyHIPE and polyurethane scaffolds supported cell proliferation at similar rates. The 
PolyHIPE scaffold reached a plateau sooner, as indicated by the flattening of the 
growth curve, whereas the polyurethane supported significantly higher metabolic 
activity (cell number) on days 21 and 28. The Biotek scaffold did not permit cell 
growth up to a plateau at the time points investigated, but cell number continued to 
increase throughout the culture period. From day 7 onwards, cell numbers were 
significantly lower than both other scaffold types. 
The PolyHIPE and polyurethane scaffolds had significantly higher mineralisation than 
the Biotek scaffolds, with the polyurethane having the highest calcium staining on 
both day 21 and day 28. Mineralisation did not significantly increase between day 21 
and day 28 on the Biotek or PolyHIPE scaffold. This is likely due to the cells on the 
Biotek scaffold being in the growth phase, and cells on the PolyHIPE scaffold having 
limited volume in which to deposit mineral, as shown by the matrix distribution 
(Fig. 5.13).  
There was no significant difference in collagen production between the PolyHIPE and 
polyurethane scaffolds on day 21 or 28, but both contained significantly more collagen 
than the Biotek scaffold.  
 
Figure 5.13: Distribution of calcium as shown by ARS staining before destain with 
perchloric acid for (Top) PolyHIPE (Bottom) Biotek. The far left scaffold in each 
image is the no-cell control. 
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5.4.10 Micro-computed tomography  
In order to evaluate architecture and determine whether the spatial distribution on 
mineralised matrix deposition could be quantified accurately, scaffolds were scanned 
using MicroCT. MLOA5-K were cultured on all three scaffolds in accordance with 
the experiment outlined in §5.5.9. Scans were performed on seeded and unseeded 
scaffolds on day 21 and day 28 on all three scaffold types. Before scanning, samples 
were fixed in accordance with §3.2.10 and kept refrigerated in PBS until analysis. 
Before mounting in the polystyrene holder, scaffolds were blotted with paper towel to 
remove excess PBS. The VOIs for each scaffold and time point are given in figure 
5.14.  
 
Figure 5.14: MicroCT comparison of unseeded, D21 and D28 VOIs for each scaffold 
type. Bright spots visible on seeded scaffolds are the high density mineral deposits. 
Scale bars: PolyHIPE & Biotek – 1 mm, PU – 3 mm. 
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From figure L it is clear that there are mineral deposits detectable on each scaffold 
type. In order to quantify this, greyscale index (GSI) histograms were compared to 
determine whether there were a higher percentage of denser voxels in the seeded 
scaffolds than the unseeded using a protocol similar to that of Puwanun, et al. [395]. 
This was done by two different methods, with the minimum threshold either being set 
as the scaffold GSI (Fig. 5.15) or a GSI above the scaffold density (Fig. 5.16). The 
former should allow you to see the scaffold and any deposited mineral, whereas the 
latter only shows deposited mineral. 
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Figure 5.15: Comparison of GSI for all three scaffolds at D21 and D28 with scaffold 
included in the threshold (n=3). 
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From comparing the GSI of seeded and unseeded scaffolds (Fig. 5.15) it is not clear 
that seeded scaffolds are denser. In fact, for the PolyHIPE and polyurethane scaffolds 
the unseeded scaffolds have a higher percentage of higher GSIs, with the peak for the 
seeded scaffolds occurring at a lower density, and no discernible difference in GSI for 
the Biotek scaffolds. This peak may be due to the presence of PBS in the scanned 
sample, with more being retained in the PolyHIPE and polyurethane scaffolds due to 
the comparatively higher level of extracellular matrix deposited in these scaffolds as 
seen by calcium and collagen staining, and the fact that the polyurethane scaffold acts 
as a sponge.  
By adjusting the minimum threshold so that minimum GSI is set as a density greater 
than the scaffold and comparing the distribution of GSIs above this point, the effect of 
the water and scaffold material should be removed (Fig. 5.16). Using this protocol, all 
three scaffold types have a higher percentage of denser GSIs in seeded scaffolds when 
compared to the control. This difference is most noticeable in the polyurethane 
scaffolds on day 28 and the Biotek scaffolds at both time points, with the difference 
in the PolyHIPE scaffolds being barely noticeable at day 21, but more pronounced at 
day 28.  
To ensure that the MicroCT was indeed detecting mineralised matrix, cultures on 
polyurethane scaffolds were repeated; however, this time some were maintained in 
BM rather than SM, meaning that the osteogenic supplements were not present. 
Comparisons of ARS and DR80 staining and MicroCT scanning were performed on 
days 21 and 28, with thresholds set to exclude scaffold material (Fig. 5.17).  
Cultures only mineralised in SM, as indicated by ARS staining, although there was no 
significant difference in collagen production at either time point. Seeded scaffolds 
were only denser when maintained in SM, confirming that the MicroCT is detecting 
mineralised extracellular matrix, rather than just the presence of cells.  
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Figure 5.16: Comparison of GSI for all three scaffold types at D21 and D28 with 
minimum GSI set to exclude scaffold material (n=3). 
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Figure 5.17: Comparison of GSI when MLOA5-K are cultured in SM or BM. Density 
greater than the scaffold only detectable in SM. (A) ARS and (B) DR80 comparison of 
SM and BM culture (n=6). 
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To examine whether it is indeed the presence of PBS that was affecting the GSI 
distribution, 5 × 5 polyurethane scaffolds were seeded with 60,000 IDG-SW3 and 
maintained in EM for three days before a further culture of 21 days in SM. Scaffolds 
were then fixed using the normal protocol (§3.2.10) before being dehydrated. This was 
performed by submerging scaffolds in increasing ethanol concentrations (50, 70, 80, 
90, 100, 100 vol%) for ten minutes at each concentration before submerging samples 
in HMDS for three minutes then leaving to air dry in a fume cabinet overnight. 
Samples were then scanned using MicroCT using the standard protocol (§5.4.14), but 
the GSI threshold was set at 30-255. This includes the scaffold material and the 
mineralised matrix.  
Comparison of wet and dry polyurethane VOIs clearly demonstrates the influence PBS 
was having on the scanned samples. Furthermore, in dry scaffolds, the percentage 
intensity of the GSIs is able to reveal the mineralised matrix deposition without the 
need to threshold out the scaffold material (Fig. 5.18).  
As well as detecting mineral deposition, MicroCT can also reveal the architecture of 
the entire scaffold in a non-destructive manner. Both the Biotek and PolyHIPE 
scaffold are designed to be woodpile structures. To determine whether the final 
product matches the initial design, scans of the entire scaffold were performed, 
reconstructed, and electronically cross-sectioned using CTvox. These were compared 
to SEM images of scaffolds cut with a scalpel to examine microarchitectures (Fig. 
5.19).  
From the MicroCT and the SEM of the Biotek scaffold it is clear that it does not have 
the described architecture. The edge of the scaffold has merged where it has been 
stamped from a larger sheet and the layers of fibres do not alternate properly, meaning 
that there is not a regular porosity throughout. MicroCT images of the PolyHIPE 
scaffold have very poor contrast due to them being 80% air and MicroCT being a 
density-based imaging modality. Despite this, it can be seen that these scaffolds have 
retained their fibre offset, resulting in a regular macroporosity throughout. This is 
confirmed by the SEM images of the PolyHIPE scaffold, where the offset can clearly 
be seen, as well as the internal microporosity. However, the perimeter of the scaffold 
suffers from fibre merging, resulting in all four layers of fibres combining (Fig. 5.19, 
bottom left).  
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Figure 5.18: Comparison of wet (A) and dry (B) unseeded PU VOIs. On seeded, dried 
VOIs, scaffold struts are clearly denser (brighter) and mineral deposits are even 
visible (circled in red, C& D). This higher density is also clear in the GSI histogram 
without thresholding out the scaffold (E). Scale bar: 2.5 mm. 
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Figure 5.19: MicroCT and SEM images of the Biotek and PolyHIPE woodpiles. Top 
Row: MicroCT of whole (left), edge (centre) and cross-section (right) of Biotek. 
Second Row: SEM of Top (left), whole (centre) and cross-section (right) of Biotek. 
Third Row: MicroCT of whole (left), and two cross-sections (centre & right) of 
PolyHIPE. Fourth Row:  SEM of edge (left), and two cross sections (centre and right) 
of PolyHIPE. 
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5.4.11 Generation 3 PolyHIPE – improved architecture and reproducibility  
The generation 1 PolyHIPE scaffold was the four-layer woodpile attached to the 
functionalised coverslip. The second generation reduced the fibre spacing through the 
incorporation of Tinuvin and permitted the removal of the scaffold from the coverslip, 
resulting in it being free standing. However, the method of polymer addition during 
the fabrication relies on surface tension to stay in place, limiting the height of the 
scaffold to four layers and compromising its architecture at the perimeter (Fig. 5.20). 
 
Figure 5.20: Render showing polymer addition for generation 1 and 2 scaffolds. 
Technique relies on the HIPE droplet staying on the coverslip through surface tension. 
This results in a ‘contact lens’ shaped scaffold that is exacerbated as more layers are 
added. CAD render used with the kind permission of Ross Burdis.  
The effect of this method of polymer addition can be seen in figure 5.21. Although the 
architecture is retained in the centre of the scaffold, at the edge there is not sufficient 
HIPE on the preceding layer for the subsequent layer to form from, resulting in fibre 
merging.  
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Figure 5.21: Effect of polymer addition method on fibre architecture. (A) SEM image 
of a second generation scaffold. (B) schematic identifying the regions where fibre 
merging occurs. CAD render used with the kind permission of Ross Burdis. 
In order to overcome this, HIPE needs to be added in a manner which does not rely on 
surface tension. Therefore, a custom 15 × 15 mm square well was 3D printed in ABS. 
In the base of this, a square glass coverslip was placed which was covered with a layer 
of HIPE. After the first layer of fibres was written, HIPE could again be added that 
covered the entire well, negating the effects of surface tension.  
To avoid surface tension, HIPE covered the entire base of the ABS well. To mitigate 
fibre merging between layers, HIPE was always added evenly over the entire area of 
the well. To keep the bottom layer of fibres aligned and parallel, a perimeter the length 
and width of the scaffold was written first, inside which the first layer of fibres were 
polymerised. Subsequent layers of HIPE were added with a 22g hypodermic needles 
for precise spatial and volumetric delivery. Only HIPES in the range of EHA0P80 to 
EHA15P80 with 0.1 wt% Tinuvin produced scaffolds with acceptable architecture. 
Above 15 wt% EHA, polymerisation between fibres occurred, producing sheets rather 
than distinct fibres.  
This optimised protocol allowed scaffolds to be produced without fibre merging up to 
22 layers in height. The final dimensions of the third generation scaffolds were 6.75 × 
6.75 mm squares, 6 layers in height, with a mean fibre diameter and spacing of 325 
µm and 315 µm, respectively (Fig. 5.22). There was no significant difference in 
diameter and spacing between the EHA0P80 and EHA15P80 compositions. 
Reproducibility and architecture were significantly improved. 
226 
 
 
Figure 5.22: SEM images of generation 3 PolyHIPE scaffolds. (A) microscope image 
showing two third generation scaffolds (B-G) SEM of 6-layer EHA0/EHA15P80 
generation 3 scaffolds. 
Cellular performance of the generation 3 scaffolds was evaluated by seeding with 
25,000 MLOA5-K in 100 µL of BM in a bespoke well plate to maximise seeding 
efficiency (Fig. 5.23). Each well is 7 × 7 mm and completely filled when a scaffold 
and 100 µL of media is added. Metabolic activity and mineralisation were assessed 
over a 3-week period (Fig. 5.24). 
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Figure 5.23: Bespoke seeding well plate for generation 3 scaffolds. 
Cell metabolic activity significantly increased at each time point. By day 21, there was 
substantial mineralised matrix deposition, as indicated by high levels of ARS and 
DR80 staining. Direct comparisons to generation 2 scaffolds are not possible due to 
the significantly different architecture. 
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Figure 5.24: Generation 3 PolyHIPE scaffolds supported (A) cell growth and (B) 
mineralised extracellular matrix production over a three-week period (n=5). 
 
 
228 
 
5.4.12 Cells do not fully penetrate the internal porosity within 3 weeks 
Ingrowth into the internal porosity of the fibres of the generation 3 PolyHIPE scaffolds 
was assessed using histology. 200,000 hES-MPs were seeded onto 6-layer EHA0P80 
generation 3 scaffolds in BM then maintained for 21 days in OIM. Scaffold 
mineralisation was assessed via Alizarin Red S staining (Fig. 5.25) and ingrowth by 
sectioning and H&E staining (Fig. 5.26). 
ARS staining revealed mineralised nodules on the fibres and in the matrix deposited 
between the scaffold fibres. hES-MPs appeared to have an elongated phenotype that 
ran parallel with the fibre direction. 
 
Figure 5.25: Representative photographs of ARS stained single phase PolyHIPE 
scaffolds (n=12). (A & B) show mineralised nodules in the extracellular matrix 
deposited by hES-MPs present between the fibres. (C & D) show the elongated hES-
MP cells aligning with the fibre direction and spanning the fibre spacing. 
(E) macroscopic photographs of mineralised hES-MP cultures. Scale bars all 400 µm. 
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Figure 5.26: Optical microscope images of generation 3 PolyHIPE scaffold sections 
stained with H&E. (A) cross-section of a single fibre (B) cross-section of two layers 
of fibres intersecting (C&D) cross sections of scaffold material. Boxes surround 
darker areas within the fibre where cellular material is present. Arrows point to 
regions where cells did not penetrate. Images taken at 20× magnification. Scale 
bars 200 µm. 
When sectioning it was not possible to retain the woodpile architecture of the scaffold. 
Due to the presence of extracellular matrix and PBS within the macropores of scaffold, 
the tissue freezing medium was not fully able to penetrate the porosity resulting in the 
scaffold rupturing as it was frozen in liquid nitrogen. However, it was possible to stain 
and image individual pieces of the scaffold. In figure 5.26 it can be seen that the outer 
perimeter of the scaffold appears dark purple, showing where the cells and matrix have 
coated the surface of the fibre. In some regions, the immediate layers of pores below 
the surface of the fibre are also stained dark purple, indicating ingrowth (white boxes). 
However, despite the large interconnectivity of the PolyHIPE material, cells did not 
penetrate the full thickness of the fibre, with many regions left without cells (white 
arrows).  
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5.5 Discussion 
Parts of this discussion have appeared in the author’s publication ‘Emulsion 
templated scaffolds with tunable mechanical properties for bone tissue engineering’ 
[240]. A full copy of this publication is available in the appendix, §10.3. Under the 
Personal Use terms of the publication, the author has used parts of this article in full 
for this thesis.  
The work performed in this chapter primarily aimed to determine a suitable substrate 
for use in an in vitro model of postmenopausal osteoporosis that will be developed in 
chapter 6. First, the ability of the generation 1 PolyHIPE scaffolds to support bone-
cell cultures was evaluated, with the effect of substrate stiffness and plasma treatment 
examined. Once their suitability was confirmed, they were developed into 
generation 2 scaffolds that utilised a UV light absorber to improve the printing 
resolution and no longer required a glass substrate to retain their architecture. This 
scaffold was then compared to two alternatives; a polyurethane foam and a 
commercial polycaprolactone woodpile structure produced by 3D Biotek. The cellular 
performance was assessed as well as the physical properties. The PolyHIPE scaffold 
was then further developed, with the generation 3 scaffold having superior architecture 
and reproducibility.  
Wet mechanical testing showed that cell culture conditions did not affect the stiffness 
of the material. However, samples were not plasma treated prior to testing meaning 
that they were still hydrophobic and PBS may not have fully penetrated the porous 
network. Despite this, swelling of the polymer which could affect the mechanical 
properties only occurs in solvents such as acetone; therefore, it is unlikely that full 
saturation of the PolyHIPE by culture media would have significantly changed the 
mechanical properties. Furthermore, PolyHIPEs with a high IBOA content are less 
prone to swelling [408]. It is interesting to note that tensile specimens were not always 
made from the same batch of HIPE, yet there is a high level of concordance in the 
results. This indicates that the synthesis method reproducibly creates a PolyHIPE with 
indistinguishable mechanical properties.  
Physical characterisation by determining the DOO for each of the twenty compositions 
confirmed that the manifestation of these nominal porosities is not affected by 
monomer proportion. Having the same DOO in each of the three compositions means 
that variation in internal fibre architecture is minimised between compositions as well 
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as allowing similar levels of nutrient exchange between the cells and the environment 
[409]. The compositions selected for scaffold manufacture, EHA0P80, EHA50P80, 
and EHA100P80, had the highest possible internal phase volume ratio in order to 
maximise the DOO whilst retaining a viscosity that is amenable to pipetting.  
It is known that the porous architecture of a scaffold can affect cell proliferation and 
osteogenesis, therefore optimising this will enhance the performance of the scaffold 
[362]. The ease with which porous materials can be fabricated using emulsion 
templating makes PolyHIPEs excellent materials for 3D cell culture, as exemplified 
by the commercialisation of Alvetex®, a 200 µm thick polystyrene-based PolyHIPE 
scaffold [410]. However, cellular penetration into these PolyHIPE monoliths is 
dependent on their thickness and pore size [372], with Akay, et al., finding that 
regardless of pore size, cellular penetration in PolyHIPEs was rarely seen beyond 
1 mm [373]. Additionally, when plasma treating the PolyHIPE to overcome the 
intrinsic hydrophobicity, it has been shown that there is a significant depth dependence 
with regards to its efficiency. Plasma treatments have been shown to coat the inner-
surfaces of an 85% porous, 10 mm diameter 3 mm thick disk; however, any porous 
object beyond a few millimetres thick will not be homogenously coated, with the least 
deposition occurring at the core [411], [412]. Therefore, PolyHIPE monoliths need to 
be thin for optimal cell and plasma penetration. By creating scaffolds from HIPEs 
using microstereolithography, this depth limit can be overcome as individual fibres 
will not be too thick for cell ingrowth and plasma penetration (<1 mm), but the overall 
depth of the scaffold can be much larger than it can be for monoliths.  
This allows focus to shift onto the macroscopic structure of the scaffold, resulting in 
the ability to produce much more complex scaffolds. The minimum void diameter for 
osseous deposition is considered to be between 50 and 100 μm [363] with the 
recommended size being 300 μm and larger [364]. The scaffolds fibres fabricated here 
have pore sizes in the region of 20–30 μm, which is lower than the minimum required 
for bone deposition. This would be problematic if culturing on a disc of the bulk 
PolyHIPE material; however, the macroscopic pores formed between the fibres during 
the fabrication of the generation 1 woodpile scaffold are between 300 μm (vertically) 
and 650 μm (laterally). This results in a hierarchical porosity, with a range of sizes 
over an order of magnitude. The presence of micro-pores creates a rougher surface 
topography, which likely increases cell attachment and may also increase cell 
migration [373].  
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It is not surprising that untreated scaffolds were not able to support cell attachment. In 
order to form a stable emulsion with water, the continuous phase of the HIPE must be 
hydrophobic and it has been clearly demonstrated that it is necessary to overcome this 
for a polymer to be used as a biomaterial or tissue engineering scaffold [413]. To do 
this, two plasma treatments were selected, pcAir and pdAAc. Plasma contains a 
mixture of electrons, radicals, ions, neutrals and photons [414], and when generated 
from volatile, organic compounds such as acrylic acid, it can be used to deposit a thin 
film of ‘plasma polymer’ onto virtually any solid material. It allows tight control over 
film thickness, is performed in a clean environment, and can be implemented 
regardless of the substrate geometry with minimal or no pre-treatment necessary [415].  
When plasmas are generated from organic compounds, the molecules are liable to 
fragment; however, by using a low ratio of power to plasma flow rate, it is possible to 
retain a similar functionality to the initial compound by preserving functional groups 
[416]. pdAAc adds negatively charged carboxyl groups to the surface, as well as some 
hydroxyl groups generated either from atmospheric oxygen or water desorbed from 
the plasma chamber [417]. pcAir does not generate plasma from an organic compound, 
instead just drawing in air to the plasma vessel. This results in just oxygen-containing 
hydroxyl groups being deposited onto the surface, which also have been shown to 
support protein and cell adhesion and improve wettability [418], [419]. Although 
scaffolds used in this thesis were not intended for clinical application and therefore 
were not subjected to the sterilisation techniques necessary for implanted materials, 
plasma treatments can survive these harsh treatments, with Haddow, et al., 
demonstrating that plasma polymerised surfaces were not degraded by gamma-
irradiation or ethylene oxide sterilisation [417]. The ability of plasma polymers to 
survive ethylene oxide treatment is an important finding in the study of polymeric 
materials for tissue engineering as this technique does not degrade the material, 
whereas gamma-irradiation is likely to do so.  
Plasma modification is effective at penetrating the porous network of a 3D scaffold, 
improving the wettability of the PolyHIPEs and consequently improving the cell 
adhesion [411]. The inclusion of acrylic acid has been used previously to enhance cell 
culture on PolyHIPEs. In particular, Hayward et al., introduced it into the internal 
phase of the HIPE before its addition to the continuous phase. After curing, they 
showed carboxylic functionality on the PolyHIPE pore surfaces that did not adversely 
affect the adhesion of human hepatocytes [372]. 
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Similar cell metabolic activity on these scaffolds indicates that both treatments are 
suitable when improving the adhesion and proliferation on the PolyHIPEs. However, 
the application of pcAir is less time consuming, requires fewer processing steps (e.g. 
does not require liquid nitrogen to cool the monomer) and avoids handling of 
potentially harmful monomers (acrylic acid). Therefore, the results suggest that the 
simpler, faster plasma modification technique is sufficient when considering cell 
viability alone.  
Metabolic activity on the EHA0 scaffolds made from the stiffest PolyHIPE appears to 
be lower than the more elastic EHA50 and EHA100 materials on both day 8 and 15. 
Given that fibre thickness and spacing are maintained throughout, it would be expected 
that relative scaffold stiffness would follow the same pattern as the material stiffness. 
The difference in metabolic activity between the two more elastic scaffolds is much 
less noticeable, which may be due to a much smaller difference in stiffness; the 
difference between EHA0 and EHA50 is approximately 45 MPa, whereas EHA50 to 
EHA100 is approximately 4.5 MPa. This lower metabolic activity on the EHA0 
composition agrees with the total DNA quantification. The amount of DNA present is 
also lower on the EHA0 compositions, with little difference between EHA50 and 
EHA100 (data not shown). Previously published work demonstrated using confocal 
imaging that on PolyHIPE scaffolds with the highest levels of metabolic activity, 
groups of cells could bridge the gaps between the fibres and two-photon imaging 
demonstrated that they could penetrate the fibres (Fig. 5.27).  
 
Figure 5.27: Confocal microscopy (A and B) images of a EHA100P80 scaffold 
showing cells completely covering fibres and filling the spaces between the fibres. (C) 
Two-photon image showing actin (red) and nuclei (blue) within the fibre, the white 
line indicates the fibre surface. Adapted and reprinted from Owen, et al., under the 
Creative Commons Attribution Licence [240]. 
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Neither the composition of the scaffold nor the pdAAc coating had a significant effect 
on ALP activity. However, cells seeded on EHA0 scaffolds with a pdAAc coating did 
have significantly higher ALP activity compared to all other scaffolds, indicating this 
scaffold stimulated osteogenic differentiation. This suggests that the combination of 
the EHA0P80 PolyHIPE and pdAAc treatment resulted in the best substrate for 
osteogenic differentiation between those examined here. This is interesting given that 
EHA0 scaffolds did not result in significantly higher ALP activity than EHA50 and 
EHA100 scaffolds; neither did pdAAc scaffolds when compared to pcAir.  
The stiffest scaffolds (EHA0P80) have a significantly lower amount of DNA (p<0.05) 
but similar metabolic activity to other scaffolds, which together with the higher ALP 
activity suggests that more cells in this condition differentiated rather than 
proliferated. It is possible that this is due to the cell’s response to the stiffness of the 
material, as substrate mechanical properties have been shown to influence stem cell 
fate [420]–[422]. However, whilst stiffer substrates have been demonstrated to be 
conducive to osteogenic differentiation, those substrates had much lower Young’s 
moduli than these PolyHIPEs and cells in those previous experiments were cultured 
in media without dexamethasone. In addition, subsequent work suggests that stiffness 
alone cannot commit a stem cell to a specific lineage, with other factors such as 
substrate chemistry and density of cell binding ligands also influencing differentiation 
[423]. For the PolyHIPEs investigated here, relative stiffness alone did not appear to 
induce differentiation as significantly higher ALP activity only occurs in conjunction 
with pdAAc. With regards to the effect of acrylic acid on osteogenic differentiation, 
conclusive evidence for a relationship is yet to be seen as there is evidence in the 
literature indicating stimulatory [424] as well as no [425] effects. It has been shown 
that plasma deposited acrylic acid does not diminish the cells’ ability to perceive 
differences in substrate stiffness when comparing the osteogenic response of MSCs to 
varied substrate stiffness [426]. Therefore, the reason for the enhanced ALP activity 
could be that the pdAAc coating provides sufficient ligands for the cells to respond to 
the stiffer EHA0P80 scaffold fibres whereas pcAir does not. Hence, no significant 
difference was seen between any pcAir treatments and the stiffer scaffold material 
only influenced osteogenic differentiation under a specific condition. 
Woodpile scaffolds formed from porous and non-porous fibres of the same material 
were not compared directly in this study. However, it is likely that the differences seen 
when cells are grown on microporous monoliths in comparison to planar substrates 
are relevant when trying to understand the potential benefits of microporous scaffold 
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struts. First, it seems likely that porous fibres will improve diffusion-based processes 
throughout the PolyHIPE scaffold. Furthermore, scaffolds with non-porous fibres and 
macro-pores much larger than the cell size, e.g. 100s of microns, are likely to induce 
the same cellular behaviour as planar surfaces because the cell attaches to the strut in 
the same manner (shape and orientation) as a tissue culture plate [427], [428]. In 
contrast, scaffolds with micropores within the fibre allow the cells to have a more 
physiologically relevant morphology, as demonstrated when Alvetex® PolyHIPE 
inserts were compared to tissue culture polystyrene. Here it was shown that the use of 
these substrates profoundly improves the ability of mesenchymal stem cells to 
differentiate into osteogenic phenotypes, that cells retained a more similar phenotype 
to that seen in vivo, and that they had increased levels of osteogenic markers, such as 
ALP activity, osteocalcin production, and calcium deposition. 
Other groups have demonstrated the benefits of strut microporosity. For example, in 
selective laser sintered polycaprolactone scaffolds where a microporosity within the 
fibres of the scaffold was formed during the sintering process [429], [430]. The 
interconnected network formed was shown to improve cell ingrowth and colonisation 
of the scaffold. Similar to this, rapid prototyping and particulate leaching have 
previously been combined to introduce a controllable microporosity into scaffolds 
with larger macro-channels, allowing the influence of pore architecture on mechanical 
and biological properties to be explored [431]. 
Full cellular penetration of the fibres would also enable continuous neo-tissue 
formation throughout the scaffold, a clear advantage in tissue engineering 
applications. In the work presented here, partial cell ingrowth was observed into the 
porous PolyHIPE fibre by two-photon microscopy and histology. Although cells did 
not fully infiltrate the fibres here, in parallel work by Paterson where the same type of 
PolyHIPE was used to create microparticles, hES-MPs were observed to fully invade 
the material. However, this level of penetration was only seen at later time points (day 
30 and 60). At a similar time point (day 15), comparable levels of infiltration were 
observed, indicating that the low level of cell permeation seen here may have been due 
to the shorter culture period (Fig. 5.28).  
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Figure 5.28: Ingrowth of hES-MPs into PolyHIPE microparticles on day (A) 15 and 
(B) 60. At day 15, dark bands of cells can be seen around the perimeter of the 
microparticles, similar to that observed around the fibres in this work. By day 60, cells 
have fully penetrated the microparticles and deposited large amounts of extracellular 
matrix outside the particles, binding them together. Adapted and reprinted with the 
kind permission of Dr. Thomas Paterson, University of Sheffield [396].  
The single-photon technique used to create the scaffolds was not capable of a smaller 
fibre spacing whilst retaining the fibre diameter as partial polymerisation of the HIPE 
would occur between the fibres, resulting in a solid sheet or web effect, depending on 
the distance. To remedy this, a two-photon technique could have been used as this 
permits a much higher resolution as absorption only occurs within the immediate area 
surrounding the focal spot. However, the single-photon technique has a manufacture 
time of approximately 13 minutes for a 13 mm × 13 mm generation 1 woodpile 
structure, producing each fibre in a single pass. A two-photon setup would take much 
longer, with each fibre potentially requiring multiple passes to achieve the desired 
width and depth. Therefore, introduction of Tinuvin, a UV light absorber, into the 
continuous phase of the emulsion was utilised to reduce out-of-focal spot 
polymerisation and increase resolution whilst retaining manufacture speed. 
Tinuvin® 234 was selected due to the ease with which it can be incorporated into the 
current synthesis protocol. Due to its solubility in the continuous phase, it can readily 
be added to the polymer and dissolved with the surfactant by sonicating in a water 
bath. The ability of Tinuvin to cease polymerisation at 4 wt% even at high laser power 
shows that is a potent additive. The production of films rather than fibres at 0.5 to 2 
wt% is analogous to the work of Sušec et al., who used Tinuvin® CarboProtect® to 
reduce the penetration depth of light into PolyHIPEs, increasing the resolution [387]. 
This is how ribbons were created rather than fibres, as the laser could only penetrate a 
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few microns into the HIPE. 0.1 wt% was found to produce fibres rather than ribbons, 
and SEM analysis of the scaffolds showed a 30% reduction in fibre spacing compared 
to scaffolds without the light absorber.  
Side skin formation is thought to be formed due to a partial polymerisation of the HIPE 
outside of the focal spot of the laser. Here, the polymer is sub-activated resulting in an 
incomplete polymerisation which collapses and forms a closed sheet around the fibre. 
From cross-sectional SEMs, the addition of Tinuvin appears to have partially reduced 
skin formation, with a larger proportion of the fibre having an open pore surface. 
However, no effect on side skin thickness was seen. This may be because although 
out-of-focal spot polymerisation has been minimised by quenching the scattering of 
UV light through the HIPE, reducing the presence of polymerising free radicals 
between fibres thereby decreasing spacing, it is still occurring in the immediate 
vicinity of the fibre to the extent that a skin is formed. This is because Tinuvin is only 
soluble in the continuous phase, not the internal phase, and therefore transmission of 
UV light scattered through the water phase is not quenched. These findings agree with 
the work of Sherborne, whose work focussed on determining why the skin forms when 
PolyHIPEs are structured using microstereolithography [432].  
Metabolic assays performed on PolyHIPE scaffolds fabricated from EHA0P80 either 
with or without 0.1 wt% Tinuvin had no significant difference, even over an 18 week 
period, indicating that its addition is not cytotoxic and it does not leach out over time.   
Free standing scaffolds that do not require a functionalised glass coverslip were 
developed as this base acts as a barrier, limiting nutrient diffusion and flow through 
the scaffold. Although PolyHIPEs which could undergo a large extension at failure 
were initially selected to allow the possibility of dynamically straining the scaffold 
during culture, it was immediately found that scaffold stiffness was essential to 
maintain the complex architecture. As it has been shown that porosity influences the 
stiffness of the material, attempts to reduce porosity but retain the EHA50 monomer 
composition were made. This required the use of MIPEs; however, the stiffness still 
was not high enough to maintain the architecture. Additionally, MIPEs have negligible 
pore interconnectivity and therefore have fully enclosed pores within the polymer. As 
a result, washing will not be able to fully remove uncured polymer from the system, 
which could leach out during cell culture and contaminate the sample. Without the 
methacrylate groups on the coverslip for the HIPE to adhere to when curing, it was 
found that keeping the base layer of fibres parallel was not possible. SEM showed that 
238 
 
with the exception of the bottom layer of fibres, the architecture of the regular scaffold 
had been retained.  
Three scaffolds were compared for use in the in vitro model; PolyHIPE, polyurethane 
and Biotek. In terms of architecture, the PolyHIPE and Biotek scaffolds are preferable 
to the polyurethane for use in an in vitro model due to their reproducible architecture. 
As their 3D geometry is controlled by additive manufacturing techniques 
(microstereolithography and extrusion, respectively), there should be less variability 
between scaffolds in comparison to the foam due to the control available over fibre 
position. This reproducible, regular architecture should produce more a more 
consistent cellular response and is also beneficial for computationally modelling fluid 
flow through the scaffold. However, although polyurethane substrates have a more 
stochastic architecture, they are a well-characterised scaffold in the field of bone tissue 
engineering, having been previously been reported to support extensive osteogenesis 
in vitro and in vivo, under both static and dynamic conditions [9], [406], [433], [434]. 
For model development and to have statistically valid results, a large number of 
scaffolds will be required. Therefore, ease of manufacture must also be considered. 
Clearly, the Biotek is the superior scaffold in this category as it is bought premade. 
However, 12 scaffolds cost $199, making large scale cultures an expensive endeavour. 
The polyurethane foam is purchased as a large block which is then cut down to size, 
which is neither financially or time expensive. In comparison, the PolyHIPE raw 
materials are cheap; however, the largest time investment is required to produce the 
scaffolds. 
With regards to cell performance, both the PolyHIPE and polyurethane scaffold 
outperformed the Biotek scaffold in terms of cell viability, calcium deposition and 
collagen production. The Biotek scaffold was seeded and cultured as per manufacturer 
instructions. However, the relatively low cell number and matrix production is likely 
due to the hydrophobicity of PCL [435] inhibiting cell proliferation throughout the 
scaffold, as seen in figure 5.13 where the mineral distribution is patchy and uneven in 
comparison to the PolyHIPE. It may be that this high hydrophobicity is intended to 
retain the seeding droplet within the scaffold, improving seeding efficiency in 
comparison to a more hydrophilic chemistry. However, this ultimately inhibits cell 
proliferation throughout the scaffold. 
Initially, it appears that the PU scaffold has outperformed the other two in all three 
categories. However, it has a larger volume than the PolyHIPE scaffold. Due to the 
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complex, stochastic nature of the PU scaffold and the multiscale porosity of the 
PolyHIPE scaffold it is not possible to normalise the results accurately to scaffold 
volume. However, were the scaffolds solid blocks, the volume of the polyurethane 
cylinder and Biotek scaffold would be ~280 mm3 and the PolyHIPE ~130 mm3. 
Therefore, it can be seen that per unit volume the polyurethane scaffold was not greatly 
superior to the PolyHIPE as mineral deposition was not 2.15 times higher.  
From ARS staining, it was clear that mineral distribution was even throughout the 
PolyHIPE and polyurethane scaffolds, but patchy on the Biotek. However, these 
differences in mineral distribution were not immediately apparent using MicroCT. 
Although scans on days 21 and day 28 revealed denser, mineralised regions, MicroCT 
was not able to detect all of the mineralised regions revealed by histological staining. 
When differences in the GSI histograms were analysed with a minimum threshold set 
to include the scaffold, the unseeded polyurethane and PolyHIPE scaffolds had a 
distribution of GSIs equivalent to a higher density than the seeded scaffolds, with the 
seeded samples peaking between 65 and 75 GSI and the unseeded at ~90 GSI. From 
the ARS staining it is clear that the seeded scaffold contain more dense material than 
the unseeded; therefore, a material other than the scaffold and extracellular matrix is 
influencing the results.  
Although samples were mounted in a polystyrene foam holder, the density of this 
polymer is even less than the scaffold and was chosen due to its x-ray transparency. 
Therefore, this was not the material impacting the density histogram. As a result, it 
became clear that PBS retained within the scaffold was skewing the distribution. As 
the seeded scaffolds had extensive matrix deposition which retains PBS within the 
substrate, and PBS has a lower density than the scaffold material, they have a lower 
peak GSI than the unseeded control scaffolds. Control scaffolds retain less PBS and 
therefore have a higher peak GSI. This effect was not seen in the Biotek scaffolds due 
to the minimal extracellular matrix deposition allowing the PBS to drain away.  
By setting the minimum threshold to a GSI that excludes the scaffold and therefore 
the PBS, the distribution of GSIs pertaining to the extracellular matrix can be 
compared. Here we can see that on all three scaffold types at day 28 there is a greater 
percentage of higher GSIs in the seeded scaffolds than the unseeded. When cultures 
were maintained in BM rather than SM, there are similar amounts of collagen 
synthesis as shown by DR80 staining, but negligible mineral staining. When these 
scaffolds are scanned by MicroCT, there is no difference in GSI distribution between 
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seeded and unseeded polyurethane scaffolds, confirming that the difference seen in 
SM is due to mineralised matrix deposition, not just the presence of cells or 
collagenous extracellular matrix. 
The effect of drying the scaffolds prior to scanning is clearly visible. The pores of the 
polyurethane scaffolds no longer seem to be filled with a similar density material to 
the polymer due to the absence of PBS. Furthermore, without PBS skewing the GSI 
distribution, mineral deposits and scaffold material are clearly visible on the same 
reconstructions, meaning that segmentation to analyse mineral distribution would be 
possible.  
Although the presence of PBS here negatively affected the scan clarity, other groups 
have successfully discerned mineral from the scaffold material under wet conditions. 
Vetsch, et al., examined how the curvature of a defect affects tissue formation by 
cutting different shape channels into a scaffold and examining ingrowth by repeated 
MicroCT scanning at various time points [436]. By scanning a hydroxyapatite sample, 
they were also able to determine the GSI equivalent to the bone mineral, allowing for 
effective segmentation of the scaffold and matrix. Using this protocol, they were able 
to measure the spatial and temporal change in bone deposition. Repeated MicroCT 
scanning in vivo can affect bone metabolism due to the radiation [437]; however, the 
protocol used by Vetsch, et al., has been shown to not impact the osteogenic 
performance of the human MSCs used when total DNA, ALP activity and calcium 
deposition were compared between irradiated and non-irradiated samples [438]. In 
addition to this, work by Cartmell, et al., found that mineral deposition on scaffolds 
can be scanned up to five times by MicroCT without significantly inhibiting the 
function of the cells [439]. Therefore, it seems that the difficulties presented by the 
presence of PBS in the scaffold stem from the parameters used to scan the samples. 
Scanning operating procedures were determined using dry samples to maximise clarity 
of the low density polymer scaffolds. When wet experimental conditions were then 
scanned the presence of PBS skewed the histogram significantly, meaning that it was 
not possible to determine the presence of mineral without thresholding out the scaffold 
and water. In the future, scanning parameters would be changed to allow mineral and 
the scaffold to be accurately segmented. This would mean that in the in vitro model 
the same samples could be repeatedly scanned and areas of formation and resorption 
could be accurately tracked. In comparison to histological staining, this approach 
would allow the spatial aspect of bone remodelling to be evaluated as well as the 
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change in total mineral. Furthermore, it would reduce the number of samples required 
as separate scaffolds would not be necessary for each time point. It would also reduce 
inter-sample variability, as the assumption that multiple scaffolds seeded separately 
and then cultured under the same conditions will behave identically is no longer 
required.  
In addition to comparing mineral deposition, MicroCT can also reveal the scaffold 
architecture in a non-destructive manner. In comparison to the original design of the 
Biotek scaffold, it is clear that the fabricated geometry does not match the intended 
architecture (Fig. 5.29). MicroCT and SEM reveal that the perimeter of the scaffold is 
not well defined, with all the fibres from each layer merged together. As this scaffold 
is extrusion-printed, this is likely from where the scaffolds have been stamped from a 
larger sheet. In addition to the perimeter of the scaffold not matching the original 
specifications, the scaffold fibres and spacing do not retain the offset originally 
intended. Instead of each fibre lying above the space in the previous layers, they appear 
more randomly distributed, often lying directly above each other. This removes the 
regular macroporosity and defined pore size from the scaffold, resulting in a more 
stochastic architecture. These variances are not limited to this batch of scaffolds, as 
these differences have also been noted by Marin, et al., and Brunelli, with the former 
finding that these discrepancies affect the micromechanical environment of the 
scaffold [398], [440].  
 
 
Figure 5.29: a) 3D CAD model of the intended geometry of the Biotek scaffold. b) 
scaffold design specifications provided by the manufacturer. Adapted from Marin, et 
al., and reprinted with kind permission of Elsevier [368]. 
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Both the PolyHIPE and Biotek scaffolds are intended to have a woodpile architecture 
with offset fibres. From MicroCT and SEM it is clear that structuring using 
microstereolithography rather than extrusion results in an architecture that is much 
more similar to the original, intended design. However, there is a trade-off between 
manufacture time and printing resolution, with extrusion based technologies being 
able to fabricate structures significantly faster than light-based techniques [441].  
MicroCT works by generating x-rays, passing them through the sample and then using 
a detector to determine their intensity. This can be converted into 2D sections of the 
sample that can be combined during reconstruction into a 3D image. The ability of the 
sample to attenuate the x-ray beam is related to its atomic number and therefore 
density [442]. The PolyHIPE scaffold has limited x-ray attenuation capability due to 
the high level of macroporosity combined with low density of the 80% porous fibres. 
This results in very poor contrast, with only the fibre edges being clearly defined. 
Although the background settings were changed to maximise the system’s ability to 
detect low density materials, MicroCT still struggles to generate high quality scans of 
this material. Despite this, the macroarchitecture is visible and the retention of the fibre 
offset is clear. However, SEM imaging reveals that the perimeter of the scaffold is 
merged due to the reliance on surface tension to hold the pre-polymer in place during 
fabrication.  
Taking into account the fabrication costs, cellular performance and architecture, the 
polyurethane scaffold was selected as the most suitable for creating an in vitro model 
of postmenopausal osteoporosis. The Biotek scaffold was prohibitively expensive to 
be used on a large scale, failed to support extensive matrix deposition, and had a high 
level of sample variability. Therefore, the choice was between the PolyHIPE and the 
polyurethane scaffold. Both were cheap to manufacture in terms of raw materials, but 
the PolyHIPE was significantly more time intensive for large scale production. Both 
supported similar levels of mineralised matrix deposition, but despite the PolyHIPE 
scaffold’s superior architecture, the sponge-like behaviour of the polyurethane 
scaffold means that it would be easier to add a secondary seeding suspension when the 
osteoclast precursors are introduced. 
The PolyHIPE scaffold has been continually developed since its initial conception in 
late 2014. The first generation was proof of concept; that a multiscale porosity scaffold 
243 
 
could be created using photocurable emulsions that had tunable mechanical properties 
as well as supporting mineralising bone cells. These scaffolds have since had 
hydroxyapatite successfully  incorporated into the emulsion whilst retaining a similar 
architecture, which may produce a more clinically relevant scaffold should the result 
be repeated with a biodegradable polymer [390]. Additionally, they have been used as 
trabecular bone mimics for studying osteosarcoma [397]. The second generation of 
PolyHIPE scaffolds focussed on making the scaffold free standing and improving the 
architecture. Prior to this, they had been attached to a glass coverslip. Whilst this is 
acceptable for basic 3D cell culture, it does not allow the possibility of dynamic culture 
or flow through the scaffold and is not clinically relevant. By using IBOA dominated 
emulsions that give a stiffer scaffold, it was found that they could retain their 
architecture without relying on a glass base. In addition, the inclusion of a light 
absorber allowed the production of scaffolds with a greatly improved resolution, 
reducing the size of the macropores between fibres. Despite these improvements, these 
scaffolds were limited in height and had fibre merging at the perimeter. Although now 
improved for in vitro culture, they did not have the intended architecture and would 
not be clinically relevant should different polymers be used. 
Due to these limitations, the third generation of PolyHIPE scaffolds was developed. 
The use of a bespoke fabrication well allowed for excess polymer to be added when 
each layer was printed. This removed the reliance on surface tension for keeping the 
uncured polymer in place during fabrication and allowed much larger scaffolds to be 
fabricated. In addition to increasing the permissible size, it also improved scaffold 
architecture as fibre layers no longer merged at the perimeter. In addition to this, it 
improved fabrication reproducibility and has the potential to allow architectures other 
than woodpile to be fabricated.  
Whilst the third generation of the PolyHIPE scaffold was being developed, it was 
realised that this substrate had alternative applications in the field of osteoarthritis 
(OA) tissue engineering. Osteoarthritis (OA) affects over 150 million people 
worldwide and is generally considered the greatest burden musculoskeletal disorder, 
ranking even above osteoporosis [443]. As the disease progresses, lesions form in the 
articular cartilage [444], which can be treated by autologous cartilage transplantation, 
also known as mosaicplasty. This is a surgical procedure aimed at restoring lesions in 
load bearing regions by transplanting osteochondral plugs to the area from a non-load 
bearing site. These cylindrical plugs consist of both the articular cartilage and 
subchondral bone and are typically 12 – 25 mm in length and are suitable for lesions 
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up to 4 cm in diameter [445]–[447]. Tissue engineered osteochondral plugs are a 
promising alternative to mosaicplasty as they offer the possibility of implanting full-
thickness grafts without donor site morbidity and the need to create additional defect 
sites. However, this requires creating a biphasic scaffold capable of supporting two 
functional tissues with appropriate mechanical properties for the osseous and chondral 
regions, whilst retaining sufficient porosity for nutrient and waste diffusion, as well as 
angiogenesis in the osseous phase [448], [449]. Biphasic osteochondral scaffolds have 
been fabricated and shown promising results in-vitro [448], and in-vivo [450], [451] 
(Fig. 5.30). However, it has been noted that the most prevalent drawback to multi-
phase scaffolds is delamination of the discrete phases due to a non-continuous 
fabrication technique [452]. 
 
Figure 5.30: (A) typical structure of a mosaicplasty graft (B) SEM image of an 
example biphasic scaffold produced by a non-continuous fabrication technique. 
Reprinted from Li, et al., under the Creative Commons Attribution licence [453]. 
As we have seen here, a multiscale porosity can be easily and quickly introduced into 
bone tissue engineering scaffolds through emulsion templating. Furthermore, we have 
seen that the mechanical properties of these scaffolds can be modulated by tuning the 
composition and porosity of the HIPE [240]. Therefore, a biphasic osteochondral plug 
can be produced by selecting stiff and soft HIPE compositions, and as 
microstereolithography is a continuous fabrication technique, the risk of delamination 
is reduced. This approach to creating a tissue engineered osteochondral plug was 
explored in a parallel project, where biphasic scaffolds were fabricated, mechanically 
tested and shown to support bovine articular chondrocytes as well as human 
osteoblasts [454]. 
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Although this main focus of the work in this thesis is not the clinical applications of 
the scaffold, the fabrication technique used here could be replicated with 
biodegradable polycaprolactone PolyHIPEs developed within the group [432]. This 
has the potential to be an ideal bone tissue engineering scaffold, as it would be made 
from FDA approved biodegradable materials, be highly porous over multiple length 
scales allowing excellent cellular performance, and be capable of being produced with 
a wide range of architectures depending on the application due to the method of 
manufacture. In addition, the single-photon fabrication technique used has excellent 
resolution due to the high precision of laser-based manufacture without the long 
fabrication times associated with two-photon polymerisation, meaning that high 
throughput manufacture is not unthinkable.  
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5.6 Summary 
• There was no difference is the wet and dry mechanical properties of the 
PolyHIPEs, meaning that culture conditions can be assumed to not affect the 
mechanical properties of the 20 previously characterised PolyHIPE materials. 
• The degree of openness is determined by the percentage porosity, not the 
monomer composition. 
• PolyHIPE compositions containing EHA facilitated the highest levels of 
metabolic activity. 
• Substrate mechanical properties did not influence osteogenic differentiation, 
with the exception of the stiffest material in combination with an acrylic acid 
plasma treatment. 
• Printing resolution can be improved by the addition of Tinuvin, a UV light 
absorber, whilst remaining biocompatible. 
• When combined with the stiffest compositions, this allows for highly 
reproducible, free standing scaffolds to be fabricated. 
• In a comparison between the PolyHIPE, Polyurethane and Biotek scaffolds, 
the polyurethane is the most suitable for the in vitro model due to its extensive 
mineralisation, ease of manufacture and low cost. 
• Detection and localisation of scaffold mineralisation by MicroCT is heavily 
influenced by the presence of water in the sample, although its effects can be 
reduced by thresholding. 
• In comparison to extrusion, microstereolithography is a greatly superior 
technique with regards to reproducibly fabricating a woodpile architecture. 
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6. Modelling osteoporosis in vitro 
6.1 Introduction 
In 2015, 89% of musculoskeletal research animal studies were conducted on mice and 
rats [155]. Their popularity arises from a relatively low public opposition to their use, 
as well as low cost and ease of housing in comparison to other, larger animal 
alternatives [128]. However, despite being a fundamental component of pre-clinical 
research, mouse physiology does not accurately represent the human condition. This 
is demonstrated by the poor translation of pre-clinical efficacy in animal models to 
human clinical trials and the vast majority of promising discoveries failing to enter 
routine clinical use[159]–[162]. A promising alternative to the use of animals is in 
vitro modelling. 
A wide range of in vitro models of certain skeletal disorders, such as osteoarthritis, 
have been developed to permit their study with reduced use of animals [163]. In vitro 
systems that study bone remodelling have begun to be developed, offering a human-
based cell system that can be used to study the process (§2.3). However, although they 
have been utilised to study certain disease states, predominantly cancer metastases, no 
such model of osteoporosis currently exists. Oestrogen has been shown to affect both 
osteoblasts and osteoclasts in vitro in a similar way to that seen in vivo; therefore, 
designing an in vitro remodelling model that can respond to oestrogen withdrawal in 
order to mimic postmenopausal osteoporosis is a realistic aim. 
In a co-culture of bone cells it is important that the investigator is able to identify the 
presence and function of both cell types. For osteoblasts this is typically done through 
measuring ALP activity, an enzyme involved in mineralisation that can be used as a 
marker of osteogenic differentiation [22], [455], or quantifying mineralisation directly, 
for example by ARS staining for calcium [456] or Von Kossa staining for phosphate 
[457]. Mature osteoclast detection is normally done through microscopy or measuring 
TRAP or cathepsin K production as both are enzymes involved in the bone 
remodelling process [40], [352], [354], [458], [459]. Multinucleation and the 
formation of actin rings, both indicators of a mature osteoclast, can be confirmed using 
microscopy [267], but this is not feasible for 3D cultures. Therefore, measuring 
enzyme activity is a better, quantitative method of determining osteoclast activity.  
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6.2 Aims and objectives 
The aim of this chapter was to determine to what extent an in vitro model of 
postmenopausal osteoporosis can be developed. It will combine the results of chapter 
4, where IDG-SW3 and RAW264.7 were identified as the most suitable cell lines, with 
the results of chapter 5, where the polyurethane scaffold was identified as the most 
suitable substrate, and a regimen of oestrogen withdrawal to mimic the onset of 
postmenopausal osteoporosis. Ideally, it should respond in the catabolic manner seen 
in vivo when oestrogen levels decline. To achieve this, the following objectives were 
addressed: 
1. Examine the effect of PTH, a drug used in the treatment of osteoporosis, on 
markers of the constituent cells. 
2. Assess whether ALP and TRAP activity and mineralisation are suitable 
markers of osteoblast and osteoclast activity in the co-culture. 
3. Determine the effect of oestrogen exposure on monolayer and 3D co-cultures. 
4. Optimise osteoclast seeding density to maximise co-culture duration. 
5. Evaluate the effect of oestrogen withdrawal on markers in co-culture. 
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6.3 Materials and methods 
Further to the materials and methods outlined in §3, the following are used in this 
chapter. 
6.3.1 Co-culture medium 
All co-cultures were maintained in IDG-SW3 differentiation media (supplemented 
media, SM) with 50 ng/mL RANKL. Where co-cultures are compared to 
monocultures of IDG-SW3 or RAW264.7 to analyse differences in ALP and TRAP 
activity, monocultures have been maintained in the same media; therefore, any 
differences observed are not due to the presence of absence of βGP and AA2P.  
6.3.2 Evaluation of mineral resorption in co-cultures 
To ascertain the amount of mineral resorption taking place in the co-cultures, 
Alizarin Red S (ARS) staining was utilised. ARS is typically used to determine 
mineralised extracellular matrix deposition by osteoblasts by staining for calcium. 
However, by determining the amount of mineral present before and after the addition 
of osteoclasts, it is possible to infer the amount of osteoclastic resorption by the 
decrease in the mineral staining. This is similar in principle to the work of Hoyte, who 
used ARS to stain bone sections in vivo and then quantified resorption by measuring 
the removal of the stained bone [460], and Suzuki, et al., who used diminished ARS 
staining on bone sections to demonstrate increased osteoclast resorption [461]. 
This method of estimating resorption requires a baseline level of mineral to already be 
present. Therefore, co-cultures where mineral resorption was ascertained using this 
technique were only initiated after sufficient mineralisation had already occurred by 
the IDG-SW3. This was identified as 21 days of IDG-SW3 pre-culture in 
supplemented media (SM) before the addition of RAW264.7. Co-cultures were 
performed either in 48 well plates (TCP co-cultures) or 5 × 5 mm polyurethane 
scaffolds (3D co-cultures). After 21 days of culture, IDG-SW3 were found to have 
deposited approximately 360 µg/mL of ARS in the 48 well plates and 370 µg/mL of 
ARS in the polyurethane scaffolds (n=6). Any reduction in ARS staining following 
the subsequent co-culture period was assumed to be the result of osteoclastic 
resorption of mineral. The estimated baseline levels are indicated on any graphs where 
mineral resorption is ascertained by this technique.  
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ARS staining in co-cultures was performed after decellularisation, rather than fixing. 
Decellularisation was performed in accordance with the protocol of Kusuma, et al. 
[462]. Briefly, media was removed from the samples which were then washed twice 
with PBS. 0.5% Triton X-100 and 20 mM ammonium hydroxide in PBS was then 
added and incubated for either five or ten for tissue culture plastic (TCP) and 3D 
scaffold cultures, respectively. Samples were then stained in accordance with the ARS 
staining protocol detailed in §3.2.11. 
6.3.3 Parathyroid hormone preparation 
Human parathyroid hormone (1-34) (PTH, cat# A1129-1mg) was purchased from 
Generon, UK. Murine cells have previously been shown to be responsive to human 
PTH [463], [464]. A 10 µM stock solution was created by dissolving 1 mg PTH  in 
24.3 mL of PBS with 0.1 wt/vol% bovine serum albumin. The stock solution was 
aliquoted and stored at -20°C. The same amount of vehicle was added to all wells 
regardless of the drug concentration used. 
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6.4 Results 
6.4.1 Parathyroid hormone has a predominantly catabolic effect on IDG-SW3 
PTH is a common therapeutic for the treatment of osteoporosis as it has the potential 
to promote bone formation and inhibit resorption. However, application of parathyroid 
hormone (PTH) can have either a catabolic or anabolic effect of bone depending on 
the concentration, frequency and duration of its application. Continuous exposure to 
PTH, for example in hyperthyroidism, results in bone loss by inhibiting the synthesis 
of extracellular matrix proteins, including collagen I, osteocalcin, and ALP. 
Intermittent exposure can increase bone formation by promoting osteoblast 
differentiation, inhibiting sclerostin in osteocytes, activating and differentiating bone 
lining cells, and inhibiting osteoblast apoptosis. Despite its effects on osteoblast matrix 
production, the catabolic effect on bone seen during continuous exposure is stated to 
be mostly due to its indirect effect on osteoclasts. Continuous exposure to PTH 
supports a high RANKL:OPG ratio by upregulating RANKL and downregulating 
OPG synthesis [192], [225], [226]. 
One potential method of evaluating an in vitro model of osteoporosis be to determine 
whether it responds to PTH in an analogous way to that observed in vivo. To do this, 
a treatment regimen that elicits an anabolic effect needs to be determined. To explore 
the effects of PTH on IDG-SW3, cells were seeded at 25,000 cells per well in a 48 
well plate and cultured until confluent for three days at 33 °C in EM. Cells were then 
transferred to SM and 37 °C and 0 – 100 nM PTH added either continuously or 
intermittently (twice a week for either 1 hour or 24 hours). ALP activity was measured 
on day 7, meaning that intermittently treated wells were exposed to PTH twice (Fig. 
6.1).  
Concentrations of PTH of 25 nM and above inhibited ALP activity for all treatment 
durations. Total DNA was significantly lower when cells were exposed to PTH at 50 
nM and 100 nM for the 1-hour duration. ALP activity and normalised ALP activity 
were significantly higher at 1nM compared to 0 nM when the treatment was applied 
intermittently for 24 hours. For 1 hour and continuous exposures there were no 
differences between 0 nM and 1 nM for normalised ALP activity and concentrations 
of 25 nM and above had significantly lower normalised ALP activities for all treatment 
durations.  
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Figure 6.1: Response of IDG-SW3 to a range of PTH concentrations and treatment 
duration. (A) ALP activity (B) Total DNA (C) Normalised ALP activity of IDG-SW3 
exposed to various concentrations and durations of PTH (n=6) 
(*/**/***  = p< 0.05/0.01/0.001). 
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To investigate further the effect of PTH on mineralisation and osteocytogenesis, IDG-
SW3 were seeded at 25,000 cells per well in a 48 well plate and cultured until 
confluent for three days at 33 °C in EM. Cells were then transferred to SM and 37 °C 
and concentrations of PTH between 0 nM and 20 nM were applied intermittently either 
once (1X) or twice (2X) a week for 24 hours. GFP and ALP measurements were taken 
weekly and mineralisation quantified on day 28 (Fig. 6.2) 
Statistical analysis was not performed as this experiment was only repeated once in 
triplicate. However, with regards to ALP activity, there were minimal differences with 
regards to concentration or frequency of application at any time point. As with the 
initial experiment, a higher concentration of PTH led to lower total DNA, and two 
applications per week appeared to exacerbate this.  
By measuring GFP expression to infer osteocyte formation, it appears that all 
concentrations and frequencies of PTH exposure reduced GFP expression. The 0 nM 
group was higher from day 14 onwards indicating that osteocytogenesis was inhibited 
in exposed groups. When comparing mineralisation, it was clear from the staining that 
as PTH concentration increased mineralisation was lower with no visible staining at 
concentrations of 10 nM and above in the 1X group and 5 nM and above in the 2X 
group. However, it is also clear that in comparison to previous experiments, very little 
mineral was deposited even in the 0 nM group. Therefore, after destaining the ARS 
for colourimetric quantification, no differences were detectable.  
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Figure 6.2: Effect of a range of PTH concentrations and treatment frequencies on 
IDG-SW3 (A) GFP expression (mean only, 1X & 2X combined) (B) normalised ALP 
activity 1X (C) normalised ALP activity 2X (D) ARS (mineralisation) (E) photograph 
of ARS before destaining for quantification (n=3). 
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The current opinion of the scientific community is that PTH can only have an indirect 
effect on osteoclasts through modulation of the RANKL:OPG ratio in osteoblasts, with 
only a small number of researchers considering that osteoclast-linage cells may 
possess a PTH receptor [465], [466]. To investigate its effect on RAW264.7, cells 
were seeded at 5,000 per well in a 48 well plate and cultured for ten days in BM 
supplemented with 25 ng/mL RANKL. Cultures were exposed to 0 – 100 nM PTH 
which was added either continuously or intermittently (twice a week for either 1 hour 
or 24 hours). TRAP and metabolic activity were determined on day 10 (Fig. 6.3). 
There were no significant differences in TRAP activity in the 1 hr or continuously 
treated group. When applied for 24 hours, concentrations of 1 nM and above 
significantly reduced TRAP activity. There was no effect on metabolic activity for any 
concentration or treatment duration. Normalised TRAP activity was significantly 
lower in the 25 nM group in comparison to 0 nM for all treatment durations; however, 
above this concertation normalised activities rose again and were not different to the 
0 nM group.  
As no combination of PTH concentration, application frequency or treatment duration 
was found to have an anabolic similar to that observed in vivo, PTH treatments were 
not applied to the co-culture.   
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Figure 6.3: Effect of a range of PTH concentrations and treatment frequencies on 
RAW264.7. (A) TRAP activity (B) Metabolic activity (C) Normalised TRAP activity of 
RAW264.7 exposed to various concentrations and durations of PTH (n=6) 
(*= p< 0.05). 
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6.4.2 Mineralisation and ALP and TRAP activity are appropriate co-culture 
markers 
To ensure that ALP activity was specific to osteoblasts and TRAP activity to 
osteoclasts, monoculture and co-culture activities were compared. Initially, 60,000 
IDG-SW3 per well were seeded in 12 well plates, with 20,000 RAW264.7 added 24 
hours later and the culture maintained in SM supplemented with 50 ng/mL RANKL 
for seven days (Fig. 6.4).  
 
Figure 6.4: Schematic showing the co-culture regimen when RAW264.7 were added 
after 24 hours.  
DNA confirmed that presence of both cell types in the co-culture (Fig. 6.5). IDG 
monocultures had significantly less DNA after 7 days than RAW264.7 monocultures. 
ALP activity was not detectable in RAW264.7 monocultures and was significantly 
higher in IDG-SW3. Conversely, TRAP activity only occurred in RAW264.7 
monocultures and was not detectable in IDG-SW3. In co-culture, neither ALP nor 
TRAP activity was detectable despite high levels of DNA. This was likely due to 
overgrowth of the osteoblasts by the osteoclasts, stopping them from reaching 
confluence in co-culture. Although osteoblasts produce ALP whilst sub-confluent, its 
expression is intensively enhanced when they are confluent [467]. Therefore, if the 
IDG-SW3 remain sub-confluent due to the presence of the RAW264.7, their 
expression of ALP may have been undetectable for this reason. Undetectable TRAP 
activity may have been due to a too high seeding density of osteoclast precursors. 
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Figure 6.5: Comparison of day 7 (A) DNA (B) ALP activity (C) TRAP activity for co-
cultures of IDG-SW3 and RAW264.7 where osteoclasts were added on day 1 (n=6). 
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To allow the osteoblasts to establish before introducing osteoclasts, IDG-SW3 were 
cultured for 7 days at confluence in a 12 well plate in SM before adding 10,000 
RAW264.7 and maintaining for a further ten days in SM supplemented with 50 ng/mL 
RANKL (Fig. 6.6). 
 
Figure 6.6: Schematic showing the co-culture regiment when RAW264.7 were added 
after seven days. 
Again, DNA confirmed the presence of both cell types in the co-culture (Fig. 6.7).  
ALP activity was undetectable in RAW264.7 monocultures and TRAP activity was 
significantly higher in RAW264.7 than IDG-SW3, confirming their suitability as 
functional markers in a co-culture. ALP activity was significantly reduced in the co-
culture in comparison to IDG-SW3 monocultures but remained significantly non-zero. 
TRAP activity was significantly increased in the co-culture in comparison to the 
RAW264.7 monoculture. By staining co-cultures with ARS, it was confirmed that co-
cultures were able to mineralise (Fig. 6.8). 
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Figure 6.7: Comparison of day 10(+7) (A) DNA (B) ALP activity (C) TRAP activity 
for co-cultures of IDG-SW3 and RAW264.7 where osteoclasts were added on day 7 
(n=6). 
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Figure 6.8: Photograph taken at 10× magnification on an optical microscope of ARS 
stained day 10(+7) co-cultures of IDG-SW3 and RAW264.7. Scale bar 250 µm. 
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6.4.3 Oestrogen affects co-cultures in TCP and scaffolds 
For clarity, co-cultures performed in tissue culture plastic (TCP) well plates will be 
referred to as TCP co-cultures. Ones performed in polyurethane scaffolds will be 
referred to as 3D co-cultures. 
To evaluate the effect of oestrogen on the co-culture, the previous experiment was 
repeated but either 0 nM or 100 nM 17β-estradiol was added to the culture at the point 
of osteoclast addition. In addition to the TCP co-culture, 3D co-cultures were also 
performed on the 5 × 5 mm polyurethane scaffold. They were seeded with 60,000 
IDG-SW3 and maintained for three days in EM at 33°C before switching to 37°C and 
SM for a further seven days. Media was then carefully aspirated from the scaffold and 
replaced with a 60 µL seeding suspension containing 20,000 RAW264.7. Cells were 
left to attach for 45 minutes before submerging in SM supplemented with 50 ng/mL 
RANKL and either 0 nM or 100 nM 17β-estradiol. The following day, scaffolds and 
media were transferred to a new well plate to retain only adhered cells and maintained 
for a further seven days with half media changes every 2-3 days (Fig. 6.9).  
 
Figure 6.9: Schematic showing the co-culture regimen from preliminary oestrogen-
exposed co-cultures. 
Oestrogen had no significant effect on cell number in any condition (Fig. 6.10). ALP 
activity was undetectable in RAW264.7 monocultures and was higher in 100 nM 
oestrogen cultures in both TCP and 3D, although not significantly. TRAP activity was 
significantly reduced in RAW264.7 monocultures but not in TCP or 3D co-cultures, 
indicating that the upregulation of osteoclasts by the osteoblasts may be greater than 
their inhibition by oestrogen.  
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Figure 6.10: Comparison of (A) DNA (B) ALP activity (C) TRAP activity in day 
10(+7) co-cultures of IDG-SW3 and RAW264.7 in TCP or 3D (n=3). 
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6.4.4 Co-cultures are not stable over extended time periods 
RAW264.7 are osteoclast precursors. When exposed to RANKL, some fuse and 
mature to produce osteoclasts whilst others remain as monocytes. As osteoclasts have 
a finite lifespan of around 12 days, when the first generation of osteoclasts undergo 
apoptosis, there should be enough residual precursors to fuse and generate a second 
wave of osteoclasts. To determine whether this was the case, RAW264.7 were seeded 
at 5,000 per well in a 48 well plate and maintained for 28 days in BM supplemented 
with 25 ng/mL RANKL. Metabolic and TRAP activity were measured weekly 
(Fig. 6.11). 
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Figure 6.11: (A) Metabolic and (B) TRAP activity of RAW264.7 over 28 days (n=6). 
Metabolic activity increased for the first three weeks as the RAW264.7 became 
confluent. TRAP activity was highest on day 7 and reduced at each successive time 
point, indicating no successive generations of osteoclasts were generated.  
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As the presence of the IDG-SW3 has been shown to affect osteoclast activity, this 
experiment was repeated but as a co-culture. They were also exposed to oestrogen and 
oestrogen withdrawal to determine any long term effects on osteoclast activity. IDG-
SW3 were seeded at 25,000 cells per well in a 48 well plate and cultured under 
standard conditions until day 7 when 5,000 RAW264.7 were added per well and 
maintained in SM supplemented with 50 ng/mL RANKL for 28 days. Groups were 
either exposed to 0 nM or 100 nM of 17β-estradiol at the point of RAW264.7 addition. 
Oestrogen was either maintained for the entire experiment or withdrawn on day 7 or 
14 (Fig. 6.12).  
 
Figure 6.12: Schematic showing the co-culture regimen for oestrogen exposure and 
staggered withdrawal in TCP co-culture. 
Oestrogen treatment has no significant effect on DNA at any time point (Fig. 6.13). 
DNA changes were due to changes in osteoclast number as IDG-SW3 were confluent 
and do not proliferate at 37°C. DNA was significantly lower on day 14 than day 7, 
indicating osteoclast death. Day 21 and 28 were higher than day 14, indicating 
proliferation of precursors.  
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Figure 6.13: (A) DNA (B) ALP activity (C) TRAP activity of IDG-SW3 and RAW264.7 
co-cultures over 28 days (n=3). 
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Oestrogen treatment had no significant effect on ALP or TRAP activity at any time 
point. ALP activity significantly reduced between day 7 and 14 and 14 and 21. This is 
likely due to overgrowth of the wells by RAW264.7. TRAP activity also steadily 
decreased, as it did in RAW264.7 monoculture. Comparison of the wells at day 7 and 
day 28 shows that these declines were due to overgrowth by RAW264.7 monocytes, 
establishing that generation of multiple waves of osteoclasts did not occur (Fig. 6.14).  
 
Figure 6.14: Photographs of RAW264.7 cultures on day (A) 7 and (B) 28. Mature 
osteoclasts (red arrows) only visible on day 7. By day 28, only precursors are present.  
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6.4.5 Density of osteoclast precursors affects mineral resorption 
Due to only a single wave of osteoclasts being generated, attempts to extend the 
duration of the co-culture were made by varying the precursor seeding number. Co-
cultures of IDG-SW3 and RAW264.7 were performed in 48 well plates as before; 
however, osteoblasts were maintained for 21 days in SM before adding either 2,500, 
5,000 or 10,000 RAW264.7 and maintained for a further 14 days in SM supplemented 
with 50 ng/mL RANKL with either 0 nM or 100 nM of 17β-estradiol. Osteoblasts 
were cultured for three weeks before osteoclast addition to allow sufficient 
mineralised matrix to be deposited so that effects on resorption could also be 
ascertained. DNA, ALP activity and TRAP activity were quantified 7, 10 and 14 days 
after osteoclast addition (Fig. 6.15). 
 
Figure 6.15: Schematic showing the TCP co-culture regimen with varied RAW264.7 
seeding number and oestrogen exposure.  
In each condition, there was no significant change in DNA at any time point 
(Fig. 6.16). As expected, co-cultures seeded with the most RAW264.7 had the highest 
DNA content. Oestrogen had no significant effect on the amount of DNA at the same 
seeding density, with the exception of 10K at day 14, where the oestrogen exposed 
group was significantly lower. 
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Figure 6.16: Effect of varied RAW264.7 seeding number and oestrogen on (A) DNA 
(B) ALP activity (C) TRAP activity over time in IDG-SW3 and RAW264.7 co-cultures 
(n=3). 
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ALP activity was higher when fewer RAW264.7 were present at each time point. The 
presence of oestrogen had no significant effect on ALP activity at any seeding density 
or time point. 
TRAP activity followed the same pattern as ALP activity, with the highest TRAP 
activities achieved when the fewest precursors were added. There was no difference 
in TRAP activity at the same seeding density when oestrogen was applied, with the 
exception of day 10. From this, day 10 co-cultures were repeated and mineral staining 
was performed to ascertain resorption (Fig. 6.17). As before, TRAP activity increased 
with decreased RAW264.7 seeding number. 100 nM oestrogen significantly reduced 
TRAP activity at each seeding density. TRAP activities were normalised to 10,000 
RAW264.7 at 0 nM oestrogen due to batch differences in the exogenous RANKL. 
Resorption was estimated by measuring the amount of mineral remaining at the end 
of the co-culture. The lowest number of precursors, which resulted in the highest 
TRAP activities, had the least remaining mineral at the end of the co-culture, 
indicating the highest amount of resorption had taken place. Oestrogen only inhibited 
resorption when 2,500 RAW264.7 were added. At the other seeding densities there 
were no significant differences.   
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Figure 6.17: Effect of varied RAW264.7 seeding number in TCP co-cultures and 
oestrogen on (A) TRAP activity (n=7) and (B) resorption by quantifying remaining 
mineral (n=5) (C) representative images of the ARS staining of each condition. Red 
dashed line is day 21 staining before osteoclast addition. 
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6.4.6 Oestrogen pre-treatment of RAW264.7 has lasting effects after seeding 
Due to the limited window where the co-culture has functioning mature osteoclasts, 
there is not sufficient time to expose RAW264.7 to oestrogen and then withdraw it to 
mimic menopause one the co-culture has been initiated. Therefore, the effect of 
exposing RAW264.7 to oestrogen prior to seeding was investigated. If they could be 
conditioned to oestrogen during passage, similar to how MC3T3-E1 have been pre-
conditioned, then oestrogen could be withdrawn at the start of the co-culture [308]. To 
investigate this, RAW264.7 were passaged for one week either in 0 nM or 100 nM of 
oestrogen. They were then seeded at 2,500 per well in a 48 well plate and maintained 
for a further 8 days in BM supplemented with 50 ng/mL RANKL and either 0 nM or 
100 nM oestrogen before measuring TRAP activity (Fig. 6.18). 
 
Figure 6.18: Schematic showing the oestrogen pre-treatment regimen for RAW264.7 
do determine whether it has lasting effects after withdrawal. Pre-treatment refers to 
RAW264.7 exposure to oestrogen during passage. After seeding refers to when the 
osteoclast precursors are added to the culture.  
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Cultures not exposed to oestrogen had the highest TRAP activity (Fig. 6.19). Cultures 
only exposed to oestrogen after seeding had significantly lower TRAP activity than 
unexposed cultures, as previously seen. RAW264.7 with an oestrogen pre-treatment 
but no oestrogen after seeding had significantly lower TRAP activity than cultures 
without an oestrogen pre-treatment and no oestrogen after seeding, demonstrating a 
lasting effect of the pre-treatment. There was no significant difference between 
maintained oestrogen after seeding and oestrogen withdrawal after seeding. 
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Figure 6.19: Effect of oestrogen pre-treatment on RAW264.7 TRAP activity. 
RAW264.7 were passaged in either 0 nM (0 nM Pre) or 100 nM (100 nM Pre) 
oestrogen for one week before seeding. After seeding, cultures were maintained in 
either 0 nM (red) or 100 nM (blue) oestrogen for 8 days. 0 nM / 0 nM significantly 
higher than all other groups (n=6) *=p<0.05. 
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6.4.7 Oestrogen withdrawal increases mineral resorption in monolayer co-
cultures 
The oestrogen pre-treatment regimen was then applied to the co-culture. RAW264.7 
were pre-treated with 100 nM 17β-estradiol during passage for one week prior to their 
addition to the co-culture. Oestrogen could the either be maintained (pre-menopause) 
or withdrawn (postmenopause) as well as being compared to groups that were never 
exposed or only exposed to oestrogen after the co-culture was initiated (Fig. 6.20). 
 
Figure 6.20: Schematic showing the various regimens of oestrogen treatment to be 
applied to the co-culture. Pre-treatment refers to RAW264.7 exposure to oestrogen 
during passage. After seeding refers to when the osteoclast precursors are added to 
the co-culture.  
IDG-SW3 were grown for 21 days in SM in 48 well plates before the addition of 5,000 
RAW264.7 that had either been exposed to 0 nM or 100 nM for one week during 
passage. Oestrogen levels were then either maintained or withdrawn, and the co-
culture maintained for a further ten days in SM supplemented with 50 ng/mL RANKL 
(Fig. 6.21). 
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After ten days of co-culture multinucleated cell were visible (Fig. 6.22). By comparing 
the co-culture images to Hoechst 33342-stained RAW264.7 cultured with 50 ng/mL 
RANKL for 12 days, it can be seen that the brighter, round organelles in the brightfield 
co-culture images are nuclei; therefore, these cells are assumed to be osteoclasts. No 
oestrogen treatment had a significant effect on DNA, ALP activity or TRAP activity 
after ten days of co-culture. However, the remaining mineral in the “pre-menopause” 
(100 nM pre-treatment, 100 nM during co-culture) was significantly higher than the 
“postmenopause” group (100 nM pre-treatment, 0 nM during co-culture) and the 
unexposed group (0 nM pre-treatment and during co-culture). This may indicate that 
withdrawing oestrogen significantly upregulated resorption but not TRAP activity. 
However, it should be noted that all mineral levels were higher than the baseline level 
determined for IDG-SW3 after 21 days of culture in SM. Therefore, rather than 
increased resorption causing the difference between the maintained withdrawn groups, 
it may have been due to increased deposition in the maintained group.  
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Figure 6.21: Effect of oestrogen pre-treatment and withdrawal on (A) DNA (n=3). (B) 
ALP activity (n=3) (C) TRAP activity (n=6) (D) remaining mineral (n=6). Purple 
dashed lined is day 21 baseline staining (E) representative images of ARS staining. 
100/100 significantly higher than 100/0 and 0/0. 
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Figure: 6.22: Pictures of multinucleated cells on day 10 of co-culture. (Left) 
Multinucleated cells presumed to be osteoclasts (red arrows) clearly visible above 
IDG-SW3 monolayer. In C two osteoclasts border a mineral deposit (green). 20× 
magnification. (Right) Day 12 RAW264.7 cultured with RANKL and stained with 
Hoechst 33342 to show nuclei for cell morphology comparison. From this, the 
brighter, round organelles in the brightfield co-culture images are assumed to be 
nuclei.  
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6.4.8 Mineral staining fails to detect changes in resorption following oestrogen 
withdrawal in 3D 
This protocol was then repeated in 3D on the polyurethane scaffold. 60,000 IDG-SW3 
were seeded onto 5 × 5 mm polyurethane scaffolds and cultured for 3 days at 33 °C in 
EM. Media was then exchanged for SM and the scaffolds maintained for a further 21 
days at 37 °C. As the difference in surface area between the scaffold and well plate 
was not known, either 2,500, 5,000 or 25,000 RAW264.7 that had either been exposed 
to 0 nM or 100 nM for one week during passage were then added to the scaffold. 
Oestrogen levels were either maintained or withdrawn, and the co-culture maintained 
for a further ten days in SM supplemented with 50 ng/mL RANKL (Fig. 6.23). 
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Figure 6.23: Effect of oestrogen pre-treatment and withdrawal on mineral resorption 
in 3D co-cultures. Either 2,500, 5,000, or 25,000 RAW264.7 added at start of co-
culture. Red dashed line is day 21 staining before osteoclast addition. No significant 
difference between withdrawn and maintained oestrogen at any seeding density. 
Significantly less mineral in co-cultures seeded with 25,000 RAW264.7 in comparison 
to the other two conditions (n=6).  
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By day 4, monocytes and multinucleated cells were visible on the extracellular matrix 
deposited onto the scaffolds by optical microscopy (Fig. 6.24). On day 10, this was 
also visible on H&E stained histological sections of the co-culture (Fig. 6.25). During 
sectioning the polyurethane scaffold appeared to pull apart and deposited matrix 
separated from the scaffold struts. Despite this, the extensive extracellular matrix was 
still clearly visible (light purple) around the polyurethane sections (light pink). 
RAW264.7 monocytes and multinucleated cells appear as dark purple and are present 
on the matrix. 
With regards to remaining mineral after ten days of co-culture, there were no 
significant differences between maintained and withdrawn oestrogen at any seeding 
density. However, there is significantly less mineral remaining in the 25,000 seeding 
density in comparison to the other two densities indicating the most resorption took 
place. 
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Figure 6.24: Representative optical microscope pictures of the 3D co-culture. Both 
mononuclear (blue) and multinucleated (white) cells are visible on the extracellular 
matrix deposited by the IDG-SW3 by day 4 of co-culture. 
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Figure 6.25: Optical microscope images of day 10 3D co-culture sections stained with 
H&E. (A&B) 4× magnification showing how matrix is pulled from the scaffold during 
sectioning (scale bar 1 mm) (C&D) 10× magnification RAW264.7 clearly visible on 
extracellular matrix deposited by IDG-SW3 (scale bar 400 µm) (E-H) 40× 
magnification RAW264.7 (dark purple / blue arrows) on IDG-SW3 matrix 
(light purple / red arrows) and polyurethane scaffold struts (light pink / white arrows) 
(scale bar 100 µm). 
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6.5 Discussion 
The work in this chapter applied the findings of the previous two in an attempt to 
develop an in vitro model of postmenopausal osteoporosis. Initially, the effects of 
PTH, a common treatment for osteoporosis, were examined on IDG-SW3 and 
RAW264.7 to determine whether an anabolic effect analogous to that observed in vivo 
could be replicated. Next, markers for osteoblast and osteoclast function in co-culture 
were determined before evaluating the effect of oestrogen exposure in TCP and 3D 
co-cultures. The effect of osteoclast seeding density on co-culture duration and 
mineral content were then evaluated to finalise co-culture parameters. Co-cultures 
were then subjected to oestrogen withdrawal to mimic postmenopausal osteoporosis 
in TCP and 3D.  
PTH is a common therapeutic for osteoporosis due to its dual action as a promotor of 
bone formation and an inhibitor of bone resorption and acts both directly and indirectly 
on cells within bone. Its direct action on cells is initiated by the stimulation of the 
receptor PTH1R. This receptor is predominantly found on osteoblastic lineage cells as 
well as tubular cells in the kidney, although there is some evidence that it may also be 
present on osteoclasts [465], [466]. However, whether PTH has an anabolic or 
catabolic effect on bone depends on the frequency, concentration and duration of its 
administration (Fig. 6.26). 
 
Figure 6.26: PTH can have anabolic or catabolic effects on bone depending on 
application modality. 
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Continuous exposure is associated with bone loss due to a downregulation of the 
expression and synthesis of extracellular matrix proteins and an increase in the 
RANKL:OPG ratio [226]; whereas intermittent exposure can promote osteoblast 
differentiation, inhibit their apoptosis and suppress sclerostin synthesis by osteocytes 
[192], [225], [226]. In the context of this in vitro model of osteoporosis, the aim was 
to find a PTH treatment regimen that would promote IDG-SW3 mineralisation and 
reduce RAW264.7 resorption. As previously demonstrated, IDG-SW3 do not produce 
a detectable quantity of RANKL. Therefore, any anabolic or catabolic response will 
be the result of a direct change to IDG-SW3 mineralisation capacity, rather than an 
indirect change on RAW264.7 osteoclastogenesis via modulation of the RANKL:OPG 
ratio as RAW264.7 were found to not respond to direct PTH stimulation. 
Initial experiments indicated that a PTH concentration of 1 nM applied intermittently 
for 1 or 24 hours may elicit an anabolic response, as indicated by an increased ALP 
activity. The powerful catabolic effect of continuous PTH exposure was apparent even 
at low concentrations, with a significant reduction in ALP activity. PTH 
predominantly reduced the ALP activity by reducing expression of these osteoblastic 
proteins rather than by reducing total cell number, as indicated by minimal differences 
in total DNA. As IDG-SW3 are an osteoblast-osteocyte cell model, the promotion of 
osteoblastic differentiation cannot be observed as they have already differentiated past 
this phenotype. However, as a sub-population of IDG-SW3 will terminally 
differentiate into osteocytes, it was hypothesised that its effect on sclerostin inhibition 
and role as an anti-apoptotic would promote mineralisation over longer time periods.  
To investigate this, concentrations between 1 and 20 nM were applied intermittently, 
either once or twice per week, for 24 hours over a three-week period. Interestingly, 
the highest GFP expression after 21 days was found in the 0 nM group, indicating that 
PTH exposure inhibited osteocytogenesis and maintained IDG-SW3 in their 
osteoblastic phenotype. However, despite this, there was no significant increase in 
ALP activity in treated groups and mineralisation visibly decreased as PTH 
concentration increased.  However, in comparison to previous experiments performed 
with the same cells over the same duration, mineralisation was visibly less at the same 
time point, even in the 0 nM group. Although this could have been due to the vehicle, 
it is very unlikely that a small volume of PBS and BSA would have inhibited 
mineralisation to this degree, with it being more likely due to variability in cell 
behaviour, as discussed later in this chapter. As no PTH treatment regimen where an 
anabolic response analogous to that observed when it is administered as an 
284 
 
osteoporosis therapeutic could be found, no PTH treatment was applied to the in vitro 
model developed.  
Work on optimising the co-culture was then performed. Only direct co-cultures were 
considered for this thesis, as opposed to well plate inserts that separate the osteoblasts 
and osteoclasts. This was due to osteoblastic cells being able to produce both 
membrane-bound and soluble isoforms of the cytokines that affect osteoclasts, 
meaning that indirect co-cultures would preclude membrane-bound cytokines from 
having an effect. In the literature, groups have co-seeded osteoblasts and osteoclast 
precursors simultaneously [171], [252], added the precursors 24 hours after seeding 
the osteoblasts [164], or waited multiple weeks before their addition [241], [249], 
[250]. In §4.4.13, RAW264.7 were added to IDG-SW3 24 hours after seeding and 
TRAP activity was detectable after seven days, albeit at a lower level than a 
RAW264.7 monoculture. However, in this experiment, only 1,500 IDG-SW3 were 
seeded in a 12 well plate in accordance with the work by Zhao, et al., when co-
culturing osteocytes and osteoclast precursors [211]. As the RAW264.7 were added 
24 hours later this low seeding density means that the IDG-SW3 had not reached 
confluence, and as they had now been switched to SM and 37 °C, their ability to 
proliferate further was diminished.  
In an attempt to alleviate this, 60,000 IDG-SW3 were seeded and maintained overnight 
in EM at 33 °C before the addition of RAW264.7 the following day. Despite this, 
seven days later, there was no detectable ALP or TRAP activity in the co-culture. 
Again, it was observed that despite the higher seeding density, the IDG-SW3 did not 
become confluent in co-culture. In mono-cultures of each cell type the appropriate 
marker was identifiable and the total DNA in the co-culture confirmed that both cell 
types were present. Therefore, it appears that the activity of both cell types was 
inhibited in co-culture.  
This inhibition could be due to the IDG-SW3 being unable to achieve confluence due 
to the addition of the RAW264.7, and therefore not expressing a detectable level of 
ALP. Although osteoblasts do produce some ALP whilst proliferating, its expression 
is raised significantly once they are confluent [467], [468]. Therefore, with IDG-SW3 
unable to become confluent, their ALP activity and mineralisation was undetectable. 
Alternatively, the higher metabolic activity of the osteoclastic cell line may have 
resulted in too few nutrients remaining in the culture media to support their function. 
The absence of TRAP activity in the co-culture implies that the RAW264.7 were 
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unable to fuse and generate osteoclasts. As they were seeded onto a non-confluent cell 
layer, the precursors may have been unable to successfully migrate and fuse with each 
other due to the IDG-SW3 outnumbering them 3:1. Alternatively, in the co-culture, 
experiment cells were seeded onto gelatine coated wells, whereas typical RAW264.7 
mono-cultures are seeded directly onto the well plate. Gelatine is used as a well plate 
coating to improve cell attachment; as RAW264.7 is a motile cell line the presence of 
gelatine could be inhibiting their ability to migrate and find precursors to fuse with. 
As gelatine is denatured collagen, the major protein in bone, this seems unlikely. 
However, the denaturing process may affect how well osteoclasts can adhere to 
gelatine in comparison to collagen in vivo by denaturing adhesion proteins on the 
surface. Furthermore, collagen in native bone tissue is mineralised and consequently 
would not have the same surface chemistry as a gelatine tissue culture coating.  
Therefore, it is likely that cell motility would be affected by the concentration of the 
well plate coating.  
Both of these difficulties can be overcome by adding RAW264.7 to a confluent 
monolayer of IDG-SW3. Here, the osteoblasts are confluent and therefore should 
express ALP and mineralise, and the osteoclasts are on the same plane and are not 
attached to a highly adhesive substrate, meaning that they should be able to migrate 
and fuse. To test this, IDG-SW3 were again seeded at 60,000 cells per well, but were 
now maintained for three days in EM at 33 °C to until confluent. They were then 
transferred to SM and 37 °C and 10,000 RAW264.7 added before maintaining for ten 
days. Again, total DNA confirmed that both cell types were present in the co-culture. 
However, by adding the RAW264.7 once the IDG-SW3 had become confluent, both 
ALP and TRAP activity were detectable in the co-culture. Importantly, ARS staining 
of the co-culture revealed that the osteoblasts were still able to mineralise.  
Interestingly, ALP activity was lower in the co-culture than in an IDG-SW3 
monoculture, and TRAP activity was higher in the co-culture than a RAW264.7 
monoculture. The lower ALP activity suggests that the presence of a secondary cell 
type is inhibiting the function of the osteoblasts. This is most likely due to the effective 
nutrient availability in the media being lower as another cell type is now also 
metabolising them. Additionally, in co-culture, only 50% of the media is exchanged 
during media changes in order to retain factors such as M-CSF produced by the 
RAW264.7. Therefore, as well as nutrient depletion being enhanced, the accumulation 
of potentially toxic metabolites that can reduce cell function is likely to be greater in 
the co-culture as more cells are present [469].  
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Despite this, the TRAP activity is significantly increased in the co-culture. Without 
knowledge of the findings of the previous chapters, the assumed reason for this 
increase would be that the osteoblasts are producing RANKL, thereby stimulating 
osteoclastogenesis. However, we have seen that co-cultures without exogenous 
RANKL cannot stimulate osteoclast formation (Fig. 4.19) and ELISAs have shown 
that IDG-SW3 in mono-culture are not producing RANKL, only OPG. Therefore, 
rather than increasing the ratio, co-culture should be decreasing it in comparison to 
monoculture as there is a constant amount of RANKL in the medium, and OPG is only 
produced by the osteoblasts.  
One potential reason for the increase in TRAP activity would be that when IDG-SW3 
are co-cultured with RAW264.7 for longer time periods, they are stimulated to 
produce RANKL, contrasting their behaviour in mono-culture. However, the 
upregulation of RANKL production is normally associated with vitamin D or PTH 
exposure and neither of these factors are synthesised by osteoclasts.  Despite this, it 
would be interesting to repeat the co-cultures where osteoclasts were added at later 
timepoints without exogenous RANKL addition to determine whether there is any 
osteoclastic stimulation of osteoblasts.  
It is more likely that this stimulation of osteoclastogenesis observed in co-culture is 
due to some other factor being at play. M-CSF is another cytokine produced by 
osteoblasts that has a role in osteoclastogenesis by promoting the survival and 
proliferation of osteoclast precursors [48]. In addition to this, Hodge, et al., showed 
that in vitro, it can cause human osteoclast precursors to fuse, form osteoclasts, and 
become resorptive in a dose dependent manner. They also found that it can modulate 
the resorptive capability of mature osteoclasts [47]. Although RAW264.7 produce 
their own M-CSF, a dose-dependent response to the cytokine could explain the further 
stimulation of the cells by co-culturing with IDG-SW3 if they were also producing the 
factor [166], [167]. Unfortunately, to date there do not appear to have been any studies 
discerning whether IDG-SW3 produce M-CSF.  
Interleukin-1 (IL-1) is another factor that has been associated with stimulation of 
osteoclastogenesis. Kim, et al., found that it works in synergy with RANKL to induce 
osteoclast differentiation as RANKL stimulation upregulates the expression of IL-1 
receptor (IL-1R) in bone marrow-derived osteoclast precursors. Before stimulation 
with RANKL, IL-1R expression is low in this type of precursor, but when it is raised 
by an alternative mechanism (c-fos stimulation by M-CSF), IL-1 is able to induce 
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osteoclastogenesis in the absence of RANKL [470]. RAW264.7 have been shown to 
express IL-1R, and therefore could respond to this stimuli [471]. IL-1 can be produced 
by osteoblasts as part of the inflammatory response [472], [473]; a response that could 
have been stimulated in IDG-SW3 by the addition of RAW264.7. This negative 
reaction of IDG-SW3 is also a potential reason for the reduction in ALP activity 
observed in co-culture. Alternatively, IL-1 or other inflammatory markers may have 
been present in the FBS used.  
As a suitable co-culture protocol that allowed detectable levels of the three markers to 
be measured had been developed, co-cultures were next exposed to oestrogen to 
determine whether similar effects to those seen in mono-cultures would be observed 
in co-cultures. In addition to TCP co-cultures, 3D co-cultures in PU scaffolds were 
also performed. Total DNA quantification revealed that both cell types were present 
and that the presence of oestrogen had no effect on cell number. ALP activity was 
detectable in both TCP and 3D co-cultures, and although not significant, was higher 
in oestrogen exposed cultures. As it was not possible to normalise activities to DNA 
in the co-culture, it was not possible to determine whether this change was due to 
differences in cell number or a cell-level response to the hormone. Interestingly, the 
inhibitory response to oestrogen seen in mono-cultures was not observed in co-culture, 
indicating that the stimulation of osteoclastogenesis by the IDG-SW3 was greater than 
its inhibition by 17β-estradiol.  
To this point, osteoclast cultures had only been maintained over a ten day period. To 
determine whether the effects seen would continue over longer durations, the changes 
in activity over a 28 day period were assessed. Although the metabolic activity of 
RAW264.7 continues to increase over a 4 week period, the TRAP activity decreases 
each week, indicating fewer mature osteoclasts are present. Not all RAW264.7 fuse 
and become mature osteoclasts when exposed to RANKL. Therefore, it was expected 
that when the first generation of mature osteoclasts undergo apoptosis, they would be 
replaced by subsequent generations formed from the remaining precursors. However, 
this was not the case, with only an initial generation of osteoclasts being formed. This 
was due to overgrowth of the culture by the osteoclast precursors. RAW264.7 have a 
doubling time of approximately 11 hours. This rapid multiplication means that 
although mature osteoclasts formed initially undergo apoptosis within two weeks, by 
this stage the density of the precursors is exceptionally high, limiting their ability to 
fuse and become mature osteoclasts (Fig. 6.27).  
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Figure 6.27: Schematic showing the expected and actual ability of RAW264.7 to form 
multiple generations of mature osteoclasts. 
Akchurin, et al., attempted to computationally model the likelihood that RAW264.7 
would form multiple generations of mature osteoclasts. They found via in vitro 
experimentation that in 46 long term (15-26 days) RAW264.7 cultures with varied 
plating densities and RANKL concentrations, only 59% were observed to generate 
multiple waves of osteoclasts, and that multiple waves of osteoclasts were more likely 
to occur with very high RANKL concentrations (100 ng/mL) [474]. This agrees with 
what was observed here, where in monoculture and co-culture only  25 - 50 ng/mL of 
RANKL was applied and only a single wave was observed. Although the higher 
concentration of RANKL was used in co-culture, increasing the likelihood of multiple 
wave formation occurring, the presence of OPG will have reduced the RANKL:OPG 
ratio, negating the increased probability of subsequent osteoclast waves.   
We have seen that seeding with a lower density of RAW264.7 delays the peak TRAP 
activity and permits a greater number of osteoclasts to be formed. Therefore, with the 
aim of extending the maximum duration of the co-culture, the effects of reducing the 
seeding density of RAW264.7 in co-culture was investigated. As expected, the highest 
total DNA was detected in co-cultures where the greatest number (10,000) of 
RAW264.7 were added. However, there was no significant difference in total DNA 
when the middle (5,000) and lowest (2,500) seeding number are compared. This 
indicates that at the lower seeding density less proliferation occurs, possibly indicating 
that a larger proportion of precursors had fused. ALP activities have been shown to be 
lower in co-culture than in monoculture at the same time point. The highest ALP 
activities are seen in the co-cultures where the fewest RAW264.7 were added at all 
time points. This indicates a ‘dose-response’ to the presence of the osteoclast 
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precursors, where as their number increases, the IDG-SW3 ALP activity decreases. 
The TRAP activity correlates with the ALP activity with regards to RAW264.7 
seeding density; the fewer added the higher the TRAP activity at all time points. This 
again shows that the maturation of RAW264.7 is space-dependent, and that the 
efficacy of mature osteoclast generation increases when they are seeded more sparsely.  
Interestingly, at day 10, the presence of oestrogen was observed to significantly inhibit 
the TRAP activity of the co-culture at all seeding densities. However, there was no 
significant difference in the amount of resorption that occurred, as the quantity of 
mineral remaining in comparison to the day 21 baseline was the same for treated and 
untreated cultures despite the difference in TRAP activity. The exception to this is 
when 2,500 RAW264.7 were added, as the remaining mineral in the oestrogen exposed 
group is significantly higher than in the untreated group. Therefore, at this seeding 
density, we observe the protective role of oestrogen on bone that is seen in vivo, where 
the presence of the hormone reduces bone catabolism.  
However, this protection of the mineral by oestrogen is only observed when directly 
staining the extracellular matrix, as there is no reduction in TRAP activity despite less 
resorption occurring. Therefore, we see that TRAP activity only appears to correlate 
with mineral content in vitro in the absence of oestrogen (Fig. 6.22). When cultures 
were not exposed to oestrogen, TRAP activity and remaining mineral have a strong 
negative correlation (R2 = 0.9236), whereas exposure to 100 nM oestrogen results in 
no correlation (R2 = 0.5189) due to oestrogen preventing resorption at the 2,500 
seeding density.  
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Figure 6.22: XY plot of mean±SD of TRAP activity vs. ARS staining for co-cultures 
exposed to 0 nM or 100 nM oestrogen. Correlation only without oestrogen. R2 
calculated using linear regression. 
The strong correlation of serum TRAP concentration with bone resorption seen in vivo 
is the result of TRAP accumulation in the blood as it is secreted by the osteoclasts 
along with the organic catabolites of bone resorption [350]. When TRAP was 
measured here in vitro, it was after the removal of the media. Therefore, rather than 
measuring the equivalent of the accumulation of serum TRAP in vivo, the activity of 
intracellular TRAP and TRAP within the extracellular matrix is being quantified. This 
TRAP measurement gives an indication of the current activity of the osteoclasts, rather 
than an indication of how resorptive they have been previously. As TRAP has an 
indirect role in bone resorption, for example by enabling osteoclast migration by 
disrupting osteopontin rather than directly resorbing the bone surface [349], the lack 
of correlation seen here could be due to not measuring the same type of TRAP that is 
quantified in vivo (intracellular vs. serum/secreted). 
Alternatively, the lack of detectable difference in mineral resorption despite the 
different TRAP activities could be due to low assay sensitivity when staining for 
mineral. With regards to the 10,000 and 5,000 seeding density, the day 10 TRAP 
activities were significantly lower in the presence of oestrogen. As oestrogen affects 
osteoclast formation and survival, this is presumably due to fewer active osteoclasts 
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being present. Despite this, there is no difference in the remaining mineral at this time 
point. We have seen that these higher seeding densities generate fewer mature 
osteoclasts; therefore, minimal resorption will occur even without oestrogen, so a 
small decrease in osteoclast number due to oestrogen does not have a large enough 
effect on mineral resorption to allow this difference to be detected by calcium staining. 
This effect is further compounded by the small culture surface area of a 48 well plate. 
For example, consider two culture surfaces, one with an area ten times greater than the 
other. Both have the same amount of mineral and active osteoclasts per cm2, and after 
ten days the osteoclasts have resorbed 10% of the mineral in both cultures. Although 
the same percentage has been resorbed, the amount resorbed is ten times greater in the 
larger surface area culture, meaning that a low sensitivity assay is more likely to detect 
the change.  
At the lowest seeding density (2,500 RAW264.7) we see the highest TRAP activities 
as more osteoclasts are able to form. Their TRAP activity is still significantly reduced 
by oestrogen, but in contrast to the higher seeding densities, we see that less mineral 
is resorbed in the presence of 17β-estradiol. This may be because having more active 
osteoclasts overcomes the low sensitivity of using ARS staining as a protocol for 
quantifying mineral resorption. If we assume oestrogen reduces osteoclast number by 
𝑥 %, having more osteoclasts initially means that a larger number undergo apoptosis 
in comparison to when fewer are present, and therefore there will be a larger difference 
in mineral resorption which is more likely to be detected by a low sensitivity assay. 
This hypothesis agrees with the results seen here, as although we see oestrogen having 
a protective role when 2,500 RAW264.7 are added, the remaining mineral with 
oestrogen in this culture is still less than cultures with fewer mature osteoclasts 
initially, for example those with 10,000 RAW264.7. This is because whilst a large 
amount have been stimulated to undergo apoptosis by oestrogen, there are still more 
remaining than in cultures where the conditions were not amenable to effective 
osteoclastogenesis in the first place. 
In the context of postmenopausal osteoporosis, co-culturing osteoblasts and 
osteoclasts in the presence of oestrogen is the equivalent of the pre-menopause 
‘healthy’ condition when oestrogen levels are still high. Thus far, we have seen that 
under certain culture durations and seeding densities, it is possible to have a system 
analogous to this, with oestrogen protecting the deposited mineral in comparison to 
cultures without oestrogen. However, cultures never exposed to oestrogen do not 
replicate the postmenopause condition, as their elevated resorption levels are not in 
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response to a decline in oestrogen. Therefore, for an in vitro model of postmenopausal 
osteoporosis, it is important that the cells are initially conditioned to oestrogen before 
removing it. This should then result in increased mineral resorption.  
Initially it was intended that cells would be exposed to oestrogen whilst in the co-
culture.  However, as the maximum duration of the co-culture where there are still 
osteoclasts present is approximately two weeks, this is not feasible, as demonstrated 
in figure 6.9. Therefore, it was decided to attempt to condition the RAW264.7 to 
oestrogen prior to seeding whilst they are in passage. Oestrogen levels could then 
either be maintained or reduced to 0 nM at the point of seeding, replicating the decline 
in oestrogen seen postmenopause. Conditioning oestrogen during passage prior to 
seeding has previously been shown to be effective by Brennan, et al., who utilised this 
approach to simulate pre-menopause whilst examining the effects of oestrogen 
withdrawal on MC3T3-E1 [308]. Due to the findings of chapter four, where oestrogen 
had no stimulatory or inhibitory effects on IDG-SW3 proliferation, ALP activity or 
mineralisation, only pre-treatment of RAW264.7 during passage was considered for 
these experiments. However, as in vivo both cell types are ‘conditioned’ to oestrogen 
prior to menopause, any further developments of a post-menopausal osteoporosis 
model should consider this, as it may be affecting markers that were not examined in 
this study.  
This approach to pre-conditioning RAW264.7 with oestrogen prior to their addition to 
the co-culture is a better representation of what occurs in vivo, in comparison to 
application and withdrawal of oestrogen after seeding, as it is osteoclast precursors 
circulating in the bloodstream that are conditioned to serum oestrogen levels pre-
menopause, rather than mature, active osteoclasts. Osteoclast precursors have the 
potential to be conditioned by exposure to oestrogen during passage due to its effects 
on the downstream signalling of RANK. When RANKL binds with RANK, tumour 
necrosis factor receptor-associated factor 6 (TRAF6) is recruited which in turn 
activates multiple major downstream signalling pathways that affect the proliferation, 
differentiation, function and survival of osteoclasts [475]–[477]. The Jun N-terminal 
kinase (JNK) signalling pathway is one of these, and is responsible for osteoclast 
precursor differentiation (Fig. 6.28). When stimulated it increases the production of 
the osteoclastogenic transcription factors c-Fos and c-Jun [478], [479]. This results in 
the stimulation of nuclear factor-activated T cells c1 (NFATc1), a master transcription 
factor involved in the terminal differentiation of osteoclasts that regulates osteoclast 
specific genes for TRAP, cathepsin K and OSCAR [480], [481].  
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Figure 6.28: A diagram illustrating the role of the JNK pathway on osteoclast 
precursor differentiation.  
Monocytes, the osteoclast precursors in the blood stream, express ERα. Its stimulation 
by oestrogen has the ability to disrupt the JNK signalling pathway, reducing their 
ability to undergo osteoclastogenesis [479]. This effect on the JNK signalling pathway 
is also observed in RAW264.7, and in combination with increasing apoptosis, is a key 
mechanism by which oestrogen reduces osteoclast activity [309]. 
The different oestrogen treatment regimens applied to RAW264.7 and co-cultures are 
given in table 6.1. Pre-treatment of RAW264.7 during passage was found to have 
lasting effects on their ability to undergo osteoclastogenesis In RAW264.7 
monocultures, withdrawn oestrogen was as effective at reducing TRAP activity as 
oestrogen exposure only after seeding. In TCP co-culture, a similar but not identical 
response is seen. Again, pre-treatment of RAW264.7 for one week with oestrogen 
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seems to have had a lasting effect on their ability to become resorptive osteoclasts. 
However, RAW264.7 with maintained oestrogen had significantly more mineral after 
ten days than those which had withdrawn oestrogen. This demonstrates that the 
withdrawal of oestrogen at the start of the co-culture to imitate the cessation of ovarian 
function results in increased resorption in comparison to maintained oestrogen. This 
is despite no significant difference in TRAP activity between the two groups, as was 
observed in RAW264.7 monocultures, again indicating a lack of correlation between 
TRAP activity and resorption in vitro.  
Intriguingly, there is no significant difference with regards to mineral content in 
unexposed co-cultures and withdrawn co-cultures. Furthermore, there is no significant 
difference in mineral between co-cultures only exposed to oestrogen after seeding and 
those in maintained oestrogen. This would appear to indicate that the effect of 
oestrogen during passage is reversible and without constant stimulation by oestrogen 
its effect on the RAW264.7 diminishes. This contrasts with the effect observed in 
RAW264.7 monoculture, where oestrogen withdrawal alone was sufficient to have 
lasting effects on osteoclastogenesis. This difference possibly arises from the extra 
stimulus of osteoclastogenesis provided by the presence of IDG-SW3 in co-culture. 
Their upregulation of osteoclast precursor differentiation could be counteracting the 
inhibition by oestrogen pre-treatment, meaning that without sustained oestrogen after 
seeding, it is no longer having a lasting effect on their ability to differentiate. 
Oestrogen exposure only after seeding the co-culture reduces resorption, but not as 
effectively as maintained oestrogen after pre-treatment. This is likely because when 
ERα is stimulated in precursors during passage, the downstream signalling of RANK 
is already suppressed when RANKL is applied at the start of co-culture. This 
suppression is maintained by continued stimulation of ERα in addition to oestrogen 
upregulating apoptosis. However, when ERα is only stimulated at the start of co-
culture, the point when RANKL is also applied, the initial effects of RANKL are 
greater as the JNK pathway is not already inhibited, resulting in RANKL more 
effectively stimulating osteoclastogenesis.  
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Table 6.1: A summary of the different oestrogen treatments applied to RAW264.7 
monocultures and co-cultures of RAW264.7 and IDG-SW3. 
Oestrogen Regimen Pre-Treatment After Seeding 
Unexposed 0 nM 0 nM 
Exposure after seeding 0 nM 100 nM 
Withdrawn 100 nM 0 nM 
Maintained 100 nM 100 nM 
In the TCP co-culture where oestrogen withdrawal was investigated, mineral content 
after ten days of co-culture was higher than the day 21 baseline level. In all other co-
cultures, the addition of RAW264.7 resulted in a reduction in mineral content, 
assumed to be the result of increased osteoclastic resorption. Therefore, having a 
higher mineral content after co-culture may seem to imply that rather enhancing 
mineral resorption by osteoclasts, the addition of RAW264.7 has stimulated matrix 
deposition by IDG-SW3. Although this is possible as osteoclasts can have an anabolic 
effect on osteoblasts, for example through the action of bone morphogenetic proteins 
[235]–[237], it is more likely that in these experiments IDG-SW3 mineralised more 
than normal prior to osteoclast addition. This increased mineral deposition is assumed 
to be the result of an increased cell number. Although care was taken to keep seeding 
density constant, differences in passage number, time between reanimation from liquid 
nitrogen and seeding, and how confluent the passage flask was before detaching to 
seed are all factors that will influence cell growth. As IDG-SW3 can only proliferate 
during their first three days of culture at 33 °C in EM, any difference in their 
proliferation rate at the point of seeding will have lasting effects on cell number 
throughout the experiment. Cells visually appeared confluent before switching to the 
differentiation medium; however, this is a subjective measure and it difficult to discern 
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accurately the level of confluence when cells are densely packed. This was noted when 
IDG-SW3 were maintained for 28 days at 33 °C in EM in chapter 4 rather than 
switching to the differentiation conditions; although total DNA indicates there was 
four times more DNA by day 7, this was not obvious from optical microscopy.  
This lasting effect of initial cell number on mineralisation was also observed by 
Wittkowske, who found that despite seeding at the same density, day 21 mineralisation 
of IDG-SW3 varied by up to 37% between repeats [322]. Furthermore, in some 
instances, they failed to mineralise at all, as seen here in experiments assessing the 
effects of PTH on IDG-SW3. To overcome this issue in the future, experiments could 
be seeded at a much higher density so that wells are confluent immediately [283]; 
however, this approach would require a much larger number of cells to be prepared 
for each experiment. 
The protective role of oestrogen on the deposited mineral observed in monolayer co-
culture was not seen when performed in the polyurethane scaffold at any seeding 
density evaluated. A range of seeding densities were attempted due to the difficulties 
with approximating the surface area of the scaffold, a problem that is compounded 
with the deposition of extensive mineralised matrix. Out of the three seeding densities 
tested, the addition of 25,000 RAW264.7 resulted in the most resorption in comparison 
to day 21 baseline levels. However, there was no detectable difference between the 
co-cultures maintained in oestrogen and that which had oestrogen withdrawn at the 
start of co-culture. As was observed in the TCP co-culture, this is most likely due to a 
combination of low assay sensitivity and a suboptimal seeding density. Therefore, 
with larger scaffolds and a wider range of seeding densities tested, it is likely that we 
would see a response to oestrogen withdrawal. Another issue that arises in the 3D co-
culture is the removal of resorption waste products. In the TCP co-culture, metabolites 
are removed from the culture during media changes and the washing steps before 
staining. In the scaffold co-culture, mineral-containing products from resorbed matrix 
secreted by the osteoclasts are likely to be retained in the extensive extracellular matrix 
still present in the scaffold. These will also stain positive for ARS even if they are not 
within the matrix giving artificially high results and making differences in the amount 
of resorption harder to detect.  
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6.6 Summary 
• From the conditions tested, PTH was not found to have catabolic effects on 
IDG-SW3 mineralisation. 
• ALP, TRAP and mineralisation are suitable markers for osteoblast and 
osteoclast activity in the co-culture due to their cell type specificity. 
• In co-culture, mineralisation, ALP activity and TRAP activity are only 
detectable when RAW264.7 are added to confluent IDG-SW3. 
• IDG-SW3 increase TRAP activity in RAW264.7 in comparison to osteoclast 
monocultures due to production of an unknown factor, possibly M-CSF. 
• RAW264.7 decrease ALP activity in IDG-SW3 in comparison to osteoblast 
monocultures, most likely due to increased competition for nutrients and a 
higher concentration of metabolites. 
• TRAP activity is significantly reduced by the presence of oestrogen in 
RAW264.7 monocultures but not in TCP and 3D co-cultures initiated at day 7, 
demonstrating the upregulation of osteoclast activity by IDG-SW3 can 
overcome the inhibition by oestrogen.  
• The maximum culture duration of the co-culture is 14 days as longer time 
periods result in overgrowth by osteoclast precursors. 
• Seeding density when adding RAW264.7 to IDG-SW3 has a significant effect 
on co-culture activity, with 2,500 RAW264.7 resulting in the highest ALP and 
TRAP activities and greatest mineral resorption. 
• Of the seeding densities investigated, the protective effect of oestrogen on total 
mineral is only seen when 2,500 RAW264.7 are added to IDG-SW3 after 21 
days of pre-culture and 100 nM of oestrogen is applied. 
• Treatment with oestrogen during passage before seeding has lasting effects on 
RAW264.7 TRAP activity after seeding. 
• Withdrawal of oestrogen at the point of seeding to mimic the onset of 
menopause reduces final mineral content in comparison to sustained oestrogen 
in TCP co-cultures, likely due to stimulation of resorption by RAW264.7. 
• Oestrogen withdrawal in 3D co-cultures did not have the same stimulatory 
effect on mineral resorption as it did in TCP co-cultures, possibly due to non-
optimised seeding density and assay sensitivity. 
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7. General discussion and future work 
Postmenopausal osteoporosis is an increasingly prevalent disorder that has major 
implications for society. These range from the financial costs of treatments to the 
burden of care on those who look after patients with fractures. There are ethical 
concerns about the reliance on animal testing to understand the disease further and 
develop new treatments. The poor translation of pre-clinical efficacy in animal models 
to human trials means that there is a need for an alternative method of screening and 
evaluating potential new therapeutics that have a lower financial and ethical costs as 
well as increased relevance to human physiology [159]–[162]. In vitro models of 
disease are one such alternative, and have the potential to replicate or even improve 
some aspects of preclinical testing currently done in animals. To date, there has been 
work developing in vitro mimics of healthy bone remodelling, but to the author’s 
knowledge, no research has been performed that aimed to develop an in vitro model 
of postmenopausal osteoporosis. Therefore, the main aim of this thesis was to 
investigate to what extent such a model can be developed by utilising the principles of 
bone tissue engineering.  
Despite some in vivo studies showing that osteoblasts respond to a decline in oestrogen 
by increasing mineralisation in some parts of the bone [144], [292], [293], reports on 
the response of osteoblasts to oestrogen in vitro vary, with both stimulatory and 
inhibitory effects reported [299]–[308]. The results of this work found that only 
MC3T3-E1 are stimulated by exposure to oestrogen, although the subsequent 
withdrawal of the hormone did not have further stimulatory effects, as has been 
reported in the literature [308]. Neither MLOA5 nor IDG-SW3 showed any response 
to oestrogen. To determine why this might be, in the future it would be interesting to 
assess whether either cell line expresses the gene for ERα by using PCR (polymerase 
chain reaction) and fluorescent antibody staining to determine protein expression. This 
would reveal whether the lack of response was due to them not possessing the relevant 
receptor, the receptor not correctly locating to the membrane, or because the 
subsequent intracellular pathway activation after its conjugation with 17β-estradiol 
does not affect their ALP expression or mineralisation.  
A similar approach should also be utilised to investigate the apparent lack of RANKL 
synthesis. PCR could reveal whether the mRNA transcripts for the protein are being 
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produced and if there is any fluctuation in their production over time or in response to 
stimuli. If they are being produced then it would be important to discern why the cell 
is failing to produce the protein from the transcripts. In the literature, it is common for 
changes in RANKL and OPG production and the subsequent ratio of the cytokines to 
only be reported as fold changes in mRNA from PCR with no subsequent analysis at 
the protein level [208], [270], [331]. Whilst this is an efficient way of determining 
how a cell is responding at the gene level, these changes do not always translate into 
changes at the protein  level as the fold changes in the mRNA RANKL:OPG ratio do 
not necessarily match the change seen in the actual RANKL:OPG ratio [172]. 
Alternatively, although the enhanced cell digestion protocol used to isolate membrane-
bound isoforms of the cytokines contains protease inhibitors to minimise protein 
degradation during digestion, there may have been no mRANKL detection due to the 
protein being lost or denatured during the digestion process. Therefore, an alternative 
approach would be to stain for RANKL on the cell membrane using a fluorescent-
tagged antibody for the cytokine. This approach has the potential to reveal whether 
osteocytes generated from IDG-SW3 also possess mRANKL on their cell processes 
as MLO-Y4 do [211], as some, albeit a very low concentration, of mRANKL was 
detectable by ELISA at day 35.  
IDG-SW3 were found to upregulate the TRAP activity of osteoclasts generated from 
RAW264.7. However, without the addition of exogenous RANKL they were unable 
to induce osteoclastogenesis. This means that an unknown factor was being produced 
by the osteoblasts that had the ability to increase osteoclast formation. Due to its role 
in osteoclast precursor proliferation and differentiation, this was most likely M-CSF 
[47], [48]. Future work should therefore focus on determining whether this was indeed 
the cytokine responsible for the increased TRAP activity by analysing the expression 
of M-CSF mRNA transcripts as well as protein-level assays, such as ELISAs.  
Seeding density of RAW264.7 was found to be perhaps the most influential factor on 
osteoclast formation, lifespan, and activity. When non-noptimised, osteoclast 
precursors were able to rapidly overgrow the culture, inhibiting the activity of 
osteoblasts and the formation and activity of osteoclasts. Therefore, it was essential 
that they were seeded at the correct density for changes in resorption to be detectable 
in vitro. In TCP co-cultures, the ideal seeding density was approximately 2,500 to 
5,000 cells per cm2. In 3D co-cultures, the addition of 25,000 RAW264.7 resulted in 
the lowest mineral content on the scaffolds after the co-culture period indicating the 
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greatest amount of resorption had occurred. However, the difference in remaining 
mineral between maintained and withdrawn oestrogen was not significant. The 
difficulty with determining the appropriate seeding density in 3D stems from 
complexity of the architecture of the scaffold and associated problems with calculating 
its surface area.  
Using a technique such as MicroCT, it is possible to get an accurate reconstruction of 
the polyurethane scaffold that can then be used to non-destructively discern a wide 
range of physical properties from pore size to surface area. However, due to the 
random architecture of the polyurethane foam, each scaffold will have a different 
surface area. Therefore, using this approach would either require scanning each 
scaffold prior to seeding, or scanning multiple scaffold initially and using the average 
surface area. Even if this approach was undertaken, the RAW264.7 were not added to 
the scaffold until the 21 days of IDG-SW3 pre-culture had been completed. By this 
time point, the pores of the scaffold are filled with the extracellular matrix deposited 
by the osteoblasts. This collagenous matrix which fills the scaffold cannot be detected 
by MicroCT and therefore its effects of surface area cannot be considered using this 
method. Furthermore, this matrix is likely to act as a sieve upon the addition of the 
seeding suspension, meaning that it is unlikely that the osteoclast precursors will be 
evenly distributed throughout the scaffold in comparison to the TCP co-culture. This 
in turn will result in a variable density of precursors throughout the scaffold. It is 
because of these difficulties that a more iterative, trial-and-error approach was taken 
to discern seeding number in 3D, and from the results presented in this thesis it is 
indicated that a seeding density close to 25,000 RAW264.7 per 5×5 polyurethane 
scaffold would result in analogous effects to those observed in TCP co-cultures.  
Given that the ability of RAW264.7 to undergo osteoclastogenesis is heavily 
dependent on seeding density, it would be beneficial to use a substrate with a regular 
geometry over the polyurethane foam scaffold that has a random architecture. This 
makes it much more straightforward to calculate accurately scaffold surface area. In 
this thesis, two such scaffolds were investigated; the Biotek 3D Insert-PCL and the 
PolyHIPE scaffold. Both MicroCT and SEM revealed that despite the Biotek scaffold 
being advertised and sold as a precisely manufactured woodpile architecture, it does 
not have a reproducible geometry as both fibre morphology and position are variable. 
These differences occur both in comparison to the intended design and between 
samples. In comparison, the PolyHIPE scaffold does have a tightly controlled 
architecture due to it being fabricated via microstereolithography rather than extrusion 
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printing. In the generation three scaffold, fibre morphology was consistent between 
layers and fibre position could be tightly controlled ensuring a consistent offset 
between layers. However, due to the very high porosity of the scaffold, it has very 
poor contrast when being analysed by MicroCT. With regards to its use in an in vitro 
model of bone remodelling, this poor contrast has both advantages and disadvantages 
depending on the study being performed.  
When attempting to investigate the physical characteristics of the scaffold in a non-
destructive manner, the lack of contrast makes it very difficult to determine properties 
such as scaffold porosity, surface area, fibre diameter and fibre spacing, due to the 
difficulties in discerning the edges of each strut. This in turn makes it difficult to 
generate a computational model of the scaffold, which would be essential when 
simulating how it would respond to mechanical stimuli via a finite element model, or 
how fluid would pass through the scaffold using computational fluid dynamics. 
However, when analysing mineralisation, a scaffold with low x-ray attenuation is 
beneficial. This is because the densest and therefore most visible material present will 
be the inorganic mineral deposited by the osteoblasts, making it easier to track bone 
formation and resorption. Although contrast agents such as osmium tetroxide can be 
utilised to visualise cells by MicroCT, its use here may mask where mineralised matrix 
is being deposited due to its high radiopacity, resulting in any areas with cells giving 
high contrast regardless of how mineralised it is. Furthermore, it is extremely toxic, 
prohibiting longitudinal scanning of the sample and making it expensive to dispose of 
safely [482]. Therefore, it would be ideal if the contrast of the PolyHIPE scaffold could 
be increased when performing physical analysis, but left at its current level during cell 
culture.  
Increasing the x-ray attenuation of polymeric material to increase its contrast in 
MicroCT can be done through the addition of high atomic number materials. 
Previously utilised approaches include the incorporation of iodine, barium and 
tungsten, either by mixing in salts or nanoparticles, or by covalently linking the atoms 
to the polymer backbone [483], [484]. These approaches increase the radiopacity of 
polymers, but their inclusion can affect the physical and chemical properties of the 
polymer, meaning that the amount added should be as low as reasonably possible. 
With regards to their inclusion in photocurable PolyHIPEs, the presence of such 
elements is also likely to affect their polymerisation during fabrication, meaning that 
the standard laser parameters could not be used when they are present. This would 
result in a different scaffold being fabricated for physical analysis in comparison to 
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the ones used in cell culture, defeating the purpose of increasing the contrast in the 
first place. Therefore, an alternative approach may be to apply a coating the scaffold 
post-fabrication. This could be done via sputter coating with gold using the same 
protocol as when scaffolds are prepared for SEM analysis. This means that the scaffold 
contrast can be increased without affecting the architecture, and as the gold films 
deposited are only nanometres thick, this approach will not influence the physical 
characteristics derived from the MicroCT scan. 
In addition to surface area calculations being more straightforward on a regular 
geometry substrate such as the PolyHIPE scaffold, performing any future work with a 
different scaffold may also be beneficial in terms of cellular performance. The 
polyurethane foam used in this thesis was made from a non-medical grade, non-
degradable polyether polyurethane previously shown to support osteogenic 
differentiation [9]. Subsequent work using this material found that without soaking in 
media or gelatine coating prior to seeding, cell attachment and distribution throughout 
the scaffold was poor due to cells forming clumps rather than spreading evenly [402]. 
Although gelatine coating and media soaking was employed for all polyurethane 
scaffolds used in this thesis and cells and extracellular matrix were visible throughout 
the structure, no live/dead analysis of cells seeded onto the scaffold was performed to 
confirm how many cells remained viable. Therefore, to alleviate any potential 
concerns with the scaffold, future work should utilise either the PolyHIPE scaffold 
due to its regular architecture or an alternative polyurethane foam. A potential 
candidate is the recently developed medical-grade polyurethane scaffolds incorporated 
with hydroxyapatite that were utilised to make an in vitro model of implant fixation 
[404]. 
The difficulties in detecting osteoclastic resorption in the co-culture systems presented 
here were compounded by small culture surface areas used here and the low sensitivity 
of the assay used to indicate resorption. With regards to the small culture surface areas 
used, this issue is most easily overcome by increasing the well or scaffold size in which 
the co-culture is performed. However, this approach increases the amount of culture 
media and supplements required and therefore the associated cost per experiment. 
Once it was determined that none of the potential osteoblast cell lines investigated here 
produced sufficient RANKL to initiate osteoclastogenesis, it was apparent that 
exogenous RANKL would have to be added to the co-cultures. Supplemented media 
with a final RANKL concentration of 50 ng/mL costs approximately £1 per mL. TCP 
co-cultures in a 48 well plate could be maintained in 500 µL of media with 50% being 
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exchanged every 2-3 days over a ten-day period. Therefore, increasing the culture 
surface area by quadrupling the well size (12 well plate) would have increased the 
media cost per well over the course of an experiment from ~~£1.25 to ~£5, or £90 to 
£360 for the final TCP co-culture experiment presented here alone. Therefore, it was 
decided to proceed with smaller well sizes to allow more experiments to be performed, 
to the potential detriment of assay sensitivity.  
When a patient’s bone loss is being classified and assigned a T score, this calculation 
is based on their bone mineral density (BMD) computed from a DXA scan [106]. 
Similarly, when OVX rat models are used to investigate osteoporosis and potential 
therapeutics, changes in bone morphometry are commonly evaluated by MicroCT, a 
density based imaging technique that tracks the changes in BMD [156]–[158]. 
Therefore, although it is not just bone mineral that is resorbed by osteoclasts, the 
Alizarin Red S assay selected to determine resorption in the co-cultures was chosen as 
it indicates changes in the mineral content. These changes can be identified 
qualitatively, as Lutter, et al., demonstrated that resorption pits are visible in 
mineralised matrix deposited by osteoblasts in vitro [485], but more importantly, 
changes can also be quantitatively determined through destaining and colourimetric 
analysis. This means that percentage changes in mineral in vitro could theoretically be 
compared to in vivo data, to see whether changes seen in response to oestrogen are 
analogous.  
Although this approach can reveal changes in mineral content in comparison to a 
baseline level, it is an indirect measurement of osteoclastic resorption that examines 
what is left rather than what is removed. The low sensitivity of this approach stems 
from the fluctuation in the baseline level of mineral deposited by the IDG-SW3 as 
discussed in chapter six, as well as the precision of the assay. Through serial dilution, 
the minimum detection limit of ARS when destaining in 5% perchloric acid was found 
to be 18.8 µg/mL, similar to the minimum detection limit of 17.1 µg/mL reported 
when destaining in ammonium acetate [289]. All the ARS assays reported in this thesis 
had a concentration higher than this; therefore, the issue with the ability of the assay 
to detect changes in mineral was not that levels were below what could be detected, 
but rather that colourimetric analysis of the destained solution cannot precisely discern 
between two similar concentrations. By analysing solutions at 380 to 400 µg/mL at 
5 µg/mL increments it was found that only intervals of 10 µg/mL were significantly 
different, meaning that any concentration of mineral reported could be ± 5 µg/mL 
(Fig. 7.1). With reported mineral levels after resorption typically being between 250 
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and 350 µg/mL, this means that errors due to assay precision are between 2.9 and 4%. 
This means that this approach to determining osteoclastic resorption may not have 
been powerful enough to detect small differences.  
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Figure 7.1: Ability of colourimetric analysis to discern between different ARS 
concentrations ****=p<0.0001 (n=96). 
When bone is resorbed by osteoclasts, it is not just the inorganic mineral phase that is 
removed, but also the organic phase consisting of collagen and other proteins. 
Collagen peptides released into the culture media can be used as biochemical markers 
of bone formation and resorption in vitro as they are in vivo, where their concentration 
in serum or urine correlates with bone turnover [486]. The concentration of carboxy- 
and amino-terminal propeptides of procollagen type 1 (P1CP and P1NP, respectively) 
can be used as markers of bone formation. Collagen type 1 in bone is initially 
synthesised as procollagen. Once released in to the extracellular space, P1CP and 
P1NP are enzymatically cleaved from both termini of the collagen molecule, and 
therefore the concentration can be used to quantitatively assess newly formed collagen 
[487]. Similarly, the carboxy- and amino-terminal telopeptides of collagen type 1 
(CTX and NTX, respectively) can be used as markers of bone resorption. CTX is 
released from the bone matrix by the osteoclastic protease cathepsin K during bone 
resorption [488], and therefore its concentration correlates with resorption. In vitro, 
the concentration of these peptides can be assessed via ELISA and used as markers of 
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bone turnover, as demonstrated by Papadimitropoulos, et al., in their in vitro bone 
organ model [250]. Although measurements of these peptides do not reveal the mineral 
content of in vitro cultures, analysis of co-culture supernatants would help confirm 
that any reduction in mineral was indeed due to osteoclastic resorption without the 
need for further repeats of any experiment, as media can be taken without terminating 
the experiment.  
TRAP is an enzyme involved in bone resorption that correlates with bone resorption 
in vivo due to its accumulation in the blood during bone turnover. Although its activity 
in vitro has been used extensively to show osteoclast activity as a marker of 
osteoclastic differentiation, here it was not found to correlate with in vitro resorption. 
This is likely due to the fact that the TRAP activity quantified in vitro here is the 
intracellular activity rather that the serum equivalent of the TRAP activity in the 
culture media. This means that rather than an indication of how much mineral 
resorption has occurred in the culture this far, the activity indicates how many 
osteoclasts are currently active. Due to the short lifespan of osteoclasts and the cyclic 
nature of their formation, this TRAP activity does not necessarily correlate with 
historic resorption. TRAP is an osteoclastic enzyme indirectly involved in bone 
resorption, meaning that whilst it is essential for osteoclasts to resorb bone, it does not 
degrade the bone matrix. Due to its involvement in collagen hydrolysis, cathepsin K 
activity could also be used as a measure of how much resorption is currently taking 
place, and may more strongly correlate with resorption due to its direct involvement 
in the process. In vitro assays for cathepsin K are commercially available for cell 
lysates and media supernatants. However, as with TRAP activity, its activity only 
reveals the activity of the osteoclasts currently in the culture, rather than the historic 
resorption that has taken place.  
For any future studies exploring an in vitro model of osteoporosis or any model of 
bone turnover for that matter, it is clear that a range of assays for the activity of both 
cell types is necessary. Alkaline phosphatase activity is a good indication of osteoblast 
activity, but does not accurately predict how much mineral will be deposited as it is 
not directly involved in matrix mineralisation [489]. Therefore, calcium or phosphate 
quantification are necessary to reveal how much mineralisation has occurred. 
Similarly, whilst TRAP and cathepsin K activity can reveal how active osteoclasts 
currently are in the co-culture, without quantifying changes in the extracellular matrix 
the enzyme activities cannot reveal how much resorption has occurred. Ideally, media 
and cell lysates would be collected at regular intervals throughout the co-culture. 
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These supernatants and lysates could then be analysed for P1CP and CTX peptides 
and ALP, TRAP and cathepsin K activity, both separately at each time point and 
cumulatively at the end to reveal total resorption and formation. In addition to this, 
longitudinal scanning of the co-culture using MicroCT to reveal how mineral content 
and distribution changes throughout the co-culture could demonstrate how changes in 
the enzyme activities affect the bone matrix on the scaffold. Furthermore, providing 
that osteoblasts capable of producing RANKL were selected, these supernatants and 
lysates could also reveal changes in the RANKL:OPG ratio over time. Finally, 
performing all cultures in serum-free of chemically defined medium would increase 
reproducibility and remove any effects of unknown factors on bone turnover.  
This thesis has demonstrated that it is possible to mimic the onset of postmenopausal 
osteoporosis in vitro; however, the co-cultures developed here are not yet a valid 
alternative to the work currently performed in OVX animal models. In order to achieve 
this, long term work should focus on maintaining the co-cultures over extended time 
periods and using human-origin cells for improved clinical relevance. The main 
limitation on culture duration in the work presented here was overgrowth by 
RAW264.7 precursors. One potential solution to this issue would be to have 
osteoblasts and osteoclasts cultured in separate but connected chambers of a bioreactor 
system, with osteoblasts cultured on a generation 3 PolyHIPE scaffold in one chamber 
and osteoclasts on a resorbable calcium phosphate substrate in another (Fig. 7.2). With 
the two cell types cultured separately, osteoclast precursors would be unable to 
overgrow the osteoblasts.  
An ideal bioreactor for this is the Quasi-Vivo® (Kirkstall Ltd, UK) system as it applies 
physiologically-relevant levels of oxygen and shear stress at low pressures via laminar 
flow with chambers that permit 3D cell culture on scaffolds. The chambers are 
modular, so co-cultures can be in the same or connected chambers, exposing them to 
the same common medium. This allows circulating levels of drugs and metabolites to 
be retained, rather than being removed during media changes. The separate culture of 
OBs and OCs in this system allows them to communicate with each other and would 
enable the extension of the co-culture to much longer time periods, ideally up to 8 
weeks to mimic the OVX procedure in rats [130]–[133]. Such a system would allow 
all of the assays for an ideal in vitro described previously to be performed, as media 
could still be analysed, lysates generated, and longitudinal MicroCT scans taken. The 
main limitation of such a system would be that the mineral deposited would not be the 
mineral resorbed, making it a representation of uncoupled bone remodelling rather 
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than bone turnover through BMUs, and that only the influence of soluble rather than 
membrane bound isoforms of cytokines can exert influence on the other cells in the 
culture.    
 
 
Figure 7.2: Schematic showing a potential layout of a bioreactor system used for long 
term co-cultures. A peristaltic pump is used to flow and recirculate media through the 
chambers. 
The murine co-cultures performed in this thesis required the exogenous addition of 
RANKL to stimulate osteoclastogenesis. Therefore, when selecting a suitable cell type 
for any future studies, it is imperative that they produce RANKL. This means that the 
concentration of this cytokine can change in response to hormone or drug 
concentration, better mimicking what occurs in vivo. Previous studies have 
demonstrated that primary human osteoblasts produce sufficient RANKL to induce 
osteoclast differentiation in co-culture; therefore, identifying a donor capable of this 
should be the first step when developing any future system [249], [252], [253].  
Furthermore, the use of RAW264.7 in the co-culture should be replaced by CD14 and 
CD45 positive human monocytes derived from peripheral blood (hPBMC) as these 
have been used extensively to generate osteoclasts in the study of remodelling 
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fundamentals and in vitro models of bone remodelling [164], [165], [169], [170], 
[206], [209], [234], [244], [249]–[253]. By sourcing monocytes from women both pre- 
and postmenopause, any difference in osteoclastogenic potential could also be 
examined.  
Co-cultures containing hPBMC precursors have been maintained for three [250], four 
[249], and five [249] weeks, reporting prolonged osteoclast activity and no 
overgrowth. Therefore, it seems possible that extending the duration of the co-culture 
in a bioreactor system over longer time periods is possible. However, should 
overgrowth or loss of osteoclasts occur due to apoptosis over time, the separate 
cultures of osteoblasts and osteoclasts in the Quasi-Vivo® system would allow the re-
seeding of the hPBMCs at later time points, mimicking the arrival of precursors in the 
bloodstream. If a single addition of hPBMCs was capable of producing osteoclasts 
over the entire co-culture then it would not be necessary to culture the osteoclasts and 
osteoblasts separately. This would allow membrane-bound isoforms of RANKL to 
stimulate osteoclastogenesis, as well as other molecules dependent on osteoblast-
osteoclast contact, such as intercellular adhesion molecule (ICAM)-1 [169]. 
Furthermore, it would better represent coupled bone remodelling, as the matrix 
deposited by osteoblasts would then in turn be resorbed by osteoclasts.  
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8. Conclusion 
This thesis explored the feasibility of developing an in vitro model of postmenopausal 
osteoporosis using the principles of bone tissue engineering. In TCP co-cultures with 
an optimised seeding density, using oestrogen withdrawal to mimic the onset of 
postmenopausal osteoporosis resulted in increased mineral resorption, analogous to 
the effect seen in vivo. However, out of the conditions assessed in 3D co-cultures, no 
equivalent response was observed. This indicates further work is required to optimise 
osteoclast seeding number, as well as using a wider range of assays to monitor bone 
remodelling over time.  
The work presented in this thesis has advanced the field of developing in vitro models 
as alternatives for animal testing. Importantly, it has demonstrated that it will be 
possible to mimic the onset of postmenopausal osteoporosis in vitro. However, 
additional development and refinement is necessary to create a widely accepted, valid 
alternative to current animal models. The main areas to be addressed include creating 
a model that uses human-origin cells and maintaining three-dimensional co-cultures 
over longer duration. This will result in a more physiologically relevant in vitro model 
that should improve translation from pre-clinical studies to human trials whilst 
minimising our reliance on animal models.  
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10. Appendix 
10.1 Standard curves 
Standard curves for the ALP, DNA, ARS and DR80 assays are given in figure 10.1. 
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Figure 10.1: Standard curves for the ALP, DNA, ARS and DR80 assays. These can be 
used to convert plate reader outputs (absorbance/fluorescence) to a known 
concentration of enzyme product, DNA, or stain. 
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10.2 Figure permissions 
Where figures not covered by the Creative Common Attribution License were 
reprinted from a publication, permissions were granted via RightsLink® (Fig. 10.2) 
 
Figure 10.2: Reprint permissions granted via RightsLink®. 
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(Fig. 10.3).  
 
 
Figure 10.3: Written permissions for figures not available through RightsLink®. 
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10.3 Emulsion templated scaffolds with tunable mechanical 
properties for bone tissue engineering 
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